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SUMMARY
Many in vitro assays have been developed for the identification of potential 
human carcinogens, with endpoints that range from point mutations to visible 
chromosomal aberrations involving many millions of base pairs. Molecular 
biology techniques have demonstrated that these two mechanisms and other 
DNA changes, including damage intermediate between the two, are important 
in tumorigenesis. Therefore, assays that can detect a wide range of 
mechanisms leading to DNA damage have more relevance for the detection 
of carcinogens than assays which detect only a single endpoint.
In this thesis two mammalian cell mutation assays, the HPRT/V79 
Chinese hamster and TK/mouse lymphoma assays, were compared for their 
ability to respond to genotoxic chemicals. Molecular analysis of the mutants 
was used to determine the nature of the DNA damage incurred. Two 
chemicals were studied, ethyl methanesulphonate (EMS) and mitomycin C 
(MMC), which are known to differ in their biological activity. EMS is a potent 
point-mutagen, whereas MMC induces a higher frequency of chromosome 
breakage events.
The data presented in this thesis shows that the HPRT and TK assays 
differed in their ability to detect mutation induced by EMS and MMC. Whilst 
EMS was capable of inducing a high mutant frequency at both loci, MMC 
produced relatively few mutants at the hprt locus, but induced a large number 
of mutants at the tk locus. Furthermore, in the TK assay a higher proportion 
of small, slow-growing mutants were observed with MMC than with EMS. 
Chromosome aberration assays using V79 cells were used to demonstrate the 
greater chromosome breakage ability of MMC compared to EMS.
Molecular analysis of HPRT and TK mutants showed that the 
difference in induced mutant frequency was due to the type of genetic , 
damage incurred. Intragenic changes, ranging from point mutations to loss 
of the entire gene, were recovered as viable mutants at both the hprt and tk 
loci. EMS, which caused mainly intragenic damage, induced similar mutant 
frequencies at both loci. In contrast, MMC induced mainly large, multilocus 
deletions, in which the damage was assumed to extend into genes essential 
for normal growth, since most TK mutants were slow-growing. Mutants 
carrying large scale damage were recoverable at the heterozygous tk locus, 
but not at the hemizygous, hprt locus.
A diverse range of genetic alterations have been associated with the 
cancer process, involving both the mutational activation of oncogenes and the 
mutational inactivation of tumour suppressor genes. The TK/mouse 
lymphoma assay appears to be a more appropriate test for the detection of 
chemicals capable of causing the types of DNA lesions important in human 
cancer.
Study of the hprt gene of human T-lymphocytes showed an age-related 
increase the in in vivo mutant frequency. Life-style factors, such as smoking 
and alcohol intake had no effect on the mutational response, although the 
wide variability in mutant frequency suggested that a much higher number 
of individuals would have to be studied in order to detect differences between 
exposed and control groups.
Publications resulting from the studies presented here are bound in the 
back of this thesis.
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1CHAPTER 1 
INTRODUCTION
1.1. Mutation and Human Disease
A number of human diseases are known to be caused or influenced by damage 
to DNA (Edwards, 1988). It has been estimated that genetic damage, in the 
form of hereditary diseases and congenital malformations, (based on the onset 
of the disease before the age of 25), contributes greater than 5.3% of human 
diseases (Baird et al., 1988). This figure will probably prove to be conservative 
as more genes are identified, and changes in particular DNA sequences are 
associated with human disorders. This, plus the involvement of somatic 
mutations in a number of non-hereditary diseases ranging from various 
cancers (Bishop, 1988) to atherosclerosis and senile cataracts (Hartman, 1983), 
illustrates the contribution of DNA damage to the burden of human disease.
Little can be done to reduce the background level of genetic diseases, 
which will always be present (White and Caskey, 1988), since although genetic 
diagnosis may reduce the incidence of some inherited diseases, spontaneous 
mutations will always arise in the population. However, the identification of 
chemicals that damage DNA (genotoxins)' in our environment would help 
reduce the risk attributable to exposure to external factors (Tomatis, 1988) 
such as occupational hazards, diet and lifestyle habits. Tobacco smoking 
carries a risk of lung cancer 22 times greater in male smokers than in male
non-smokers (US Public Health Service, 1989). Since the dangers of smoking 
have been recognised, smoking amongst males in the USA has decreased by 
about 20% with a subsequent decline in lung cancer deaths (Marcus et al., 
1989). A high incidence of lung cancer among workers involved in the 
manufacture of bis(chloromethyl) ether was found at one factory, whilst at 
another using the same process, but with protective measures, the cancer 
incidence was not elevated (McCallum et al., 1983).
Although short-term tests for genotoxicity were developed specifically 
for the detection of potential carcinogens (Ramel, 1986), they detect a variety 
of endpoints (Waters et al., 1986) that are relevant to many other human 
genetic disorders as well as to cancer (Drake and de Serres, 1980).
1.2. The spectrum of mutational changes
A variety of alterations has been found in DNA, ranging from single base 
changes to loss or gain of whole chromosomes.
a) Gene mutations are defined as nucleotide changes which affect the DNA 
sequence of a single gene. Such changes are outside the limits of 
detection using conventional light or electron microscope techniques.
Gene mutations may result from base substitutions where a 
purine is replaced by a purine, or pyrimidine by pyrimidine (transitions) 
e.g., CG base pair becomes TA base pair, or where a purine is 
substituted for a pyrimidine, or vice versa (transversions) e.g., CG -> AT, 
or CG GC (Topal, 1988). Not all base substitutions will affect protein
function (Griffin, 1986) since the degenerate nature of the genetic code1' 
means that the base change will not necessarily result in a triplet 
coding for a different amino-acid, or perhaps the changed amino-acid 
will not affect the protein involved. Alternatively mutations may occur 
outside the coding region of the gene.
Error-prone ‘ repair of gaps caused by pre-mutational lesions 
during DNA strand elongation result in the incorporation of too few or 
too many nucleotides (Roth, 1974). Such deletions or insertions, known 
as frameshift mutations, may cause a disruption in the triplex reading 
frame resulting in a greatly altered protein product.
Small changes within the gene, or in promoter regions or 
initiation and termination sites may result in an abnormal protein, as 
in fi-thalassaemia (Orkin and Kazazian, 1984), or to loss or alteration in 
activity of the normal protein, e.g., sickle cell anaemia (Weatherall, 
1991), Lesch-Nyhan syndrome (reviewed by Caskey, 1987).
Monogenic disorders follow a Mendelian pattern of inheritance 
that may be dominant (the condition is manifest in the heterozygous 
state, where only one allele is abnormal), or recessive, (where both 
alleles must be abnormal, homozygous, for the gene to be expressed. 
The genes for the disease may be autosomal or X-linked (an X-linked 
disorder in males will always be dominant). Single gene mutations 
account for about 1400 known human genetic diseases (Stanbury et al., 
1983), and 0.36% of newborns are estimated to inherit a monogenic 
disorder (Baird et al., 1988). New mutations are thought to occur at a
frequency of 5 x 10'6 mutations per gene per generation; this would 
result in about one in 100,000 newborns carrying a new mutation in any 
given gene (Winnaker, 1987). Duchenne muscular dystrophy (DMD) is 
an X-linked disorder in which affected males usually die without 
reproducing (Davies and Read, 1988). Therefore the disease would 
eventually disappear if new mutations did not occur; new mutations at 
the DMD locus are estimated to occur in one third of cases of DMD 
(Love and Davies, 1989). New mutations appear to be a particular 
problem for very large genes due to the large target size, for instance 
the DMD locus is about 2Mb (Chamberlain et al., 1988). However, as 
Winnaker (1987) points out many new mutations will be recessive or 
not expressed because they do not alter protein function, and in 
consequence no disease will be clinically apparent.
Chromosomal mutations describe both numerical and structural DNA 
changes affecting two or more genes.
Numerical changes are caused by inaccuracies during DNA 
replication resulting in the daughter cells receiving the wrong 
chromosome compliment (Evans, 1986). In man numerical changes are 
most clearly demonstrated by the trisomies, for example, trisomy 21, 
Down syndrome. Such changes are due to non-disjunction during 
meiosis when the homologous chromosomes fail to separate at 
anaphase, and result in gametes, and hence a fertilised egg, with an 
abnormal chromosome content. Most numerical abnormalities are 
therefore new mutations and are not inherited. In contrast to gene
mutations and structural chromosome changes which involve damage; 
to DNA, numerical aberrations can also occur from defects in the 
proteins of the spindle apparatus (Omfelt. 1986) and in the attachment 
and segregation of the chromosomes during cell division (Vig, 1986). 
Polyploidy is due to multiplication of the complete chromosome set, 
whilst aneuploidy results from deviations in the number of an individual 
chromosome (Holliday and Jeggo, 1985).
Numerical changes in whole chromosomes or in part of a 
chromosome leading to changes in copy number of particular genes, may 
also occur through structural damage (Evans, 1988). Chromosome 
breaks may lead to deletions, and asymmetrical translocations may 
result in acentric fragments which can be lost on cell division (Carrano 
and Natarajan, 1988). Alternately chromosomes involved in 
translocations may try to pair with homologous sequences on the two 
separate normal chromosomes they represent, leading to asymmetrical 
segregation at meiosis. In germ cells this will result in both monosomic 
and trisomic embryos being produced (Evans, 1986). Chromosomal 
deficiencies may result in the expression of suppressed or recessive 
genes (Cavenee et al., 1983), whilst duplications may cause 
overproduction of the gene product (Pool et al., 1989). Translocations 
and inversions can disrupt gene clusters with related functions, or 
position genes near strong regulatory elements or promoters, leading to 
abnormal gene expression (Rabbitts, 1985).
Although most chromosomal defects in the embryo result in 
spontaneous abortions or perinatal deaths, some are compatible with
life. Evans (1988) has estimated that about 1 in every 160 live 
newborns carries a major chromosomal mutation, and Baird et al. (1988) 
found chromosomal aberrations to account for 0.18% of genetic diseases. 
By far the most common chromosomal defect is a trisomy of 
chromosome 21, which results in Down Syndrome, and occurs in 0.12% 
of live newborns (Weatherall, 1991). Examples of other clinical 
syndromes include Patau (trisomy 13), Edward (trisomy 18) and 
Klinefelter (47,XXY). In Turner Syndrome (45,X) the infertile 
phenotypic females are monosomic for the X-chromosome (XO).
c) Multifactorial disorders require an often unknown number of genes to 
be mutated before the disease is expressed. A variety of conditions fall 
into this category and include certain cancers, non-insulin dependent 
diabetes mellitus, spina bifida and clubfoot. Baird et al, (1988) estimate 
that multifactorial disorders account for 4.6% of genetic diseases present 
at birth, or with an onset before 25 years of age. They suggest however 
that this figure would be 60% if diseases over the whole life span were 
included, for example late onset cancers, duodenal ulcers, cardio­
vascular disorders.
1.3. Mutation and Cancer
In 1914 Theodore Boveri proposed that chromosome damage could be the 
cause of cancer, in what has become known as the somatic mutation theory. 
However, due to the technical difficulties in detecting genetic damage, it was 
not until sixty years later that evidence for the role of genetic alterations in
tumorigenesis was established (Rowley, 1973; Klein, 1979; reviewed by Bishop,. 
1989). The correlation between mutation and cancer was supported by 
observations of both human cancers and tumours induced in animals. This 
evidence has been extensively reviewed by Varmus (1989).
Pathological examination of tumours from cancer patients suggest that 
cancer cells result from genetic changes that confer growth advantages over 
normal cells (Nowell, 1976). As the clone of mutated cells expands, additional 
changes in the cells take place, involving growth regulatory genes, or genes 
giving some other selective advantage to a sub-population of the original clone, 
and eventually progressing to the production of tumours (Cairns, 1975; Marx, 
1989). Since mutations are irreversible the cancer can only be cured by 
elimination of the abnormal cells. As further evidence for the role of 
mutations in tumorigenesis normal cells mutated in the laboratory have been 
found to cause tumours when reintroduced into susceptible animals 
(McCormick and Maher, 1989).
Microscopic observations of tumour cells reveal abnormal karyotypes; 
both numerical and structural changes have been observed (Rabbitts and 
Rabbitts, 1989). Some chromosomal changes are regularly associated with a 
particular type of cancer (Heim and Mitelman, 1989), suggesting a non-random 
pattern of aberrations that make specific contributions to the malignancy.
Inherited cancer-prone conditions are often associated with DNA 
defects. Inherited disorders affecting enzymes involved in DNA repair, for 
example Xeroderma pigmentosum, Bloom’s Syndrome, Fanconi’s anaemia, 
result in an increased incidence of mutation and hence an increased risk of all 
types of cancer (Arlett and Cole, 1986). In disorders such as retinoblastoma
and Wilm’s tumour an inherited mutation in one allele of a gene concerned in. 
growth control, and subsequent loss or mutation of the second allele, results 
in a very strong likelihood of the particular cancer type developing (Weinberg, 
1989).
It should be noted that certain human and animal viruses can be 
tumorigenic (Peters, 1989). Retroviruses (RNA tumour viruses) transcribe 
DNA which integrates into the host chromosome (Varmus, 1982; Panganiban, 
1985). Insertional mutagenesis of viral DNA (Nusse, 1986) causes disruption 
to cellular DNA sequences, or introduces strong viral regulatory elements into 
the mammalian genome which result in over-expression of cellular genes, for 
example, the insertion of strong promoter ALV (avian leukosis virus) 
sequences adjacent to the c-myc gene (Hayward et al., 1981). During the life 
cycle of retroviruses copies of cellular genes may be incorporated into the viral 
genome, including transduced genes which are involved in the mechanism of 
tumour development (Peters, 1989). These viral oncogenes have been shown 
to differ from their normal cellular homologues by mutations involving both 
gross structural changes and point mutations (Bishop, 1983).
1.3.1. The role o f oncogenes and tumour suppressor genes in carcinogenesis 
Perhaps the most significant evidence for the role of mutagenesis in cancer 
has evolved from the demonstration that specific viral and cellular oncogenes 
are involved in the mechanism of carcinogenesis (Bishop, 1987). Studies of 
proto-oncogenes indicate that they have a normal function in cells, concerned 
with cell differentiation and proliferation, and code for proteins found 
throughout the growth regulatory pathway (Hall, 1986). Their products have
been shown to be connected with growth factors or their receptors (Waterfield, 
et al., 1983; Downward et al., 1984), to encode for regulatory protein kinases 
(Marshall, 1988), and to modulate transcription of other genes within the 
nucleus (Heldin and Westermark, 1984). Activation of oncogenes through 
genetic changes result in an altered gene product; either by a quantitative 
alteration in the normal gene or a qualitative change leading to the production 
of an abnormal protein. These abnormalities are expressed even in the 
presence of a normal allele of the same gene; that is they are genetically 
dominant (Bishop, 1983).
In contrast, a second type of gene, which is genetically recessive, may 
be involved in the carcinogenic process. The first indication that certain genes 
could regulate a defective growth gene in a cancer cell and make it responsive 
to normal growth control, came from studies with somatic cell hybrids, which 
showed that when malignant cells were fused with normal cells, the resulting 
hybrids were non-tumorigenic (Harris et al., 1969; Stanbridge, 1976). These 
studies, together with evidence of specific chromosomal deletions associated 
with certain human malignancies (Cavenee et al., 1983), led to the hypothesis 
that certain genes, tumour suppressors, must be inactivated before a cell can 
become malignant (Stanbridge, 1985). Tumour suppressor genes function by 
regulating cell proliferation and development in normal cells (Ponder, 1988). 
It is the loss or inactivation of both copies of these genes that play a role in 
cancer development (Sager, 1989), by removing the 'brake" that controls 
tumour growth.
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1.3.2. Mutations in cellular oncogenes and tumour suppressor genes 
As mentioned earlier, cancer is a multifactorial disorder, requiring a cascade 
of genes to be altered during both early (initiation) and late (progression) 
stages for the disease to develop (Farber, 1984; Weinberg, 1989). The 
hypothesis that the successive accumulation of multiple genetic events are 
required for tumour production is supported by the fact that cancer incidence 
increases with age (Stein, 1991). For most cancers occurring in adults 
estimates of five to seven hits appear to fit the pattern of age distribution of 
many tumours (Knudson, 1977; Fearon and Vogelstein, 1990).
Oncogenes involved in the cancer process may be activated by a number 
of different mechanisms including numerical and structural chromosome 
changes (Gebhart, 1987), and point mutations (Bos, 1988) (Table 1.1.). Some 
of these changes are consistent features of specific tumour types, whilst others 
occur at random (Yunis et al.y 1987).
Chromosome rearrangements, such as translocations and inversions, can 
affect either the expression of the oncogene or lead to an altered gene product 
(Croce, 1987). In Burkitt’s lymphoma the c-myc gene located on chromosome 
8 is consistently translocated to chromosome 14 (80% of patients), or 
alternately chromosome 22 (15%) or chromosome 2 (5%) is translocated to 
chromosome 8 in the 3’ end of the c-myc gene (Croce and Nowell, 1985). 
These chromosomes carry the genes for immunoglobulin : chromosome 14, 
IgH, heavy chain; chromosome 22, IgK, light chain; chromosome 2, IgK, light 
chain (Boehm and Rabbitts, 1989). It is thought that as a result of the 
translocation immunoglobulin controlling elements (promoters and enhancers)
nOncogene Neoplasm Activation
abl CML Translocation
erb B1 Squamous cell carcinoma; 
astrocytoma
Amplification
erb B2 Adenoma of breast, ovary and 
stomach
Point mutations
gip Carcinoma of ovary and 
adrenal glands
Point mutations
9sp Adenoma of pituitary; 
carcinoma of thyroid
Point mutations
myc Burkitts lymphoma; carcinoma 
of lung, breast, cervix
Translocation 
Amplification
L-myc Carcinoma of lung Amplification
N-myc Neuroblastoma; small cell 
carcinoma of lung
Amplification
H-ras Carcinoma of liver, lung, 
pancreas; melanoma
Point mutations
K-ras Leukaemia; carcinoma of 
colon, thyroid, melanoma
Point mutations
N-ras Carcinoma of genitourinary 
tract, thyroid
Point mutations
ret Carcinoma of thyroid Rearrangement
Table 1.1. - Examples of oncogenes activated in human tumours
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regulate and greatly increase c-myc transcription, or alternatively c-myc mRNA 
stability may be increased (Rabbitts, 1985).
In chronic myeloid leukaemia (CML) the presence of the Philadelphia 
(Ph’) chromosome, detected in 96% of all CML patients, is associated with an 
altered gene product. A reciprocal translocation between chromosome 9 
(carrying the c-abl oncogene) and chromosome 22 (carrying the c-sis 
oncogene) occurs. A breakpoint cluster region (bcr) on chromosome 22 is 
disrupted and c-abl is relocated within the proximal (55) bcr sequences
leading to the formation of Ph’. This is believed to be the critical event in 
CML, causing bcr and c-abl to be transcribed as a single gene of increased 
enzyme activity (de Klein, 1987). The distal (3’) bcr sequences are relocated 
with c-sis to chromosome 9, an event which is thought to be insignificant in 
CML.
Gain or loss of genetic material affecting gene dosage is also apparent 
in malignancies, and has been particularly noted in solid tumours (Alitalo and 
Schwab, 1986). The cytological indicators of DNA amplification are double 
minutes and homogenously staining regions on chromosomes (Cowell, 1982) 
which often involve 1000 kb of amplified material and in some cases have been 
shown to include proto-oncogenes. Amplification of N-myc occurs in many 
neuroblastoma cell lines and tumours (Schwab et al., 1983), c-myc amplification 
has been reported in small cell lung carcinoma (Little et al., 1983), and 
amplification of Ki-ras has been shown in mouse adrenal tumours (George et 
al., 1984). Since amplification is seen only in neoplastic cells, not in normal 
cells, it is unlikely to be an initiating event in carcinogenesis, but rather to 
play a role in tumour progression.
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Gene dosage may also be affected by the acquisition of a single extra 
copy of a gene, through polyploidy or aneuploidy (Nowell and Croce, 1988). 
Trisomy 7 is consistently observed in malignant melanoma; located in 
chromosome 7 is the proto-oncogene c-erb B which codes for part of the 
receptor for epidermal growth factor, and increased expression of this receptor 
has been demonstrated.
The development of transfection assays using untransformed recipient 
cells proved useful in detecting members of the ras oncogene family (Bos,
1988), and furthermore demonstrated that the transforming ability is usually 
conferred by a single base substitution mutation resulting in an amino acid 
change in the protein product. These point mutations are found at a 
restricted number of sites, mainly at codons 12, 13 and 61 (Barbacid, 1985). 
This site limitation suggests either the existence of "hot spots" for mutation 
or the induction of random mutations that then undergo selection for 
transforming ability.
The occurrence of ras gene mutations in human cancers has recently 
been reviewed by Bos (1989). Although activated ras genes are found in a 
variety of tumours, the incidence varies considerably. Eighty percent of 
adenocarcinomas of the pancreas carry a mutant ras gene, as do 50% of colon 
and thyroid carcinomas, whereas in other tumours, for example breast 
adenocarcinomas and neuronal tumours, mutated ras is rarely or never 
detected. Bos (1989) suggests that in the latter case the absence of ras 
mutations may be due to the cell type from which the tumour arises; in some 
cell types ras proteins may not stimulate cell growth, or alternatively a ras 
mutation may predispose to a certain type of tumour.
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Many chemically induced animal tumours also carry a mutated ras gene. 
In many animal systems a correlation is seen between the carcinogen used and 
the base substitution induced. For example, Zarbl et al. (1985) showed 
methylnitrosourea-induced mammary tumours in rats carry a G to A transition 
at the second base of codon 12 of the H-ras gene in 90% of the tumours 
studied. In other animal systems a variety of mutations have been detected 
with a particular mutagen, with often more than one member of the ras 
family being involved (Guerrero and PeUicer, 1987). This latter observation 
implies that activation of ras may occur during the progression stage of cancer 
development. In contrast, the detection of ras in 7,12-dimethyl- 
benz(a)anthracene induced skin tumours during the benign papilloma stage, 
when not all progressed to malignancy, suggests that ras activation can also 
be an early, initiating event (Balmain et al., 1984).
In contrast, loss of genetic material through non-disjunction, mitotic 
recombination and deletions has been linked to the inactivation of tumour 
suppressor genes (Sager, 1989). Retinoblastoma is a childhood embryonal 
tumour that occurs in sporadic and hereditary forms (Weinberg, 1988). In 
familial retinoblastoma a mutant retinoblastoma (RB) gene (often caused by 
point mutations) is inherited from one parent and a normal gene from the 
other parent (Stratton et al., 1989). During cell proliferation the wild-type 
allele is occasionally lost, removing an inhibitory control of cell growth. The 
sporadic form of retinoblastoma requires two hits by somatic mutation 
involving deletions and point mutations (Dunn et al., 1988). Loss of the RB  
gene or its function is the only consistent feature in retinoblastoma, and it is
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not known whether other mutations are required for retinal tumours to 
develop.
In human colorectal cancers at least four to five mutations in various 
genes appear to be necessary for the development of malignant tumours 
(Stanbridge, 1990) and three to four of these changes appear to involve 
candidate tumour suppressor genes (Vogelstein etal., 1988). Alterations, often 
occurring in both alleles of the APC (adenomatous polyposis coli) gene are the 
earliest genetic events that have been detected in colon cancer (Powell et al., 
1992), and have been found in both sporadic tumours and in patients which 
familial adenomatous polyposis, an inherited disease predisposing to colon 
tumours (Groden et al., 1991). On the same chromosome (chromosome 5) the 
MCC (mutated in colon cancer) gene may also play a role in some sporadic 
forms of colon cancer, although MCC has been found to be mutated less 
frequently than APC in tumour tissue (Kinzler et al., 1991).
Another candidate tumour suppressor gene, DCC (deleted in colorectal 
carcinoma) is located on chromosome 18, and deletions involving allelic loss 
have been detected in 70% of colorectal cancers (Fearon et al., 1990). The 
DCC gene is thought to participate in the control of cell growth through cell- 
surface interaction, the disruption of which is a critical event in the malignant 
process (Stanbridge, 1990).
Chromosome deletions or mitotic recombination resulting in loss of a 
large part of chromosome 17, on which the p53 gene is located, have been 
observed in 75% of colorectal carcinomas (Fearon and Vogelstein, 1990). The 
remaining p53 allele has frequently been found to carry point mutations. 
Similar changes in p53 have been observed in DNA from tumours of many
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tissues including lung, liver, breast and brain. Indeed, mutations of p53 are 
the most common genetic changes found in human neoplasms which suggest 
that the same critical pathway for controlling growth is disrupted in cancers 
of many different tissues.
In a variety of human tumours, a missense mutation occurs in one p53 
allele resulting in an abnormal protein being produced, and the second allele 
is lost, due to deletion or recombination events. This has been demonstrated 
in tumours from many tissues including colon (Baker et al., 1989), breast 
(Prosser et al., 1990), stomach (Tamura et al., 1991), brain (Nigro et al., 1989), 
liver (Bressac et al., 1991; Hsu et al., 1991) and lung (Iggo et al., 1990). 
Individuals with Li-Fraumeni syndrome inherit p53 mutations producing an 
altered protein, and are at risk of developing multiple, independent cancers 
during their lifetime (Li, 1988). The abundance of missense mutations inp53 
suggests that there may be selection for an abnormal protein conferring a 
growth advantage to the tumour cells.
These mutations do not occur at random, but are clustered in the four 
regions of the gene most highly conserved in different species (Soussi et al.,
1987), indicating that these amino-acids are essential for normal function of 
the protein. Certain codons within these regions also appear to be "hot-spots" 
for mutation, and for different tissues particular mutational hot-spots appear 
to be prevalent (Levine, 1992). For example codon 175 mutants are most 
frequently found in human colorectal tumours (Baker et al., 1990), whereas 
codon 249 is most frequently mutated in human hepatocellular carcinomas 
from China and South Africa (Bressac et al., 1991; Hsu et al., 1991). This 
difference may be due to the environmental carcinogens to which particular
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tissues are exposed, for example the p53 mutations in the liver have been 
attributed to aflatoxin Bl exposure, whereas different carcinogens would be 
most likely to act in the colon. The different abnormal proteins produced 
appear to have distinct biochemical properties and may act by only stimulating 
growth in a particular cell type or tissue (reviewed by Vogelstein and Kinzler, 
1992).
It is of interest to note here that although p53 alterations, similar to 
those found in human hepatocellular carcinomas, have been observed in 
chemically induced liver cancer of the rat (Lilleberg et al., 1992), in the mouse 
no p53 mutations have been detected in chemically-induced liver tumours 
(Goodrow et al., 1992; Kress et al., 1992; Davies et al., 1992). This suggests 
that other critical pathways for growth control are important in the mouse, 
and may question the ability of this rodent to detect human liver carcinogens.
In the last decade several candidate tumour suppressor genes have been 
identified, with a variety of cellular functions and which are implicated in a 
variety of human cancers (Table 1.2.). Loss of gene function may occur both 
as the initiating event (e.g. APC in colorectal cancer) and as a late event 
leading to more aggressive tumour states (e.g. p53 in colorectal cancer).
It is also possible that heritable alterations in the level of gene 
expression may occur by mechanisms not involving DNA damage. Methylation 
of cytosine is involved in the regulation of transcriptional activity (Holliday,
1989); hypermethylation is associated with non-expression, hypomethylation 
with expression. Feinberg and Vogelstein (1983a) have observed 
hypomethylation of ras oncogenes in human tumours, but not in surrounding 
normal tissue. Further evidence for the possible role of methylation in
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Tumour
suppressor gene
Neoplasm Function Location
RB Retinobastoma, 
osteosarcoma, 
carcinoma of breast, 
lung, bladder
Transcription
factor
13ql4
p53 Astrocytoma, 
carcinoma of breast, 
colon, lung, liver, 
brain, stomach, bone, 
ovary, lymphoid 
tumours
Transcription
factor
17pl3
WT1 Wilms' tumour Transcription
factor
1 lpl3
APC Colon carcinoma G-protein
activation?
5q21
DCC Colon carcinoma Cell
adhesion- 
communicat ion
18q21
MCC Colon carcinoma G-protein
activation
5q22
NF1 Neurof ibromatos is GAP related 17qll.2
PTP Renal cell carcinoma Protein-
tyrosine
activation
3p
This is not an exhaustive list; other tumour suppressor genes have been 
located, but not yet cloned.
Table 1.2. Tumour suppressor genes found in human neoplasms
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carcinogenesis is provided by the drug azacytidine which can reactivate 
previously silent genes by inhibition of methylation. Although thought to be 
non-mutagenic, azacytidine is a potent carcinogen inducing a variety of 
tumours in rodents (Holliday, 1989).
1.4. Environmental Mutagens and Carcinogens
It has been estimated that between 60%-90% of human cancers are 
attributable to environmental factors used in its broadest sense to include 
radiation, diet, tobacco smoking and occupational exposure (Perera and 
Boffetta, 1988), and thus would be prevented by elimination of the causative 
factors. Tomatis (1988) has suggested that in Europe a reduction of cancer 
incidence is possible, in theory, from the present maximum rates of between 
330 and 240 per 105 per annum to rates between 164 and 105 per 105 per 
annum. This reduction would not be limited to cancer, other human diseases 
to which mutation contributes could also be reduced, although perhaps not to 
such a dramatic extent. However, it should be noted that the occurrence of 
cancer is not uniformly spread across the population, and that other factors, 
such as genetic susceptibility (Lehmann and Norris, 1989; Schull, 1991) must 
be included in any assessment before the contribution of environmental factors 
to risk in the population at large can be estimated.
Evidence for the involvement of chemical agents in at least some stages 
of the carcinogenic process originally came from epidemiological data. As far 
back as 1775 Percival Pott noted that chimney sweeps had a high incidence of 
cancer of the scrotum which he attributed to exposure to soot. The first 
chemical mutagen to be identified was mustard gas (Auerbach and Robson,
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1946) although its carcinogenic properties were only later recognised from 
epidemiological studies on lung cancer in workers in a Japanese mustard gas 
factory after World War II (Wada et al., 1968).
Although some cancers are clearly due to high level exposure to a single 
chemical or industrial process, life-time exposure to low-levels of a variety of 
chemicals, both man-made and natural, present in our environment is more 
relevant to the majority of neoplastic diseases (Clayson, 1987). The 
identification of such agents is thus difficult, for example 40 known or 
suspected rodent carcinogens have been found in a total of 700 organic 
chemicals present in US drinking water (Perera and Boffetta, 1988) and 16 
rodent carcinogens have been identified in roasted coffee beans (Ames et al., 
1990). However, Ames et al. (1990) have pointed out that nearly all vegetable 
and fruits consumed by man contain many natural mutagenic chemicals, and 
suggest that low concentrations of mutagens or carcinogens may not be as 
hazardous as is generally thought. Animal defence mechanisms probably 
adequately cope with low doses of most chemicals, and Ames et al. suggest that 
it is exposure to high doses relative to the toxic dose that is important in 
assessing carcinogenic potential.
The International Agency for Research on Cancer (IARC) has identified 
over 30 chemicals or chemical mixtures as being established human 
carcinogens (Table 1.3.) (IARC, 1987); the majority of these compounds are 
also mutagenic. There are however exceptions, for example asbestos fibres 
inhaled into the lung remain lodged to cause prolonged irritation and cellular 
effects which can lead to cancer of the pleural cavity. Hormones such as
21
oestrogen may act by interfering with regulation of cell growth and 
differentiation (Shelby, 1988; Weisburger and Williams, 1989).
Cancer is a multistep process (Weinberg, 1989), divided into at least 
three stages: initiation, promotion and progression. Tumours appear to arise 
from the clonal expansion of a single cell in which a mutation has occurred 
which allows limited expansion of the progeny of this cell. Subsequent 
sequential mutations in growth regulatory genes in cells within this clone 
allows selection of sub-clones with faster-growing characteristics, until 
sufficient mutations have accumulated to make the tumour malignant (Nowell, 
1976). In human colorectal cancer at least four mutations have been found at 
various stages of tumour development (Fig.1.1.), and mutations in more than 
one gene have been detected in tumours of other tissues. In cancers of 
epithelial cells the initiating event appears to involve loss of a tumour 
suppressor gene controlling a critical pathway for cell growth (Vogelstein and 
Kinzler, 1993).
Chemicals inducing gene or chromosome mutations are known to act 
during both the initiation and progression stages; mutations in many different 
genes may be required for full malignancy to develop (Bishop, 1988). Although 
some chemicals can act as complete carcinogens, many initiating agents, 
particularly at low doses, require subsequent repeated exposure of the tissues 
to promoting agents to produce tumours (Dotto et al., 1985). Tumour 
promoters do not alter DNA, but may stimulate cell division allowing 
subsequent mutations in a subpopulation of the growing initiated cells 
(Hennings et al., 1983). Thus cancer development is a complete process
22
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involving both irreversible (mutation) and reversible reactions with chemical^ 
agents and ideally both classes of chemical should be identified.
1.5. Screening for Chemical Carcinogens and Mutagens
If a chemical can be shown to cause cancer in humans, then it can be reliably 
classified as a human carcinogen. However, classification is not that simple; 
epidemiological studies have identified only about 30 chemicals and 11 
industrial processes that are causally related in human cancer (Tables 1.3 and 
1.4.) (IARC, 1987). Such studies are disadvantaged by only detecting agents 
after the clinical onset of cancer which might have a long latent period for 
development, approximately 20 years for many carcinogenic agents, and are 
limited by uncertain, mixed exposures.
Thus animal bioassays are required by most food and drug regulatory 
authorities for the prediction of the safety of new chemicals for human use or 
consumption. The use of animal bioassays are however also disadvantaged. 
The high cost of a single test, about £700,000, the time taken (3 years) for the 
results to be obtained, the difficulties in extrapolation of results in rodent 
species to the human situation, and the ethical problems of using animals, 
must all be considered when testing for potential human carcinogens.
It is usually required (OECD, 1983) that chemicals be tested in two 
species (male and female) to the maximum tolerated dose (MTD). In practice 
usually rats and mice are the species of choice. However consideration must 
be given to possible differences in metabolism between the chosen species and 
man. For instance, phenobarbitone is a potent inducer of liver tumours in 
mice (Evans et al., 1986), but epidemiological evidence of its use in humans
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Carcinogenic agent_______________
4-aminobiopheny1
Phenacetin-containing analgesics
Azathioprine
Benzene
Benzidine
Bis(chloromethyl)ether 
Chlornaphaz ine 
Myleran
MOPP (combined chemotherapy)
Chlorambucil
Cyclophosphamide
Diethylstilbestrol
Melphalan
Mustard gas
2-Naphthylamine
Coal tars and pitches
Soots
Mineral oils 
Shale oils 
Treosulphan 
Vinyl chloride
1-(2-chloroethyl)-3(4-methyl 
cyclohexyl)-1-nitrosourea 
Oestrogens, non-steroidal 
Oestrogens, steroidal 
Oral contraceptives, combined 
Oral contraceptives, sequential 
Arsenic compounds 
Asbestos
Chromium compounds (hexavalent) 
Methoxsalen + UV 
Nickel and nickel compounds 
Talc containing asbestiform 
fibres
Target organs__________________
Bladder
Renal pelvis, bladder
Lymphoma
Leukaemia
Bladder
Lung
Bladder
Leukaemia
Leukaemia
Leukaemia
Bladder, leukaemia
Cervix, vagina, breast
Leukaemia
Lung
Bladder
Skin, lung, bladder
Skin, lung
Skin
Skin
Leukaemia
Liver, lung, brain, lymphatic 
and haematopoietic systems 
Leukaemia
Cervix, vagina, breast
Endometrium
Liver
Endometrium 
Skin, lung
Lung, pleura, peritoneum
Lung
Skin
Nasal sinus, lung 
Lung
Table 1.3. Chemical agents classified as IARC Group I human carcinogens 
(IARC. 1987)
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Industrial process Target organs
Aluminium production Lung, bladder
Auramine manufacture Bladder
Boot and shoe manufacture Leukaemia, nasal sinus
Coal gasification (older processes) Skin, lung, bladder
Coke production Skin, lung, kidney
Furniture making Nasal sinus
Haematite mining (radon) Lung
Iron, steel and steel founding Lung
Isopropyl alcohol manufacture Nasal sinus
Magenta manufacture Bladder
Rubber industry Bladder, leukaemia
Table 1.4. Industrial processes classified by IARC (1987) as being 
causally related to human cancer
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over long periods suggest that it is not a human carcinogen (Clayson, 1987)., 
Differences in the pharmacokinetics, metabolism and DNA-repair processes 
will influence species and tissue-specific susceptibilities of a chemical to induce 
cancer. Analysis of the US National Toxicology Program (NTP) database for 
222 chemicals tested in both mice and rats showed a concordance for 
carcinogenicity of about 77% between the two species (Ashby and Tennant,
1988). This illustrates the difference in response between species, even closely 
related ones, and the predictive value from rats, or mice, to humans would be 
expected to be less than 77%. In addition, the high cost of animal bioassays 
means that the lowest possible number of animals are used, and experiments 
are not normally repeated, resulting in statistical limitations in analysing the 
data from such studies.
Recently the administration of chemicals to the MTD has been 
questioned (Clayson, 1987; Ames and Gold, 1990). Clayson (1987) has 
described MTD as "the highest dose that does not lead to deterioration in the 
animal’s clinical condition, nor lead to more than a 10% reduction in body 
weight gain". He suggests that studies to define MTD are often too short for 
adverse reactions to be assessed, and there may be undetected tissue-specific 
toxicity which could affect tumour development, such as increased cell 
proliferation and interference with homeostatic control mechanisms, that 
would not be clinically apparent. Stimulation of cell division by high doses 
may account for the large numbers of chemicals which are positive in animal 
bioassays, about half of those tested, and might explain the low concordance 
between animal data and short-term tests for genotoxicity (Ames and Gold,
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1990). These authors cite among the reasons to suspect mitogenesis of 
increasing cancer rates:
that dividing cells allow the fixation of mutations 
during cell division single-stranded DNA is more sensitive to damage 
cell divisions allows mitotic recombinational events and non-disjunction, 
known to be important for the loss of tumour suppressor genes 
cell division can increase the expression of myc and fos oncogenes 
cell division allow demethylation of cytosine in DNA
Thus the toxic properties of a chemical may play an important role in 
the induction of tumours during bioassays for carcinogenicity.
When the first test for mutagenicity was developed by Muller in 1927 
using Drosophila the major concern was for the detection of mutagens that 
were capable of damaging germ cells, and increase the burden of inherited 
disorders. Testing for mutagenicity and carcinogenicity were initially treated 
as separate areas of research (Sobels, 1987). However, later the apparent role 
of mutation in the carcinogenic process became recognised, and a 2-stage 
model of carcinogenesis was proposed consisting of initiation (caused by a 
mutation), followed by promotion to full malignancy. The involvement of 
mutation was supported by a report by McCann et al. (1975) that showed the 
Ames Salmonella assay to correctly identify 90% of carcinogens and 87% of 
non-carcinogens tested. As more chemicals were studied it became apparent 
however that the percentage of rodent carcinogens positive in in vitro assays 
for genotoxicity was declining. This led to the introduction of yet more short­
term tests, with diverse endpoints, in the hope of identifying those chemical
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carcinogens not positive for classical mutational endpoints. Over 200 short­
term tests have been reported (Waters et al., 1986). The potential advantages 
of in vitro tests over animal bioassays are the enormous savings in cost and 
time: in vitro assays cost between 1% and 10% of animal studies and take only 
days or weeks to obtain results.
However, it is now apparent that not all carcinogens are mutagenic in 
in vitro tests, and conversely some compounds exhibiting in vitro mutagenicity 
may not be rodent carcinogens. In an NTP study, 73 chemicals previously 
tested in 2-year rodent carcinogenicity studies, were tested for mutagenicity 
in four in vitro assays (Tennant et al., 1987). The in vitro tests used were: the 
Ames test, chromosome aberrations and sister chromatid exchanges in Chinese 
hamster ovary cells, and mutation at the thymidine kinase locus of mouse 
lymphoma, L5178Ytk+/‘, cells. The concordance for all four tests with rodent 
carcinogenicity was about 60%. The summarized results of Tennant et al., 
(1987) are given in Table 1.5. The overall outcome was that no group of tests 
was any better than a single test alone at predicting rodent carcinogenicity. 
The four tests appeared to divide into two groups: the Ames test and 
chromosome aberrations detected less carcinogens but also correctly identified 
more non-carcinogens, whilst sister chromatid exchanges and the L5178Ytk+/' 
assay identified more carcinogens but also found more non-carcinogens to be 
genotoxic. However, as discussed earlier, the mouse carcinogenicity assay was 
not much better at predicting rat carcinogenicity (or vice versa) than the in 
vitro tests for genotoxicity.
There are many reasons why a chemical exhibiting mutagenicity may 
not be carcinogenic, or a carcinogen may be negative in short-term tests. No
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SAL ABS SCE TX
Measure + + + 4-
Carcinogens 20 24 24 20 32 12 31 13
Non-carcinogens 4 25 9 20 16 12 31 13
Sensitivity (%) 45 55 73 70
Specificity (%) 86 69 45 45
Positive predict (%) 83 73 67 66
Negative predict (%) 51 50 52 50
Concordance (%) 62 60 62 60
SAL, Salmonella; ABS, 
SCE, sister chromatid 
TK, L5178Ytk+/'.
chromosome 
exchanges;
aberrations
Sensitivity = no. carcinogens positive
no. carcinogens tested 
Specificity = no. non-carcinogens negative
no. non-carcinogens tested 
Concordance = (no. carcinogens +ve) + no. non-carcinogens -ve)
total chemicals tested
+ , positive in the in vitro test.
-, negative in the in vitro test.
Table 1.5. Comparison of rodent carcinogenicity and in vitro 
qenotoxicity (Tennant et al♦, 1987^
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in vitro assay is capable of mimicking the conditions in the animal in relation 
to absorption, pharmacokinetics or metabolism. Since most chemicals require 
metabolic activation to the ultimate reactive species (Li, 1984), a source of 
exogenous enzymes is supplied in in vitro tests. This is usually in the form of 
a chemically-induced rodent liver microsome preparation supplemented with 
co-factors (S9 mix). Since the activating enzymes are induced at the expense 
of detoxifying enzymes, the possible detoxification processes that may prevail 
in vivo are ignored (Douglas et al., 1988). In addition, some compounds are 
activated by enzymes not present in the supplement, for example 
dichloroethane reacts with glutathione (Rannug et al., 1978), and cycasin is 
reduced by fi-glucosidase produced by the microbial flora of the gut (Laqueur, 
1968). Many carcinogens are organ or tissue specific which may be due to 
differences in levels of metabolic enzymes, to transport of the chemical to 
particular organs, or to differences between tissues in DNA-repair capabilities. 
In a rodent carcinogenicity bioassay over 30 different tissues may be examined 
post mortem, whereas in in vitro tests for genotoxicity only one cell type is 
usually used, which may even be a single-celled organism, as in the Ames test.
Some compounds have been classified as non-genotoxic carcinogens, that 
is, they are not mutagenic. However, Heddle (1988) has suggested that a 
carcinogen should not be classified as non-genotoxic until it is shown in vivo 
that no damage to DNA has occurred. Indeed, classical mutational endpoints 
used in in vitro assays do not detect certain types of DNA changes seen in 
cancer, such as amplification and hypomethylation of oncogenes (reviewed by 
Ramel, 1988). The use of molecular biology techniques may in the future 
provide answers to some of these uncertainties. However, there does appear
31
to be a correlation, although not perfect, between genotoxicity and the ability, 
of a chemical to cause multiple-site cancers in both sexes of mice and rats. In 
contrast, non-genotoxic carcinogens tend to be site-, sex- and species-specific 
(Ashby et al., 1989).
It is estimated that over 50,000 chemicals are at present marketed with 
500 new chemicals added each year (Bingham, 1988). About 2,000 chemicals 
have been tested for rodent carcinogenicity, and about 20,000 chemicals have 
been tested in at least one in vitro test (ICPEMC, 1988).
In vitro assays are also useful in the study of complex mixtures, for 
example from cigarettes, foodstuffs, water, car exhausts, when fractionated 
extracts are tested for mutagenicity and the appropriate fractions then 
analysed chemically (DeMarini et al., 1989a). They have also been used for the 
identification of antimutagens (Ames, 1983) and for monitoring body fluids 
from human populations (Venitt, 1987). At present, in vitro tests for 
genotoxicity still have an important role to play in screening for genotoxic 
carcinogens, and chemical mutagens which may be implicated in human 
diseases other than cancer.
1.6. The in vitro assays for genotoxicity
In vitro tests for genotoxicity are usually employed as the first stage of 
screening new chemicals for carcinogenic potential. The UK Department of 
Health, Committee on Mutagenicity guidelines (1989) currently recommend 
that "information on gene mutation, chromosome mutation and aneuploidy are 
provided". The guidelines suggest that a bacterial gene mutation assay and a 
test for clastogenicity (chromosome breakage) are usually sufficient, except in 
cases of sustained and/or extensive human exposure when a third test, namely
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gene mutation in mammalian cells, should also be included. A brief description, 
of these tests is given below.
1.6.1. Bacterial gene mutation assays
The most widely used is the Ames test which detects reverse mutations in 
genetically engineered strains of Salmonella typhimurium (Maron and Ames, 
1983). The strains have been constructed to detect either base-pair or frame- 
shift mutations in specific DNA sequences at the histidine locus, and 
revertants are able to grow without added histidine in the nutritive agar. The 
bacteria are repair-deficient and have mutations making the cell wall more 
permeable to chemicals; two strains also carry a plasmid (R-factor) that 
enhances mutagenesis. Usually 5 strains are used, but strains sensitive to 
oxidative damage are also available.
The criticisms of the Ames test (Williams and Weisburger, 1988) have 
been the lack of xenobiotic-metabolising ability of bacterial cells, and the 
possible over-sensitivity of the DNA due to the lack of a nuclear membrane 
protecting the genetic material. Cytotoxicity is difficult to quantify, as is 
mutant frequency since the standard assay counts the number of mutants per 
plate, not as a fraction of the surviving population.
1.6.2. Chromosome aberration tests
Chromosome aberrations are structural changes that are cytogenetically 
visible. Cells, human blood lymphocytes or mammalian cell lines, are treated 
with the potential genotoxin, then arrested at metaphase using a spindle 
inhibitor and harvested for analysis. Stained preparations of metaphase 
chromosomes are condensed and visible under the light microscope.
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Chromosome aberrations may be produced by a number of mechanisms, 
including direct DNA strand breakage and breakage during DNA repair, but 
the common endpoint is a discontinuity in the chromosome (Baan, 1987). This 
is seen as loss of part of the chromatid or chromosome or as rearrangements 
of varying complexity due to inaccuracies in repairing the breaks (Bender et 
al., 1974). Most of the visible damage will be lethal to the cell due to the gross 
loss of genetic information or because the chromosomes are unable to divide 
during mitosis. Chromosomal aberrations are however used as an indication 
that more subtle damage has also occurred, such as small deletions and 
balanced translocations, that are compatible with cell viability (Scott et al.,
1990).
Tests for chromosome aberrations are more expensive than assays for 
gene mutations due to the time and skill required for scoring karyotypes. 
They do however detect chromosome damage over the entire genome, and 
certain rodent carcinogens negative in the Ames test are reported to induce 
chromosome aberrations (Ishidate et al., 1981).
A simpler test, involving the scoring of micronuclei is also used to detect 
chromosome damage. Micronuclei arise from acentric fragments of broken 
chromosomes and whole chromosomes that due to damage are unable to 
attach to the spindle apparatus, and are lost from the nucleus during cell 
division (Baan, 1987). The induction of micronucleated cells is used as an 
indication of previous chromosome aberrations (Heddle et al., 1983).
1.6.3. Mammalian gene mutation assays
The mutations most commonly used to study gene mutation in mammalian 
cells are deficiencies in enzymes involved in the salvage pathways for purines
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and pyrimidines (Cole et al., 1990). Since these nucleotide bases can be; 
provided by de novo synthesis, the salvage enzymes are not essential for 
survival of cells in culture. Selection of mutants deficient in a salvage enzyme 
is made by using the appropriate toxic base analogues which are incorporated 
only into non-mutant cells which have a functional enzyme, thus causing cell 
death.
The most used test systems are resistance to 6-thioguanine (6TG) due 
to lack of hypoxanthine phosphoribosyl transferase (HPRT) activity (Chu, 
1983), and resistance to trifhiorothymidine (TFT) due to lack of thymidine 
kinase (TK) activity (Clive et al., 1979). These systems are dealt with in more 
detail elsewhere in this thesis. Mutational changes in cells hemizygous (single 
copy) or heterozygous (two copies but only one active) for these genes are 
usually studied, to enable loss of enzyme function to occur in a single step. As 
discussed later however, it appears that hemizygous and heterozygous genes 
detect a different range of genetic damage (DeMarini et al., 1989b).
In contrast resistance to the cardiac glycoside ouabain occurs as a semi­
dominant mutation in one of the two functional alleles present in the cell. 
Only point mutations that allow binding of ouabain to the cell membrane 
Na+/K +ATPase enzyme without affecting membrane transport are measurable 
at this locus, since larger changes result in loss of the essential function of the 
enzyme (Muriel et al., 1987).
The inclusion of mammalian cell assays for gene mutation in screening 
for potential carcinogens is considered relevant (Arlett and Cole, 1988) since; 
a) these cells are more complex than bacteria, and b) a few chemicals have 
been shown to be positive in mammalian gene mutation assays but negative 
in both bacterial gene mutation assays and tests for mammalian cell
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clastogenicity. Unlike bacterial gene mutation assays, mammalian systems, 
allow quantification of mutant frequency (i.e. mutants per surviving cells), and 
are not confined to changes in only certain gene sequences but measure 
forward mutations throughout the DNA of the selected gene (Williams and 
Weisburger, 1988).
1.7. Aims of the present study
In view of the increase in understanding the role played by mutation in the 
activation of oncogenes and inactivation of tumour suppressor genes, the 
question that must be addressed is 'Which in vitro tests are the most relevant 
to the changes associated with carcinogenicity?"
With perhaps the exception of cell transformation assays, (which have 
given rather inconsistent results), none of the in vitro test systems employs 
an endpoint which is itself of intrinsic toxicological interest, or of known 
significance in terms of carcinogenesis. The Ames test detects only point 
mutations in specific sequences of the histidine locus of a prokaryotic genome. 
Chromosome aberration tests score only gross chromosome changes at least 
50% of which are not viable (Arlett and Cole, 1988). Mammalian cell mutation 
assays are based on phenotypic changes and take no account of the mutational 
events that have occurred in the gene.
Analysis of mutations at the molecular level allows comparison of the 
types of genetic damage detected by different mutations assays. In addition 
a greater knowledge of the range of DNA changes induced by different 
chemicals in mammalian cells may allow a more accurate prediction of their 
toxicological effects.
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The present study was undertaken to compare the range of DNA 
damage detected in the HPRT assay in Chinese hamster lung, V79, cells and 
in the TK assay using mouse lymphoma, L5178Y, cells. Two chemicals 
differing in the types of genetic lesions that they produce were used to induce 
mutation : ethyl methanesulphonate, a potent point mutagen but 
comparatively weak inducer of chromosomal damage, and mitomycin C, a weak 
inducer of point mutations but a potent clastogen.
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CHAPTER 2 
MATERIALS AND METHODS
All chemicals used were of the highest quality available, usually Analar grade 
or higher. Bench chemicals were obtained from Fisons Scientific Equipment 
or Sigma Chemical Co. Ltd. unless otherwise stated, and fine chemicals and 
biological materials purchased from Gibco BRL and BCL (Boehringer Corp. 
Ltd) unless indicated differently.
2.1. The test chemicals
2.1.1. Introduction
Assessment of the carcinogenic potential of a chemical using in vitro 
mammalian cell culture assays is usually measured as the ability of the 
compound to damage DNA, detected as selectable gene mutations, or as 
chromosome aberrations. These two endpoints are usually considered to arise 
by independent mechanisms (Kao and Puck, 1969; Natarajan et al., 1984) and 
a chemical may be more responsive to one end point than the other. This may 
be due to different patterns of reactions with DNA, resulting in some lesions 
which may be more efficient at breaking chromosomes, whilst other lesions 
may be more likely to result in point mutations (Jensen and Thilly, 1986; 
Natarajan et al., 1984). Furthermore some chemicals cause chromosome 
breakage by mechanisms which do not involve direct interaction with DNA. 
Such mechanisms have recently been reviewed by Scott et al. (1991) and 
include inhibition of the enzymes involved in DNA synthesis or repair 
(DeMarini et al., 1987), imbalances in DNA precursor pools (Kunz, 1988) and 
the production of oxygen radicals (Meneghini, 1988).
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2.1.2. Ethyl methanesulphonate (EMS)
CH
O
II
S C,H
EMS is a direct-acting mutagen in both prokaryotic and eukaryotic cells 
(van Zeeland, 1988) and a carcinogen in rodents (Bartsch et al., 1983). As a 
monofunctional alkylating agent, EMS donates a single ethyl group to reactive 
nucleophilic sites within DNA, mainly at N and O atoms in bases, but also at 
O atoms within the phosphodiester backbone (Singer, 1983). Although 
alkylation of the N-7 site of guanine is the major reaction product, the 
Opposition of guanine (which is involved in hydrogen-bonding between base 
pairs in DNA), appears to be the primary mutagenic lesion (Heflich et al., 
1982). The product 0 6-ethylguanine, can mispair with thymine, resulting in 
GC to AT transitions on DNA replication (Figure 2.1.). Repair of the lesion is 
by removal of the ethyl group by the enzyme 0 6-ethyltransferase.
Although EMS is considered to be primarily a point-mutagen, due to its 
low toxicity at doses which induce a high frequency of point mutations, EMS 
is also capable of causing structural chromosome damage. The mechanisms 
by which EMS induces chromosome aberrations is unclear; some studies have 
suggested a role for 0 6-ethylguanine (Asita, 1989), while other investigations 
have implicated different lesions, including N7-ethylguanine and apurinic sites 
(Natarajan et al., 1984). Breaks in DNA may occur during excision repair of 
the lesion or by inhibition of DNA replication by the alkylation product.
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a) The Opposition of guanine normally hydrogen bonds with cytosine in 
double stranded DNA.
b) Ethylation of the Opposition prevents normal base-pairing. Instead 
guanine base-pairs with thymine..^
Figure 2.1. Mispairing of 0G-ethylguanine.
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2.1.3. Mitomycin C (MMC)
Mitomycin C is an antibiotic and antitumour agent used in cancer treatment. 
It is a weak mutagen in bacterial (McCann et al., 1985) and mammalian cells 
(Jensen and Thilley, 1986), causes chromosome aberrations (Jensen and 
Thilley, 1986) and is a rodent carcinogen (Weisburger et al., 1975).
Mitomycin C is capable of acting as both a monofunctional and 
bifunctional alkylating agent. The O6- and N2-positions in guanine have been 
implicated as the main sites in DNA for monofunctional binding of MMC 
(Dusre et al., 1989; Tomasz et al., 1988). The involvement of a 0 6-guanine- 
MMC monoadduct in the mutagenic activity of the compound is supported by 
the finding that cell lines deficient in 0 6-alkyltransferase are more sensitive 
to MMC than cell lines possessing this repair enzyme (Dusre et al., 1989).
The potent chromosome breaking ability and cytotoxicity of MMC is 
attributed to its bifunctional activity. Two-electron reduction of MMC 
involving first the loss of the methoxy group at Cl and then the carbamoyl 
group at CIO, results in its ability to crosslink DNA. Tomasz et al. (1988) have 
shown that the N2-position of guanine is the functional site that reacts with 
MMC (Figure 2.2.) and Teng et al. (1989) have demonstrated the preference 
of MMC for CpG sequences as sites for interstrand crosslinking, and GpG 
sequences to be involved in intrastrand binding.
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Figure 2.2. The crosslinking reaction of mitomycin C and guanine bases in 
DNA
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When both DNA strands are crosslinked by MMC, excision repair cannot, 
use the complementary strand to copy the correct sequence, thus damage can 
only be corrected by recombinational repair using the second, homologous 
chromosome, if present. Crosslinking also causes double-strand breaks in 
DNA, either by a direct weakening of the sugar-phosphate backbone or 
indirectly by enzymic strand breakage during repair processes. Double-strand 
breaks play a major role in the induction of chromosome aberrations.
2.2. The HPRT mutation assay in V79 cells
2.2.1. Introduction
The protocol used for this study was essentially as described by O’Donovan 
(1990) for the 3rd UKEMS Collaborative Trial. As with most mammalian cell 
assays which detect forward mutation at a specific locus, V79 cells are treated 
with the test chemical, then cultured for a sufficient time to allow the fixation 
and expression of any induced mutations. During this period constitutive 
levels of enzyme and mRNA in cells mutated at the hprt locus will be 
eliminated by degradation and dilution at successive cell divisions. Selection 
of HPRT-deficient cells then takes place using a chemical agent, 6-TG, that 
allows only the mutant cells to grow.
2.2.2. The V79 cell line
This cell line was originally derived from mature, male Chinese hamster lung 
by Ford and Yerganian (1958). The cells used in this study were obtained 
from Flow Laboratories in 1985 as V79379A, which is a subclone of V79-1. Cell 
stocks had been frozen under liquid nitrogen, and a new ampoule was removed 
for each mutation assay. The cells had a doubling-time of about 12 h, and a
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cloning efficiency of 83-90% when grown in Dulbecco’s modified Eagles, 
medium (DMEM) supplemented as described below. The modal chromosome 
number was 22 ± 1.
2.2.3. Culture conditions
The cells were grown as monolayers in DMEM (Gibco, Cat. No. 041-1965)
Hi)
supplemented with 5%^heat-inactivated foetal calf serum (Tissue Culture 
Services), 2 mM L-glutamine, 100 U/ml penicillin and 100 fig/ml streptomycin 
(growth medium). The serum had been previously tested for its ability to 
support optimal growth of the cell line; the same serum batch was used for all 
experiments.
Cultures were maintained at 37°C in an atmosphere of 5% C02 in air
and at maximum humidity.
At subculture cells were detached from the surface of the polystyrene
culture flasks by trypinisation. The growth medium was removed from the
Mj) ^/A
cultures and 5 ml of a 0.025%. trypsin/0.01%.EDTA solution was swirled over
A A
the surface of the cells and aspirated off using a vacuum pump. The cultures 
were incubated at 37 °C for about 2 min or until the cells began to detach from 
the surface of the culture vessel, then 10 ml of fresh medium was added and 
the cells were suspended by gentle aspiration with a siliconised Pasteur 
pipette.
Cells were counted using an electronic particle counter (Coulter 
Counter, Mode Dn). The mean of 3 aliquots of a cell suspension was used to 
estimate a cell population.
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2.2.4. The HPRT mutation assay 
A scheme for the protocol used is given in Figure 2.3.
2.2.4.1. Preparation o f cell cultures
Twenty-four hours (Day -1) prior to treatment V79 cells in the exponential 
growth phase were trypsinised and their number estimated. This cell 
suspension was used to seed 175 cm2 flasks containing 40 ml DMEM growth 
medium, each with 2 x 106 cells and incubated overnight.
2.2.4.2. Preparation o f test agents
EMS: a stock solution of 5 mg/ml EMS (Sigma, Cat. No. M0880) was prepared 
by weighing out 100 mg of EMS and dissolving in 20 ml DMEM without 
serum. Bottles, each containing 20 ml DMEM without serum, were prepared 
containing appropriate aliquots of the stock EMS solution to give 0, 100, 200, 
500 or 1000 jug/ml EMS. Duplicate bottles were prepared for each 
concentration.
MMC: a stock solution of 1 mg/ml MMC (Sigma, Cat. No. M0505; 2 mg MMC, 
48 mg NaCl) was prepared by adding 2 ml phosphate-buffered saline (Dulbecco 
’A’; PBS(A)) to the vial containing solid MMC. After fully dissolving the 
powder the solution was removed and further diluted 1 in 10 in DMEM 
without serum to give a stock solution of 100 /xg/ml. PBS(A) was used in the 
initial step to ensure complete dissolution of the solid. Duplicate bottles were 
then prepared containing 0, 0.0625, 0.125, 0.25 or 0.5 /xg/ml MMC in 20 ml 
DMEM without serum.
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Duplicate cultures 
at 2 x 106 cells
I
incubated 24 h
i
Treated with mutagen 
for 3 h. Washed and 
respread
cytotoxicity
estimate
(2 x 102/dish)
maintenance
(106/flask)
incubated 
3 days
respread (106/flask)
cloning efficiency 
(2 x 102/dish)
selection of 
mutants in 6-TG 
(1 x 10s/dish)
selection of 
wild-type in 
HAT (50/dish)
4
expansion of 
isolated clones 
for nucleic acid 
analysis
Figure 2.3. Protocol for the HPRT mutation assay in V79 cells.
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Both EMS and MMC were prepared immediately prior to treatm ent o f, 
the cells.
2.2.4.3. Treatment with mutagens
The medium was aspirated from each flask which had been prepared the 
previous day and replaced with the contents of one of the bottles containing 
the test solutions. The flasks were incubated for 3 h and then the medium 
was removed and the cells washed in DMEM growth medium. The cells were 
trypsinised and suspended in 10 ml DMEM growth medium for each flask and 
their numbers estimated.
2.2.4.4. Estimation of cytotoxicity of the test compounds
The cell suspensions were diluted and 200 cells used to seed 3 x 50 cm2 dishes 
containing 5 ml DMEM growth medium. After 6 days incubation the medium 
was gently removed, the cells stained by gently swirling 5 ml of a 1%^  aqueous 
solution of methylene blue over the colonies and leaving for 60 min. After 
rinsing the dishes several times with tap water they were inverted onto filter 
paper and left to dry overnight at room temperature. Colonies were counted 
by eye.
2.2.4.5. Estimation of mutant frequency
After mutagen treatment 1 x 106 cells were seeded in 175 cm2 flasks containing 
40 ml DMEM growth medium for maintenance. The cells were again 
subcultured at 1 x 106 cells/flask after 3 days to prevent contact inhibition 
between cells.
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Six days after mutagen treatment, which allowed a period for the
fixation and expression of any mutations arising from the treatment, the cells
were trypsinised and counted. Aliquots of each cell suspension, containing
1 x 105 cells were seeded in 90 mm dishes containing 10 ml DMEM growth
tw/<)
medium and 5 /xg/ml 6-TG (made up in 0.5%^sodium carbonate). Five dishes 
were prepared for each cell suspension.
The cloning efficiency of the total cell population was determined by 
plating 2 x 102 cells from each maintenance flask in 3 x 50 mm dishes 
containing 5 ml DMEM growth medium without any selective agent.
Since HPRT-proficient cells were also required for nucleic acid analysis, 
cells were plated at 50 cells per 50 mm dish in DMEM growth medium 
containing 100 /xM hypoxanthine, 16 /xM thymidine and 0.4 /xM aminopterin 
(HAT medium supplement; Sigma Cat. No. H0262). This low seeding density 
in HAT medium allowed the isolation of individual colonies of HPRT+ 
phenotype since mutant cells are unable to grow in HAT medium.
Colonies were counted using an inverted microscope after 7 days 
incubation.
2.2.5. Expansion o f HPRT* and H P R T clones
To isolate individual clones for expansion, the medium was removed from the 
dish and a stainless steel cloning ring was anchored with silicon grease around 
the colony to confine the cells. A drop of trypsin/EDTA solution was used to 
detach the cells, which were removed with a Pasteur pipette to 25 cm2 flasks 
containing 5 ml DMEM growth medium. As their numbers increased, each 
culture was checked in medium containing 6 -TG or HAT, to ensure that they 
had retained the HPRT' or HPRT+ phenotype as appropriate. The cultures
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were then grown without selective agents, with progressive transfer into, 
larger flasks until a population of 5 x 106 cells was obtained. Each culture was 
then pelleted at 500 x g, washed twice in PBS(A) and the cell pellets were 
stored at -70°C.
2.3. The human T-lvmphocvte clonal assay for HPRT m utants
2.3.1. Introduction
The study of somatic mutation in human populations usually involves the 
sampling of peripheral blood cells, since these are the most readily accessible 
cells for analysis. Mutations at the hprt locus that have occurred in vivo can 
be measured by the in vitro cloning of T-lymphocytes in the presence of 6-TG.
T-lymphocytes can be stimulated by the mitogen phytohaemagglutinin 
(PHA) to produce surface antigens and to undergo a limited period of cell 
division (Strauss and Albertini, 1979). The long-term proliferation of the cells 
is possible by the addition of the T-cell growth factor, interleukin-2 (IL-2), 
which allows the cloning of stimulated T-lymphocytes (Paul et al., 1981). The 
presence of feeder cells is also essential for the expansion of T-lymphocytes. 
These sterilised cells may serve several functions (Paul et al., 1981): they may 
provide growth or differentiation factors such as IL-1; they act as filler cells 
where limiting dilutions of T-lymphocytes are to be cloned; feeder cells that 
are immunologically dissimilar to the T-lymphocyte sample may stimulate cell 
division.
The T-lymphocyte clonal assay is carried out in microtitre plates using 
limiting dilutions of cells so that single clones originating from one cell are 
produced in the wells. Viable clones may be identified either by visual 
screening or by uptake of tritiated ([3H]) thymidine. Although [3H] thymidine
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incorporation has been reported by Featherstone et al. (1987) to be a m ore, 
sensitive method for detecting slow growing clones, it was found to give 
unrebable results for mutation plates due to some uptake of [3H] thymidine 
by the 6-TG-inactivated wild-type cells. Morley et al. (1985) reported the 
slightly greater number of positive wells detected by [3H] thymidine 
incorporation, compared with visual scoring, but mutant detection was not 
sufficiently greater to warrant the more expensive and labour intensive 
radioactive method.
For this study viable clones were scored visually using a method based 
on that of Henderson et al. (1986).
To accommodate setting up a large number of assays, blood samples 
were collected over a six week period. Since different production batches 
might introduce experimental errors between assays, all reagents were 
purchased as single batches prior to commencement of the study, and stored 
under the optimum conditions as specified by the manufacturers.
2.3.2. Blood sample collection and lymphocyte separation 
Blood samples were collected by Professor K.R. Butterworth (BIBRA). The 
samples were obtained by venepuncture, mixed with 30 units sodium heparin 
per ml of blood and stored overnight at room temperature.
Mononuclear cells were separated from whole blood by density gradient 
centrifugation, based on the method of Boyum (1968). Briefly, when diluted 
blood is layered on top of a mixture of sodium metrizoate and Ficoll 
(Lymphoprep) at a density of 1.077 g/ml, a biphasic discontinuous density 
gradient is created. Erythrocytes and granulocytes are aggregated by Ficoll
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and sediment at low speed centrifugation, whereas mononuclear cells collect,
at the interface between the Lymphoprep and plasma layers.
The blood sample (10 ml) was mixed with an equal volume of PBS(A)
and carefully layered over 15 ml of Lymphoprep (Nygaard Ltd) in a siliconised
glass centrifuge tube. The tube was centrifuged at 400 x g for 30 min at room
temperature. The monocyte suspension at the interface was carefully removed
with a siliconised pasteur pipette and transferred to a clean tube. The cells
were washed twice in PBS(A) and the mononuclear cells recovered by
centrifugation at 170 x g.
After estimating the cell numbers by counting on haemocytometer slides
under an inverted microscope, the mononuclear cells were resuspended at
106 cell/ml in RPMI 1640 medium (Dutch modification, containing 20 mM
Hepes buffer, 1.0 g/1 NaHC03, 6.4 g/1 NaCl; Flow Labs). The medium was
supplemented with 100 U/ml penicillin (Gibco), 100 ^g/ml streptomycin
C h )
(Gibco), 2 mM L-glutamine (Gibco) and 15%^heat-inactivated foetal calf serum 
(Tissue Culture Services Ltd). Cultures were incubated at maximum humidity 
in 5% C02 in air at 37° C for either 20 or 40 h.
The medium containing non-adhering cells was removed and the 
T-lymphocyte population recovered from it by centrifugation at 170 x g. Viable 
cell numbers were estimated by the ability of living cells to exclude 0.4%(WA/) 
trypan blue.
2.3.3. Preparation of feeder cells
The HPRT' lymphoblastoid cell line, GM1899A, was kindly supplied by Dr J. 
Cole (MRC Cell Mutation Unit, University of Sussex) and was originally from
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the Human Genetic Mutation Cell Repository. Advice on the culture of th is ,
cell line was obtained from Mrs S.E. James (MRC Cell Mutation Unit).
Aliquots of GM1899A were kept frozen in liquid nitrogen at 106 cells/ml
Cv h )
in RPMI 1640 medium supplemented with 209fyfoetal calf serum (FCS) and 
10% dimethyl sulphoxide (DMSO). An ampoule of cells was removed as 
required and rapidly thawed at 37 °C. The cells were washed twice in 
RPMI 1640 growth medium to remove the DMSO that might inhibit growth 
of the cells. The cell line was maintained in RPMI 1640 growth medium at 
densities below 106 cells/ml by subculturing to between 0.5-1.0 x 104/m l every 
3-4 days.
Feeder cells were prepared immediately prior to setting up the cloning 
assays by incubating at a cell density of 106/m l in PBS(A) containing 50 fig/ml 
mitomycin C for 30 min at 37 °C in 5% C02 in air. The cells were then washed
r
three times in PBS(A) and resuspended at 105 cells/ml of growth medium.
2.3.4. T-lymphocyte cloning procedure
Microtiter® plates (96 well, flat-bottomed; Nunc) wer^ inoculated with 100 pd 
feeder cell suspension to give 1 x 104 feeder cells per well. Dilutions of the 
T-lymphocyte samples were prepared as appropriate to give either 2 x 104 per 
well (5 plates/sample, for selection of mutants) and either 2, 5 or 10 cells per 
well (1 plate/sample for each dilution, for the estimation of cloning efficiency). 
One non-selective plate containing only 1 x 104 feeder cells/well was also 
prepared for each set of samples to check the efficacy of the mitomycin C 
treatment. Each well was supplemented with 20 units/ml IL-2 (rIL-2, human 
recombinant; BCL) and 5 /xg/ml purified phytohaemagglutinin (PHA-P; 
Wellcome Diagnostics). Selective plates also received 2.5 /xg/ml 6-TG (made
up in 0.5%^Na2HCO3). Plates were incubated at 37°C in 5% C02 in air and, 
maximum humidity for 16 days.
After the incubation period the wells were scored visually using an 
inverted microscope. Growing colonies appeared as 'buttons" with defined 
outlines, as opposed to the small, irregular clumps of dead and dying cells. 
Only wells containing  colonies of 50 or more pleomorphic cells were considered 
to be positive.
2.3.5. Calculation o f cloning efficiency
Since the division of clones among the wells follows a Poisson distribution, the 
cloning efficiency (CE) can be calculated by the following equation:
- In P0
CE = -------------------------
X
where, P0 is the proportion of negative wells and X is the average number of 
cells plated/well.
Mutant frequency (MF) can be calculated as:
CE selective plates
MF = -----------------------------------------------------
CE non-selective plates
2.3.6. Statistical analysis
The data from the individuals were analysed by Dr D.P. Lovell (BIBRA) using 
similar methods to those of Cole et al. (1988). To determine whether certain 
factors influence mutant frequency, stepwise multiple regression was carried 
out on the logarithmically transformed mutant frequencies using the 
information on the individual’s personal characteristics and life-style habits as 
the dependent variables. Such an approach tries to explain the variation found
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in a set of individuals by differences in the factors. This approach is, as Cole 
et al. (1988) have pointed out, convenient but has the potential to mislead if 
two of the factors are confounded. The statistical significance is, then, 
dependent upon the choice of factors used in the analysis. The untransformed 
mutant frequencies were also used in the analyses and similar results were 
obtained when the data were transformed by logarithms. One-way analysis 
of variance was also used to explore possible differences as a consequence of 
variation in the factors.
2.4. The chromosome aberration test in V79 cells
2.4.1. Introduction
Chromosome aberration tests record gross structure chromosome changes that 
are visible under the light microscope. Cells are usually studied at the 
metaphase stage of cell division (Evans, 1976), since at this phase the 
chromosomes are most condensed, and therefore visible. To obtain as many 
scoreable cells as possible the cultures are arrested at mitosis with a spindle 
inhibitor, usually a derivative of the plant extract, colchicine, which results in 
the cells accumulating at metaphase. Treatment with a hypotonic salt 
solution then causes the cells to swell, and the chromosomes become dispersed 
throughout the cytoplasm so that they he in a single plane when spread on 
microscope slides.
Cells are usually treated with the test chemical while they are in the 
exponential phase of growth to ensure they are in all stages of the cell cycle. 
Most chemical clastogens induce chromosome lesions at all stages of the cycle, 
but the cells must progress through the S-phase, when DNA replication occurs, 
for the lesions to be transformed into aberrations at mitosis. Such chemicals
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are termed S-dependent; if they induce lesions during the Gr  or S-phases,, 
then unrepaired lesions will become chromatid aberrations at the following 
mitosis. Lesions induced during the G2-phase will show as chromatid 
aberrations at the 2nd mitosis after lesion induction. A second, smaller group 
of chemicals are S-independent and do not require the onset of S-phase to be 
expressed as aberrations. These chemicals, e.g. bleomycin, induce detectable 
aberrations at the first metaphase after treatment; chromosome-type 
aberrations result in treatment during G^phase, and chromatid-type 
aberrations from treatment during G2-phase.
It is therefore essential that sufficient time is allowed between 
treatment with the clastogen and harvesting the cells, for the aberrations to 
be expressed. In addition most chemicals at concentrations which are 
clastogenic, will cause cell cycle delay. However, if too many cell cycles are 
allowed between treatment and sampling, aberrations will not be detected, as 
gross structural damage is lethal, and the affected cells will be eliminated from 
the population. Generally cells are harvested 24 h post treatment, which for 
V79 cells with a normal cell cycle time of 12 h, is approximately VA cell cycles, 
allowing for a lag period for the cells to recover after treatment. Additional 
sampling times, on either side of 24 h may also be required to find the 
maximum aberration frequency, particulary if repeat tests are necessary due 
to ambiguous results.
2.4.2. Preparation of V79 cultures
The V79 cell line has been described previously (Section 2.2.2.). The cells were 
cultured in DMEM growth medium and incubated at 37° C in an atmosphere 
of 5% C02 in air and maximum humidity.
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Twenty-four hours prior to treatment 25 cm2 flasks were seeded w ith , 
5 x 105 cells in 10 ml DMEM growth medium and incubated at 37 °C.
2.4.3. Preparation o f test agents
The test agents were prepared immediately prior to dosing.
EMS : a stock solution of 10 mg/ml (Sigma) was prepared by weighing 
out 200 mg EMS and dissolving in 20 ml DMEM without serum. Appropriate 
aliquots of the stock solution were dispensed into sterile bottles to give final 
concentrations of 0, 0.5,1.0 and 2.0 mg/ml EMS, and the volumes made up to 
10 ml with DMEM without serum. Replicate bottles (6) were prepared for 
each concentration. MMC: a solution of 1 mg/ml MMC (Sigma) was prepared 
as previously described (Section 2.2.4.2.), and diluted in DMEM without serum 
to give a stock solution of 50 ^g/ml. Replicate bottles (6) were prepared using 
this solution to contain 0, 0.125, 0.25 or 0.5 /xg/ml MMC in 10 ml DMEM 
without serum.
2.4.4. Chemical treatment
The medium was aspirated from each cell culture and each flask received the 
contents of one of the bottles containing the test solutions. The flasks were 
incubated for 3 h when the medium was removed, 10 ml fresh growth medium 
was added and the flasks were returned to the incubator.
2.4.5. Mitotic arrest and fixation o f cultured cells
After either 6, 22 or 46 h after the start of chemical treatment, duplicate 
flasks for each test concentration received 0.1 ^ig/ml Colcemid (Gibco), and the 
cultures were incubated for a further 2 h. The medium from each flask was
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carefully poured into individual centrifuge tubes, the cultures were trypsinised, 
and the cells added to the appropriate tube. The cells were harvested by 
centrifugation at 170 x g for 3 min. To each cell pellet was added 5 ml of 
freshly prepared 0.07 M KC1 and 0.1 /xg/ml colcemid, and the cells were 
carefully resuspended. After leaving at room temperature for 10 min, the 
tubes were centrifuged at 170 x g for 3 min, and the KC1 solution discarded. 
The cells were resuspended in 3 ml of methanol/acetic acid (3:1 v/v) fixative 
and left to stand for 15 min at room temperature. After centrifugation, the 
cells were recovered and resuspended in 3 ml fresh fixative and kept overnight 
at 4°C.
2.4.6. Preparation and staining o f slides
The cell suspensions in fixative were centrifuged at 170 x g for 3 min, and the 
cells resuspended in 0.1-1.0 ml freshly prepared fixative to give a cloudy 
suspension. Four drops of this suspension were dropped onto clean glass 
slides, 4 slides being prepared per sample. The slides were examined under 
an inverted microscope to check the quality of chromosome spreading and cell 
density. If good spreads were not obtained, the suspension received a further 
fixative wash; if cell numbers were low more suspension was dropped onto the 
slide. The slides were allowed to dry overnight at room temperature.
The chromosomes were stained for 7 min in freshly prepared 2%(v/m)  
Giemsa stain (Difco) made up on warm tap water. The slides were washed in 
tap water, rinsed in distilled water and air dried at 40 °C. When completely 
dry, each slide was mounted by adding a small quantity of DePex mountant 
and pressing a coverslip gently into it.
2.4.7. Scoring o f chromosome aberrations
Slides were scanned under low magnification using a 10 x objective to locate
under high magnification (100 x objective, oil immersion). If the chromosome 
number was approximately diploid, 20-24 centromeres per cell, the cell was 
examined for aberrations. One hundred cells were scored for each culture. 
Aberrations were described according to the classification given in the UKEMS 
Guidelines for Mutagenicity Testing (Scott et al., 1990).
2.4.8. Classification o f aberrations
A. Chromatid type
Chromatid aberrations affect only one of the chromatids of the chromosome, 
except for isochromatid breaks.
metaphase cells. Once found each metaphase cell was more closely examined
i) Chromatid gap 
(ctg)
A small unstained region of the 
chromatid, where the chromatid 
remains aligned correctly
ii) Chromatid break 
(ctb)
A discontinuity in a chromatid in 
which a fragment is displaced
V
iii) Isochromatid break 
(ctb/iso)
A break which occurs at the same 
position on both chromatids. 
Only scored as isochromatid 
break if sister union is seen, 
either complete (SU) or 
incomplete (non-union, Nu) 
either proximal or distal to the 
break
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iv) Chromatid exchange 
(cte)
Formed by the faulty rejoining, 
of broken chromatids
a)
b)
Quadriradial
(qr) > s ~
■’S r
Isochomatid/ 
chromatid 
interchange (i/c) 
leading to 
triradial (tr)
Two chromosomes are joined by 
re a rra n g e m e n ts  of b o th  
c h r o m a t i d s .  May be 
asymmetrical or symmetrical
Chromosome (dicentric) or 
fragment (acentric) joined into 
one chromatid of another 
chromosome
c) Intrachange 
within a 
chromosome 
(ctr; ctinv; ctmin)
$
a
Exchange between arms of the 
same chromosome to form a 
centric ring
Exchange between arms of the 
same chromosome to give an 
inversion
<
Exchange within one arm of a 
chromosome to give a minute 
fragment
B. Chromosome type
Chromosome type aberrations affect both chromatids of the chromosome at 
the same position.
i) Chromosome gap 
(csg) « A small unstained region at the same posi t ion on bo th  chromatids, where they remain 
aligned correctly.
ii) Chromosome break 
(csb)
H II
Breakage of both chromatids to 
give a double acentric fragment
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iii) Chromosome exchange
(die+ ace)
I n t e r c h a n g e  b e t w e e n  
chromosomes to produce a 
dicentric chromosome often 
associated with a fragment
(csr+ace) © / /
Interchange between arms of 
the same chromosome to form a 
centric ring
(csmin)
X Very small acentric rings, called minutes, are formed as part of an exchange event. The centric 
part of the exchange may not be 
visible
2.5. The L5178Y/tk+/~ m ouse lym phom a m u ta tio n  assay
2.5.1. Introduction
The L5178Y/tk+/' mutation assay measures forward mutation at the autosomal 
thymidine kinase locus, using a cell line heterozygous for the tk gene. The 
cells are grown as a suspension culture which facilitates the production of 
large numbers of cells for treatment, and prevents possible metabolic 
co-operation between non-mutant and mutant cells, which, in the presence of 
the purine analogue could lead to death of the mutant cells. Two methods of 
cloning have been described for this assay: growth in semi solid agar (Clive et 
al.y 1979) and a fluctuation method using microtitre plates (Cole et al.t 1983a). 
Since the latter method is less time consuming, and enables clones to be easily 
isolated for expression, this method was used for the present study.
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2.5.2. The L5178Ycell line
Cells of the L5178Y mouse lymphoma clone 3.7.2C heterozygous for the tk 
locus (tk+/') were kindly supplied by Dr J. Cole (MRC Cell Mutation Unit, 
University of Sussex). The line was originally acquired by Dr Cole from Dr D. 
Clive (Burroughs Wellcome Co., Research Triangle Park, NC 27707, USA) in 
1978. Cell stocks of 1 x 106 cells/ml of RPM I1640 medium containing 109®f\>) 
DMSO were frozen under liquid nitrogen, and a new ampoule removed for 
each mutation assay. The cells had a doubling time of about 12 h and a 
cloning efficiency of approximately 90%.
2.5.3. Culture conditions
The cells were grown in RPMI 1640 medium (Dutch modification, Gibco) 
buffered with 25 mM HEPES buffer and containing 146 mg/L-glutamine. The 
medium was further supplemented with penicillin (100 U/ml; Gibco), 
Streptomycin (100 fig/ml; Gibco), L-glutamine (2 mM; Gibco), Pluronic PF
CM(0.05%; BASF), sodium pyruvate (0.5 mg/ml; Gibco) and 10%^heat-inactivated 
donor horse serum (Gibco). For routine subculturing, cells were diluted in 
fresh medium to 2 x 105/ml every 3-4 days. Cultures were maintained in 
flasks at 37° C in an atmosphere of 5% C02 in air, and at maximum humidity.
Cells were counted using an electronic particle counter (Coulter 
Counter, Mode Dn). Three aliquots of a culture were used to estimate the 
mean cell population.
2.5.4. The TK mutation assay
A scheme for the protocol used is given in Figure 2.4.
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Cultures at 1 x 106 cells/ml 
rotated 30-60 min
diluted to 5 x 105 cells/ml 
+ test agent
incubated 3 h with rotation
washed, resuspended in 50 ml
plated 1 cell well 
for Day 0 cell survival
incubated 24 h
resuspended at 2 x 103
incubated 24 h
I 1
plated 2 cells/well plated 2 x IQ3 cells/ml
non-selective medium selective medium for
for plating efficiency TK mutants
isolation of large 
and small colonies
Figure 2.4. Protocol for the L5178Y TK assay
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2.5.4.1. Preparation of cell cultures
Exponentially grown cultures of L5178Y cells were used to prepare suspensions 
of 107 cells in 10 ml medium containing 10% serum, and dispensed into a series 
of universal bottles. Duplicate bottles were prepared for each mutagen 
treatment. The bottles were incubated for 30-60 min on a roller apparatus 
(Gallenkamp) at 37 °C.
2.5.4.2. Preparation o f test agents
Stock solutions of EMS and MMC were prepared immediately prior to each 
assay as described in section 2.2.4.2. A series of bottles, each containing 10 ml 
of medium without serum, received appropriate aliquots of the stock mutagen 
solutions, at twice the required final concentration. Duplicate bottles were 
prepared for each concentration. The final doses of test agents were in the 
range 0-1000 fig/ml EMS and 0-0.25 fig/ml MMC.
2.5.4.3. Mutagen treatment
The test solutions in 10 ml medium were each added to one of the universal 
bottles containing cells to give a final volume of 20 ml, 5% serum and 
5 x 105/m l cells. The cultures were incubated on a roller drum at 37 °C for 
3 h, then centrifuged, washed twice in serum-free medium, and resuspended 
in 50 ml medium containing 20% serum. Control cultures without chemical 
treatment were similarly incubated and washed.
2.5.4.4. Estimation o f cell survival post treatment
Immediately after treatment a small sample of cells was removed from each 
cell suspension, diluted in medium to 10 cells/ml, and 0.1 ml was used to
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inoculate each well of a 96-well microtiter® plate (flat-bottomed; Nunc), to give, 
an average cell density of 1 cell per well. The plates were incubated at 37 °C 
for 9 days. Wells were scored for negative or positive growth after 
examination under an inverted microscope.
2.5.4.5. Estimation o f mutant frequency
The bulk of the 50 ml cell suspensions was incubated for 24 h after which they 
were diluted to 2 x 105 cells/ml and incubated for a further 24 h, to allow 
expression of any mutants arising from the chemical treatment.
To estimate plating efficiency, a small cell sample was removed from 
each suspension, diluted to 10 cells/ml in medium containing 20% serum and 
0.2 ml used to inoculate each of 96 weeks of a microtitre plate (average 
2 cells/well). One plate was prepared for each cell sample. The plates were 
incubated for 9-11 days.
To determine the spontaneous and induced mutant frequency at the tk 
locus, the cell suspensions were diluted to 104 cells/ml in medium with 20% 
serum. Mutants deficient in the TK enzyme were selected by the addition of 
trifluorothymidine (TFT; Sigma) to the medium at a final concentration of 
4 /xg/ml. Aliquots of 0.2 ml cell suspensions in selective medium were plated 
per well into each of two 96-well microtitre plates (2000 cells/well). 
Incubation was for 9-11 days.
The plates were scored under an inverted microscope for negative wells.
2.5.4.6. Calculations
Poisson statistics were used to calculate the number of clonable cells, based on 
the method of Kraemer et al. (1980) where:
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number of negative wells
Po= ---------------------------------
total number wells plated 
and plating efficiency (PE) is calculated as:
-lnP0
PE = ---------------------------
total number cells/well
Cell survival post treatment was determined as:
PE treatment
% survival = -------------------
PE untreated
The plating efficiency was independently calculated for each selected and non­
selected population.
Mutant frequency (MF) was calculated as:
PE selective medium
MF = ---------------------------------
PE non-selective medium
2.5.4.7. Colony sizing and expansion of clones
Colonies were sized using an ocular micrometer. Wells were identified which 
contained a single colony of an appropriate sizie and both colony and medium 
were transferred to individual 25 cm2 culture flasks containing 5 ml medium. 
The clones were expanded using progressively larger cultures until 
approximately 5 x 108 cells were obtained. During the growth phase, putative 
mutant clones were grown for several cell generations in medium containing 
TFT. For putative wild-type clones, a sample was transferred to medium
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containing TFT and if growth occurred the clone was discarded. Cell pellets,, 
washed in PBS(A) were kept at -70 °C to await nucleic acid extraction.
2.6. Methods for molecular biology studies
2.6.1. Introduction
The development of the techniques of molecular biology has greatly facilitated 
the study of genes. The use of hybridisation probes carrying homologous 
sequences allows the identification of a particular gene among the excess of
100,000 contained in the mammalian genome. Cellular RNA may also be 
probed to study expression of the gene, and these techniques can also be used 
to study mutations in the gene of interest.
This section describes the methods used for the extraction of nucleic 
acids, and the techniques for the detection of mutations in the hprt and tk 
genes of mammalian cell cultures. Briefly, both Southern and Northern 
blotting involved separation of the nucleic acid fragments by gel 
electrophoresis (DNA was first digested with restriction enzymes), and their 
immobilisation by transfer to nylon membranes. This was then exposed to a 
32P-labelled probe which hybridised to its complementary sequences in the 
gene or mRNA of interest. Unbound probe was then washed off and the 
hybridised fragments detected by autoradiography.
The cDNAs used for hybridisation probes in Northern and Southern 
blotting experiments were obtained as plasmids in bacterial hosts. The E. coli 
simply had to be grown up to produce large amounts of the plasmid molecules 
from which the cDNA could be excised. However, to produce the antisense 
RNA probes (riboprobes) for RNaseA cleavage experiments, the hprt cDNAhad 
first to be cloned into an expression vector. Gene cloning involved the
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construction of linear cDNA and vector molecules having compatible termini 
which could be ligated together. The recombinant DNA was then introduced 
into an E. coli strain to allow its amplification.
Antisense hprt RNA was transcribed from this recombinant molecule for 
the probes for RNase cleavage analysis. This method used a liquid 
hybridisation between the complementary RNA strands and enzymic cleavage 
of mismatched bases in the RNA hybrid. Fragments were separated by 
polyacrylamide gel electrophoresis and detected by autoradiography.
Most protocols used involving enzymes were those provided by the 
suppliers since these were optimized for the particular enzyme. Many other 
techniques have been passed from one researcher to another, making it 
difficult to acknowledge their originators. General methods were mainly from 
Maniatis et al. (1982). All solutions to be used with RNA were either treated 
with 0.1%^diethylpyrocarbonate (DEPC) for at least 2 h, then autoclaved, or 
made up in DEPC-treated water.
General solutions and buffers used are given at the end of this section.
2.6.2. Extraction o f nucleic acids from cultured mammalian cells
2.6.2.I. Extraction o f genomic DNA
Approximately 0.5 x 108 cells were suspended in 10 ml of lysis buffer and 
incubated at 37 °C for 3 h. One ml of 1 M Tris-HCl, pH 9.0 was added and 
protein removed from the mixture by extraction with an equal volume of 
phenol. The phenol extraction was repeated, followed by two extractions with 
phenol/chloroform, and once with chloroform alone. The aqueous phase was 
recovered at each stage. To isolate the DNA, 1 ml of 3 M sodium acetate 
(pH 5.2) and 22 ml of ice-cold absolute ethanol were added, and the DNA
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allowed to precipitate for at least 2 h at -20 °C. The DNA was recovered by
(VM
spooling around a sterile glass Pasteur pipette, rinsed in 70%  ^ethanol and 
resuspended overnight in 5 ml of 1 x TE.
To remove contaminating RNA, NaCl was added to give a final 
concentration of 0.1 M together with 100 jtig/ml RNase A  The solution was 
incubated for IV2 h at 37 °C. Sodium dodecyl sulphate (SDS) was added to give
( w/v )
0.1%^final concentration, 100 fig/ml Proteinase K added and the solution was 
incubated for a further 30 min at 37 °C. Degraded RNA and proteins were 
extracted with phenol and chloroform as before, the DNA recovered by 
precipitation with ethanol and resuspended in 2 ml sterile distilled water.
2.6.2.2. Extraction o f RNA
This method is based on that of Krawetz et al. (1986). Pellets of 
approximately 2 x 108 cells were suspended in 6 ml RNA lysis buffer and 
0.5 ml J3-mercaptoethanol added. Each sample was homogenised for 30 sec 
using a Polytron homogeniser, after which the suspensions were left at room 
temperature for 20 min to ensure complete lysis. To precipitate the RNA,
37.5 ml of 4 M LiCl was added and the samples left at 4°C overnight. The 
RNA was recovered by centrifuging at 4°C in an MSE Centaur 3000 at 
5100 x g for 90 min. After discarding the supernatant, the pellet was washed 
in 20 ml 3 M LiCl and centrifuged at 5100 x g for 20 min at 4°C. The RNA 
pellet was dissolved in 5 ml 1 x TE/0.1%^SDS, heating to 68°C for 5 min to aid 
dissolution.
The samples were extracted twice with phenol/chloroform, using a half 
volume of the organic solvents for the first extraction and one volume 
subsequently. The aqueous phase was retained and the RNA precipitated by
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the addition of 2 volumes absolute ethanol and keeping overnight at -20 °C 
before centrifuging at 5100 x g to recover the RNA. The RNA samples were 
dissolved in 0.5 ml sterile, distilled water and stored at -70 °C.
2.6.3. Extraction o f plasmid DNA
2.6.3.I. Large scale preparation of plasmids
Large scale production was used when plasmid DNA was frequently required 
for hybridisation or transcription probes.
An overnight culture of the E. coli host carrying the plasmid was used 
to inoculate 2 x 500 ml L-Broth in 2 litre flasks. The appropriate antibiotic to 
select for only cells carrying the plasmid was added: 50 ^cg/ml ampicillin or 
12.5/zg/ml tetracycline. Incubation was overnight at 37° C with shaking. The 
bacterial cells were pelleted by centrifuging at 1400 g for 20 min, after which 
20 ml of lysis buffer, containing 4 mg/ml lysozyme was added to the pellets 
from each flask. The tubes were kept on ice for 30 min, 40 ml alkaline SDS 
added and placed on ice for a further 5 min. Thirty ml of 3M potassium 
acetate (pH 4.8) was added and the lysates kept on ice for 15 min before 
spinning at 1400 x g for 10 min at 4°C and straining the supernatant through 
gauze into a sterile beaker. Isopropanol was added to 0.6 of the supernatant 
volume to precipitate the nucleic acids, which were recovered by centrifugation 
at 1400 x g for 10 min at 4°C. After resuspending the pellet in 8 ml of 1 x TE,
4.5 g caesium chloride was added to each tube, together with 0.3 ml of 
10 mg/ml ethidium bromide. The mixtures were centrifuged at 1400 x g for 
10 min at room temperature and the supernatant transferred to polycarbonate 
centrifuge tubes. Saturated caesium chloride solution was used if necessary 
to balance the tubes by weight. The tubes were filled with liquid paraffin and
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sealed with aluminium caps. The tubes were spun in an MSE Europa 65 M 
ultracentrifuge at 60,000 x g (measured at minimum length) for 64 h.
After centrifugation the closed circular plasmid DNA is seen under 
UV-light as the lower of 2 bands suspended in the caesium chloride/ethidium 
bromide gradient. This band was carefully removed into a fresh tube using a 
blunt-ended needle attached to a plastic syringe. Ethidium bromide was 
removed from the solution by several extractions with isopropanol until all 
pink colouration disappeared from the aqueous phase. This solution was then 
dialysed against 3 changes of 1 x TE. The concentration of the plasmid DNA 
was determined spectrophotometrically and adjusted to 1 mg/ml in 1 x TE. 
The DNA solution was stored at 4°C.
2.6.3.2. Mini plasmid preparations
Small scale preparations were used when only a small amount of plasmid DNA 
was required, for example when screening colonies for recombinant plasmids.
The E. coli host was grown up overnight in 10 ml L-Broth with the 
appropriate antibiotic (50 fig/m l ampicillin or 12.5 jug/ml tetracycline) to select 
for cells carrying the plasmid. The cells from 3 ml of culture were harvested 
by centrifugation at 1400 x g for 10 min at 4°C and resuspended in 100 yl of 
ice-cold lysis solution before placing on ice for 5 min. The mixture was 
transferred to an eppendorf tube and 200 yl alkaline SDS added. The tube 
was inverted to mix the contents, and kept on ice for a further 5 min. Then 
150 yl of 3M potassium acetate (pH 4.8) was added and the mixture vortexed 
before placing on ice for 5 min. The cell debris was removed by spinning at
10,000 x g for 10 min at room temperature, and proteins removed from the 
supernatant by extraction with an equal volume of phenol/chloroform. The
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plasmid DNA was precipitated by the addition of 2 volumes of absolute ethanol 
and recovered by centrifugation at 10,000 x g for 10 min.
To remove RNA from the preparation, the pellet was resuspended in 
100 [A of 1 x TE containing 20 /xg/ml RNase A and incubated for 1 h at 37 °C. 
Degraded RNA and enzyme was extracted in phenol/chloroform and the DNA 
recovered as previously described. The plasmid DNA was washed in 70%(*h) 
ethanol, centrifuged and the pellet resuspended in 100 /d sterile distilled 
water. The concentration of plasmid DNA was determined 
spectrophotometrically.
2.6.4. General molecular techniques
2.6.4.1. Quantitation of DNA
Optical densities of DNA samples, diluted if necessary in distilled water, were 
measured at wavelengths of 260 and 280 nm on a Pye-Unicam SP 1800 
spectrophotometer.
The concentration of DNA was calculated as:
50 x OD260 x dilution factor = x jig DNA/ml 
The ratio OD26o/O D 28o gives an estimation of the purity of the DNA solution; 
pure preparations have a ratio of 1.8.
2.6.4.2. Quantitation of RNA
Optical densities, diluted if necessary, were measured on a Pye-Unicam SP 
1800 spectrophotometer at wavelengths of 260 and 280 nm.
The concentration of RNA was calculated as:
40 x OD260 x dilution factor = x /xg RNA/ml
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The ratio OD260/OD280 was used to estimate the purity of the RNA solution; 
pure preparations have a ratio of 2.0.
2.6.4.3. Visualisation of nucleic acids in agarose eels
To detect DNA and RNA samples in non-denaturing gels, 0.5 fig/m l ethidium 
bromide was added to the molten agarose before pouring. After 
electrophoresis the nucleic acids were visualised by placing on a 
transilluminator with a UV-light source of wavelength 254 nm. Nucleic acids 
in the gels appear orange due to the fluorescence of bound ethidium bromide.
2.6.4.4. Restriction enzyme digestion
The reaction buffer supplied by the manufacturer was always used with the 
appropriate enzyme.
General reaction mix:
The restriction enzymes used in this study all required incubation at 
37 °C, except for Smal which was incubated at 25 °C. Incubation was for at 
least 1 h and generally overnight.
Complete digestion was checked by running 1 /d of the mixture on a 
0.8% agarose gel.
10 mg/ml BSA 
40 mM spermidine 
DNA
Restriction enzyme 
H20
10 x reaction buffer VlO total volume 
ViOO total volume 
V20 total volume
1-50 fig as required
5 U per fig DNA
to final volume, such that 
enzyme is less than 1 /10 of final 
volume
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2.6.4.5. Extraction o f DNA from low melting point agarose
The gel slice containing the required DNA fragment was weighed and 5 
volumes of 20 mM Tris-HCl, pH 8.0/1 mM EDTA was added. The tube was 
heated to 65°C for 10 min to melt the gel, then cooled to 37°C and an equal 
volume of phenol added. After vortexing for 20 sec, the layers were separated 
by centrifuging at 1400 x g for 10 min at 20°C. The aqueous phase was 
recovered, re-extracted in phenol/chloroform and then chloroform alone. The 
DNA was precipitated by adding 0.2 volume of 10 M ammonium acetate and 
2 volumes ice-cold ethanol. After leaving 10 min, the DNA was recovered by 
centrifugation at 1400 x g for 20 min at 4°C and dissolved in an appropriate 
amount of sterile, distilled water.
2.6.4.6. Isolation o f cDNAs for use as hybridisation probes
a) Isolation o f the hamster hprt cDNA
pHPT12 was obtained from Dr P. Brookes (Institute of Cancer Research). The 
plasmid was digested with Hpall to obtain the full-length hamster hprt cDNA 
as a 1.3kb fragment (Konecki et al., 1982) which was separated from plasmid 
DNA by electrophoresis in a 0.8% low melting point agarose gel. The 1.3kb 
band was cut out and stored in the agarose at 4°C in a sealed eppendorf tube.
b) Isolation of mouse tk cDNA
pMTK4 was obtained from the American Type Culture Collection as 
ATC 37556. The plasmid was digested with BamHI, which cuts twice within 
the DNA to give the entire mouse tk cDNA as a 1.5kb fragment (Lin et al., 
1985). The fragment was separated by electrophoresis in a 0.8% low melting
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point agarose, the 1.5kb fragment excised and stored at 4° C in a sealed 
eppendorf tube.
c) Isolation o f mouse actin cDNA
pAM91 was obtained from Dr G. Rumsby (Middlesex Hospital). The plasmid 
was digested with PstI to give a 1.15kb fragment containing the major part of 
the mouse skeletal actin cDNA (Humphries et al., 1981). The fragment was 
isolated by electrophoresis in 0.8% low melting point agarose, and the 1.15kb 
band cut out of the gel and stored at 4°C in a sealed eppendorf tube.
2.6.4.7. Radiolabelling o f hybridisation probes
Hybridisation probes were prepared by the method of Feinberg and Vogelstein 
(1983b) in which a mixture of random hexanucleotides is used to prime DNA 
synthesis from the cDNA template. This system has the advantage that the 
cDNA can be used directly in the agarose, as only a minimal amount of DNA 
is required.
The cDNA fragment in agarose was heated to 90°C for 10 min to 
denature the DNA and then kept at 37 °C to prevent the gel re-solidifying.
HpallHpall
pHPT12
.BamHIBamHP
pMTK4
PstI
PstIPstI
pAM91
Structure of plasmids used as hybridisation probes
Reaction mix:
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10 x random priming buffer 5 pi
dNTP solution
(10 mM each dATP, dGTP, TTP)
2 p\
Denatured DNA template 50 ng
10 mg/ml BSA 1 pi
2 /zg/ml random primers 3.5 pg/m l
[a-32P] dCTP
(50 pCi, 3000 Ci/mmole)
5 p\
1 U/pl Klenow enzyme 2 pi
h 2o to 50 pi
Incubation was at 37 °C for 1 h, then the reaction was stopped by the 
addition of 200 pi 1 x TE.
The radiolabelled probe was separated from unincorporated nucleotides 
by chromatography through a Sephadex G-50 column in the presence of 
1 x TE. The first peak of radioactivity was collected and measured by counting 
10 pi in Optiphase scintillant in a Packard 220A Tri-Carb liquid scintillation 
analyzer. Counts of 3 to 8 x 107 cpm/ml of probe solution were obtained by 
this method. The probes were kept at -20 °C and were used within one day of 
preparation.
2.6.4.8. Autoradiography
Membranes after Southern and Northern blotting were gently pressed 
between sheets of blotting paper to remove excess moisture. Damp 
membranes were sealed in plastic bags and exposed to X-ray film (Fuji RX) in
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cassettes containing two calcium-tungstate intensifying screens (Dupont, 
Cronex, Lightning Plus) at -70°C for between 3 and 14 days.
Dried polyacrylamide gels were placed directly in the cassette and 
exposed to X-ray film at room temperature for 1 min to 24 h.
The films were developed, after thawing at room temperature, if 
necessary, by immersing in Kodak GBX developing fluid for 4 min, rinsing in 
tap water, followed by immersion in GBX fixative solution for 2 min and finally 
thorough washing under running water.
2.6.5. Southern blotting
2.6.5.I. Digestion o f samples and electrophoresis
For each sample, 15 /ig of high molecular weight DNA was digested overnight 
with the appropriate restriction enzyme. After checking that digestion was 
complete, the DNA samples were precipitated in ethanol and resuspended in 
20 fjL 1 sterile distilled water. To each sample was added 5 /J of 6 x DNA 
gel-loading buffer and individual samples were loaded into the wells of 0.8% 
agarose gels submerged in 1 x TEA in horizontal electrophoresis tanks. 
Electrophoresis was for 16h at 18 V.
The DNA fragments were transferred to either Nytran (EMS-treated 
HPRT clones) or Genescreen Plus (all other samples) using the protocols 
recommended by the manufacturers. Genescreen Plus was used in later 
experiments as it was found to result in less background and to give clearer 
bands.
The agarose gels were prepared for blotting as follows:
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a) Nytranprotocol: The DNA fragments in the gel were denatured in 1.5M 
NaCl/0.05M NaOH for 30 min, followed by neutralisation in 1.5M NaCl/lM 
Tris-HCl, pH 7.4 for 30 min.
b) Genescreen protocol: The DNAs were denatured by soaking the gels in 
0.4 M NaOH/O.6 M NaCl for 30 min and neutralised in 1.5 M NaCl/0.5 M 
Tris-HCl, pH 7.5 for 30 min.
2.6.5.2. Blotting procedures
Nylon membrane, cut to the exact size of the gel was wetted in distilled water 
before soaking for 15 min in 10 x SSC. A glass plate, supported on 4 rubber 
bungs, was placed in a plastic box containing 1000 ml of 10 x SSC. Two 
lengths of 3 MM paper were placed crosswise on the plate so that the ends 
dipped into the buffer reservoir, thus creating a wick. The gel was placed flat 
on the plate with the nylon membrane on top. Two pieces of 3 MM paper, cut 
to the size of the gel, were soaked in 10 x SSC and placed over the membrane 
topped with 3 dry 3 MM sheets and a stack of paper towels. Strips of plastic 
closely surrounded the gel to prevent the towels coming into direct contact 
with the wicks. Another glass plate was put on top of the towels and a 1 kg 
weight was used to keep the layers tightly compressed.
The capillary action blotting was allowed to proceed overnight and 
successful transfer of the DNA fragments was checked by viewing the 
ethidium bromide stained gels under UV-light. Lack of fluorescence in gels 
indicated transfer was complete.
The DNA fragments were immobilised on the membranes as follows:
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a) Nytranprotocol: The membranes were rinsed in 5 x SSC to remove any , 
adhering agarose and then baked at 80 °C for 1 h.
b) Genescreen protocol: The membranes were soaked in 0.4 M NaOH for 
1 min, rinsed in 0.2 M Tris-HCl, pH7 7.5/2 x SSC and allowed to dry at room 
temperature.
2.6.5.3. Hybridisation procedures
a) Nytran protocol: The membranes were incubated in plastic boxes
containing 30 ml Nytran prehybridisation buffer at 42° C in a shaking water 
bath for 1 h. The solution was then replaced with 30 ml Nytran hybridisation 
buffer and radiolabelled cDNA probe solution, containing approximately 10 ng 
DNA (1 x 107 cpm), was added after first denaturing the DNA at 90°C for 
5 min. Hybridisation was overnight at 42° C in a shaking water bath. The 
blots were washed, under stringent conditions, with constant agitation, to 
remove unbound probe as follows:
a) 2 x 15 min in 6 x SSPE/0.1% SDS at room temperature
b) 2 x 15 min in 1 x SSPE/0.1% SDS at 37°C
c) 2 x 30 min in 0.1 x SSPE/0.1% SDS at 65°C.
b) Genescreen protocol: The blots, in plastic boxes, were incubated in the
presence of 30 ml Genescreen hybridisation buffer in a shaking water bath at 
42°C for 4 h. After this time 100 pg/ml heat denatured, sonicated salmon 
sperm DNA and approximately 10 ng (1 x 107 cpm) of radiolabelled cDNA 
probe (previously denatured at 90 °C for 5 min) were added. The blots were 
incubated overnight with shaking at 42 °C.
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The membranes were washed with constant agitation as follows:
i) 2 x 5  min in 2 x SSC at room temperature
ii) 2 x 30 min in 2 x SSC/1% SDS at 65°C
iii) 2 x 30 min in 0.1 x SSC at room temperature.
The membranes were kept damp and subjected to autoradiography.
2.6.6. Northern blotting
2.6.6.I. Electrophoresis in formaldehyde sels
Northern blots were prepared using 20 pg total RNA from each HPRT+ or 
HPRT' clone. 1% agarose gels, containing formaldehyde, were prepared by 
melting 1 g agarose in 73 ml distilled water and cooling to 60 °C before adding 
20 ml of 5 x RNA gel running buffer and 17.9 ml of 12.3 M formaldehyde. The 
agarose solution was mixed gently and gels prepared.
The RNA samples were diluted, or concentrated by ethanol precipitation 
and resuspension as necessary, to give 20 pg in 4.5 pi. The samples were 
prepared as follows:
RNA (20 pg) 4.5 pi
5 x RNA gel running buffer 2.0 pi
12.3 M formaldehyde 3.0 pi
Deionised formamide 10.0 pi
The samples were heated at 55 °C for 15 min after which they were 
stored on ice and 2 pi RNA loading buffer was added to each sample. After 
loading the samples into individual wells, the gels were electrophoresed 
overnight at 20 V in 1 x RNA gel running buffer. RNA marker lanes were cut 
from the gel after electrophoresis and stained separately. The gels were 
washed twice for 20 min each in 10 x SSC.
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2.6.6.2. Blotting procedures
The RNA species were transferred to Nytran membranes as described for 
Southern blotting (2.5.6.2.). No further denaturing of the RNA was required 
before blotting. Afterwards, the membranes were rinsed in 5 x SSC to remove 
agarose particles and baked for 1 h at 80° C to immobilise the RNA molecules.
2.6.6.3. Hybridisation procedures
Hybridisation to radiolabelled cDNA probes was described for DNA (2.5.5.3. a) 
Nytran). After hybridisation the blots were washed as follows:
i) 2 x 15 min in 6 x SSPE/0.1% SDS at room temperature
ii) 2 x 15 min in 1 x SSPE/0.1% SDS at 37°C
iii) 2 x 30 min in 0.1 x SSPE/0.1% SDS at 60 °C.
2.6.6.4. Removal o f probe from Northern blots
To allow rehybridisation of RNA to a different cDNA probe, old probe was 
removed from RNA samples by washing in 50% formamide/6 x SSPE at 65 °C 
for 30 min. The blots were then rinsed twice in 6 x SSPE and efficient 
removal of the probe was checked by autoradiography overnight at -70 °C.
For successful probe removal the blots were not allowed to dry after 
being hybridised to the first probe.
2.6.6.5. Staining of molecular weight markers from formaldehyde gels 
Since the RNA molecular weight markers used with formaldehyde gels were 
not radiolabelled and therefore not detected by autoradiography, the marker 
lanes were cut from the gel before blotting and separately stained. Direct 
staining in a solution of 0.5 /zg/ml ethidium bromide often resulted in only
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faint bands being observed, thus a longer protocol (Maniatis et al., 1982) was 
generally used which resulted in much better staining of the bands.
The agarose lanes were washed, with agitation, for 1 h in several 
changes of distilled water and then in two changes of 0.1 M ammonium acetate 
for 1 h. The gel lanes were stained in 0.5 fig/ml ethidium bromide in 0.1 M 
ammonium acetate and 0.1 M B-mercaptoethanol for 45 min, and then 
destained in 0.1 M ammonium acetate/0.01 M B-mercaptoethanol for 45 min. 
The marker bands were visualised under UV-light and photographed in the 
presence of a fluorescent ruler to measure the length from the well to the 
RNA marker bands.
2.6.7. Cloning methods
2.6.7.I. Dephosphorvlation o f terminal phosphates in linear DNA 
T^ he terminal 5’ phosphates of the expression vector pSPT18, which had been 
linearised with Smal, were removed to prevent self-religation of the plasmid. 
Reaction mix:
100 ng/fd linear DNA 25 pi
2 x CIAP buffer (page 91) 25 pi
22 C/pl calf intestinal alkaline phosphatase 1 pi
The reaction was incubated at 37 °C for 60 min. Since phosphatase can 
interfere with ligation, the enzyme was removed by phenol extraction and 
DNA in the aqueous phase recovered by ethanol precipitation.
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2.6.7.2. Filling in recessed 3’ ends
The enzyme Hpall, used to excise the hprt cDNA from pHPT12, resulted in 
ends with a 5’ overhang. However, to be compatible with the Smal blunt- 
ended cut of the expression vector into which the cDNA was to be inserted,
the Hpall cut ends had to first be filled in.
Reaction mix:
100 ng/pl Hpall cut hprt cDNA 10 pi
10 x nick-translation buffer 2 pi
2 mM d CTP 1 pi
2 mM d GTP 1 1^
2 XJ/pl Klenow enzyme 1 pi
H20  to 20 pi
Incubation was at room temperature for 30 min, followed by phenol 
extraction and ethanol precipitation.
2.6.7.3. Ligation protocol
The hprt cDNA was inserted into the expression vector pSPT18.
Reaction mix:
10 x ligase buffer 2 pi
6 U/pi T4 DNA ligase 1 pi
Vector DNA see below
hprt cDNA see below
H20  to 20 pi
The mix was incubated overnight at 15°C. Molar ratios of vector:insert 
of 3:1, 1:1 and 1:3 were used in the reaction mix. These were calculated as:
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pSPT18 vector 3104 bp
hprt cDNA insert 1411 bp
equivalent mass ratio 2 .2:1
Therefore:
1:1 molar ratio 100 ng vector, 45 ng cDNA
3:1 molar ratio 100 ng vector, 15 ng cDNA
1:3 molar ratio 100 ng vector, 136 ng cDNA
The ligation mixtures were stored at 4°C.
2.6.7.4. Transformation of E. coli with plasmid DNA
a) Preparation of competent cells
A 10 ml culture of the E. coli strain, TB1, was grown up overnight in L-broth, 
and 0.5 ml used to inoculate 50 ml of fresh medium. The culture was grown 
up for 2-3 h until the OD600 was 0.35, when the broth was chilled on ice for 
30 min. The cells were harvested by centrifuging at 1400 x g for 10 min at 
4°C and resuspended in 25 ml of ice-cold 50 mM CaCl2 in 10 mM Tris-HCl, 
pH 8.0. After keeping on ice for a further 30 min, the cells were pelleted by 
centrifugation as before and resuspended in 2.5 ml of ice-cold 
50 m CaCl2/10 mM Tris-HCl, pH 8.0. The cell suspension was kept for up to 
24 h at 4°C.
b) Cell transformation
The ligation mixture, in aliquots to contain between 1 and 5 ng/ml, was added 
to 100 /zl competent cells and stored on ice for 30 min. The cells were heat- 
shocked at 42 °C for 2 min and 1 ml L-broth added to each tube before 
incubating at 37 °C for 60 min. Aliquots of 50 yX from each transformation
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reaction were spread over the surface of L-agar plates containing 50 fig/m l 
ampicillin. Only cells transformed by the plasmid, which carried an ampicillin 
resistance marker, could grow in the presence of the antibiotic. The plates 
were incubated at 37 °C overnight.
2.6.8. Methods for RNase A  cleavage analysis
2.6.8.I. Transcription ofriboprobes
Two recombinant plasmids were recovered from the cloning exercise in which 
the hprt cDNA was inserted into the expression vector, pSPT18. One, 
designated pSPT18/27, carried the hprt cDNA insert in the "conventional" 
orientation, and the other pSPT18/12, carried the insert in the "opposite" 
orientation. Sense mRNA is normally transcribed from the non-coding strand 
of the DNA, and is complementary to this strand. In the pSPT18 expression 
vector cloning of the sequence of interest between the two phage promoters 
for RNA polymerases, allows transcription from either the non-coding or 
coding strand, depending on the promoter used. Thus, sense or antisense hprt 
transcripts could be produced from either clone using the appropriate 
promoter.
For work with RNA transcripts every precaution was taken to prevent 
contamination with RNases. As well as treating all solutions with DEPC, or 
making up the solutions with DEPC-treated water, solutions were aliquoted 
into sufficient amounts for no more than one day’s use so as to prevent 
excessive handling of the bottles. Where possible all glassware, plasticware, 
pipetters, tube racks and benches were wiped before use with chloroform or 
alcohol as appropriate. An Intelligent Heating Block (Hybaid) replaced water 
baths for all incubations.
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To produce full-length hprt transcripts the plasmid was linearised w ith , 
either EcoRI or BamHI, for transcription from the SP6 or T7 promoter 
respectively. After digestion, RNase A was added to the incubation mix and 
incubated for 30 min at 37°C, then 10 x TSE, 20% SDS and 10 mg/ml 
Proteinase K were added to give final concentrations of 1 x TSE, 0.05% SDS 
and 100 pg/ral Proteinase K, and incubated for a further 60 min. The mixture 
was extracted twice in phenohchloroform and precipitated with absolute 
ethanol. The DNA was resuspended at 1 jug/ml in sterile, DEPC-treated 
water.
The transcription reaction was set up as follows:
10 x transcription buffer (page 92) 2 pi
lOOmMDTT 2 pi
RNasin (Promega) 1 pi
NTPs (mix of ATP, GTP, UTP, 2.5 mM each) 4 pi
*100 pM CTP 2.4 pi
1 pg/pl DNA template 1 pi
[a-32P]CTP (50 pCiy 400 Ci/mmol) 5 pi
sterile, RNase-free H20  (Promega) 1.6 pi
SP6 or T7 RNA polymerase 1 pi
Final volume 20 pi
Incubated 37 °C for 60 min 
* this gives together with the radiolabelled CTP a final concentration of 
12 pM CTP. In some experiments this was increased by adding more cold 
CTP.
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Then 1 unit RNase-free DNase was added and incubated for a further 
15 min at 37 °C. The incubation mix was extracted once with phenol: 
chloroform and once with chloroform alone. To remove unincorporated NTPs, 
0.5 volumes 7.5 M NH4Acetate and 2 volumes ethanol were added and the 
RNA precipitated at -70°C for 15 min. The RNA was recovered by 
centrifugation, resuspended in 100 /d 1M NH4Acetate and reprecipitated in
2 volumes ethanol. After keeping at -70 °C for 15 min the RNA was pelleted 
by centrifugation, air-dried and resuspended in 20 /d RNase-free water.
In initial experiments 5 fig transfer RNA (tRNA) was added as carrier 
during precipitation procedures. However, this was found to be unnecessary 
if full-size transcripts were synthesised. When used the tRNA solution was 
first treated with 100 fig/m l Proteinase K for 2 h at 37 °C, then extracted
3 times with phenol, ethanol precipitated and resuspended at 10 mg/ml in 
RNase-free water.
Two commercial kits (BCL and Promega) were also tried when initial 
attempts at producing full-length transcripts were unsuccessful. The Promega 
Riboprobe Gemini system gave good results for both the hprt cDNA and the 
Gemini control plasmid supplied with the kit. The final method used to 
produce full-length hprt transcripts was based on the Promega protocol.
2.6.8.2. Polyacrylamide denaturing gel electrophoresis of transcripts 
To check the size of the transcripts synthesised, and to separate transcripts 
of the required size from any smaller transcripts that may be produced, the 
RNA was run on 5% polyacrylamide denaturing gels.
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For 5% gel:
Urea 48 g
5 x TBE
W)
2%*Bis-acrylamide
Mi)
30%^acrylamide
20 ml
7.5 ml
16-17 ml
H20 to 100 ml
H )
After dissolution, 80 /d TEMED (BRL) and 400 fd 10%^mmonium persulphate 
(Sigma) were added, and the solution poured between two 20 x 20 cm glass 
plates (one of which had been siliconised), separated by 0.4 mm spacers. A 
comb was inserted into the top of the gel to produce 4 mm wide wells, and the 
polyacrylamide was left to polymerize at room temperature for 60 min.
The gel was pre-run in 1 x TE in a vertical electrophoresis system 
(Model V16-2, BRL) for 30 min at 40 mA/750V. The RNA transcripts, at
2 td/well, were mixed with 5 fd loading buffer (90%^deionised formamide, 1
(VJ/>>) 6%) 
x TBE, 0.02%|bromophenol blue, 0.02%^xylene cyanol) and heated at 95°C for
5 min, before loading into the pre-flushed wells. The gel was run at
40 mA/750V for about 90 min or until the xylene cyanol marker dye, which
runs at about 130 nucleotides, had run off the bottom of the gel.
To visualise the transcripts, the gel was fixed for 15 min in 10% 
methanol/10% acetic acid, washed in distilled water to remove free urea, and 
transferred to a sheet of 3MM paper. The surface of the gel was protected 
with Saranwrap, and the gel dried on a gel-drier (ATTO). The gel was exposed 
to X-ray film for between 0.5 and 10 min at room temperature before 
developing the film.
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2.6.8.3. Extraction o f RNA transcripts from polyacrylamide
To recover the RNA from the gels after separation from incomplete transcripts
the method of Sambrook et al. (1989) was used.
After removal from the electrophoresis apparatus, the unfixed, undried 
gel, still on its supporting plate was wrapped in Saranwrap. A piece of X-ray 
film was placed on the bench in a darkroom and the gel inverted on top of it. 
A 1 kg weight was placed on the glass support and the edges of the plate were 
marked on the film. The film was left exposed for 5 min before developing. 
The transcript image was cut out of the film and the film was aligned on top 
of the gel. The gel piece relating to the transcript image was excised using the 
film as a stencil. The Saranwrap was peeled off and the gel containing the 
RNA was placed in a preweighed Eppendorf tube, reweighed and 1 volume 
elution buffer (0.5 M NH4Acetate, 10 mM MgAcetate, 1 mM EDTA, 0.1% SDS) 
added. The gel was crushed with a sterile blade and the tube incubated with 
shaking at 37 °C overnight. The tube was centrifuged and the supernatant 
removed to a clean tube. A further 1 volume elution buffer was added to the 
gel pellet, the tube vortexed for 5 min, and incubated with shaking for 30 min. 
After centrifugation, the supernatant was combined with the first eluate. Any 
remaining polyacrylamide was removed by passing the solution through a 
syringe packed with sterile siliconized glass wool. The RNA was recovered 
after twice precipitating in ethanol and the pellet resuspended in 20 /d RNase- 
free water. To check recovery of the radiolabelled transcripts, 1 /zl was 
counted in Optiphase scintillant in a liquid scintillation analyzer.
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2.6.8.4. RNase A cleavage assay
An aliquot of an antisense 32P-labelled RNA transcript synthesised from a 
pSPT18/27 template using T7 polymerase and containing 5 x 105 cpm, was 
mixed with 100 fig cellular RNA (isolated from either a HPRT' or HPRT+ 
clone) in 30 /xl liquid hybridisation buffer (80% formamide, 1 m EDTA, 
400 mM NaCl, 40 mM Pipes - pH 6.4). The solution was heated to 85 °C for 
5 min, the incubated overnight at 65 °C.
After hybridisation, either 2 or 20 f i g  RNase A (Type III; Sigma) and 
2 jig/ml RNase Tj (Sigma) made up in 300 /A 200 mM NaCl, 100 mM LiCl, 
30 mM Tris-HCl (pH 7.5) and 3 mM EDTA was added and incubated for either 
30,60 or 120 min at 35 °C. Digestion was stopped by the addition of 10 [A 20% 
SDS and 100 fig Proteinase K and incubated at 37 °C for 20 min. The solution 
was extracted with phenolichloroform after the addition of 5 fig tRNA as 
carrier and precipitated in ethanol. The RNA hybrids were washed twice in 
70% ethanol and resuspended in 20 fA loading buffer (90% formamide, 
1 x TBE, 0.02% bromophenol blue, 0.02% xylene cyanol). After heating to 
85°C for 2 min, 10 fA of each sample was subjected to electrophoresis in 5% 
polyacrylamide denaturing gels as described previously. After electrophoresis 
the gels were fixed, dried and exposed to X-ray film in the presence of 
intensifying screens at -70 °C for 24 h.
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2.6.9. General solutions and buffers for molecular biology
2.6.9.I. General reagents 
Alkaline SDS:
0.2 M NaCl 
1% SDS C*h)
Chloroform solvent:
chloroform:isoamyl alcohol (24:1, v/v)
Phenol solution:
Phenol saturated with 100 mM Tris-HCl, pH 8.0 
and containing 0.1 %. 8-hydroxyquinoline Cw/>i)
Phenol: Chloroform:
phenol solution:chloroform solvent (1:1, v/v)
20 x SSC
3 M NaCl
3 M Na citrate, pH 7.0
10 x SSPE
1.8 M NaCl
100 mM NaP04, pH 7.7 
10 mM EDTA, pH 8.0
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l O x T E
100 mM Tris-HCl, pH 8.0 
10 mM EDTA, pH 8.0
10 x TSE
100 mM Tris-HCl, pH 8.0 
1 M NaCl
10 mM EDTA, pH 8.0
2.6.9.2. Bacterial growth medium 
L-Broth
5 g/1 yeast extract 
10 g/1 tryptone 
10 g/1 NaCl 
pH 7.2
2.6.9.3. Lysis buffers 
DNA lysis buffer
50 mM NaCl 
10 mM EDTA, pH 8.0 
50 mM Tris-HCl, pH 7.5 
100 jug/ml Proteinase K 
0.2% SDS
RNA lysis buffer
5 M guanidine isothiocyanate 
50 mM Tris-HCl, pH 7.5 
10 mM EDTA
Plasmid lysis buffer
25 mM Tris-HCl, pH 8.0 
10 mM EDTA 
50 mM D-glucose
2.6.9.4. Incubation buffers
10 x CIAP buffer:
500 mM Tris-HCl, pH 8.0 
10 mM EDTA, pH 8.0
10 x Ligase buffer:
400 mM Tris-HCl, pH 7.5 
100 mM MgCl2 
100 mM DTT 
10 mM ATP 
500 ^g/ml BSA
10 x Nick-translation buffer:
0.5 M Tris-HCl, pH 7.2 
0.1 M MgS04
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500 fig/m l BSA 
10 x random priming buffer:
0.5 M Tris-HCl, pH 7.2 
0.1 M MgS04 
l m M D T T
10 x transcription buffer:
400 mM Tris-HCl, pH 7.5 
60 mM MgCl2 
20 mM Spermidine 
50 mM NaCl
2.6.9.5. Hybridisation buffers 
100 x Denhardt’s solution:
2% polyvinyl pyrrolidine 
2% Ficoll
2% BSA, Pentax Fraction V
Nytran prehybridisation buffer:
6 x SSPE
10 x Denhardt’s solution 
1% SDS
100 fig/m l denatured, salmon-sperm DNA
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Nytran hybridisation buffer:
50% deionised formamide 
6 x SSPE 
1% SDS
10% dextran sulphate
50 jJLg/mi denatured, salmon-sperm DNA
Genescreen hybridisation buffer:
50% deionised formamide 
1% SDS 
1 M NaCl
10% dextran sulphate
2.6.9.6. Electrophoresis buffer 
5 x RNA gel running buffer: 
0.2 M MOPS, pH 7.0 
50 mM Na acetate 
5 mM EDTA, pH 8.0
5 x TBE
445 mM Tris base 
445 mM boric acid 
10 mM EDTA, pH 8.0
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10 x TEA
0.4 M Tris-acetate 
10 mM EDTA, pH 8.0
6 x bromophenol blue DNA gel loading buffer 
0.25% bromophenol blue 
40% sucrose
RNA gel loading buffer:
50% glycerol 
1 mM EDTA 
0.4% bromophenol blue 
0.4% xylene cyanol
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CHAPTER 3
THE HPRT MUTATION ASSAY
3.1. Introduction
M ammalian cells can obtain purine and pyrimidine nucleotides for DNA 
synthesis by two pathways: de novo biosynthesis and the salvage pathway. 
Although the salvage pathway is used in preference, since it is more energy 
efficient (Hershfield and Seegmiller, 1977), enzymes involved in nucleotide 
salvage are not essential for cell growth in culture, and thus mutants deficient 
in these enzymes are able to grow using the de novo pathway.
The enzyme HPRT is involved in purine salvage (Fig.3.1.) and catalyses 
the reaction of hypoxanthine and guanine with phosphoribosyl-pyrophosphate 
(PRPP) to form the corresponding nucleotide-5-monophosphates, inosine-5- 
monophosphate (IMP) and guanine-5-monophosphate (GMP). In addition, 
HPRT will also catalyse the conversion of toxic purine analogues such as 6-TG 
(Fig.3.2) into the nucleotide-5-monophosphate, which when incorporated into 
nucleic acids causes cell death. Mutants deficient in the HPRT enzyme 
however will survive treatment with 6-TG since they do not have a functional 
salvage pathway and hence will not take up the analogue. Thus growth of 
cells in the presence of 6-TG is used for the selection of HPRT deficient 
mutants.
The positive selection of wild-type (HPRT+) cells is achieved by 
culturing cells in media containing hypoxanthine, aminopterin and thymidine 
(HAT media; Szybalski and Szybalski, 1962). Aminopterin inhibits the enzyme
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5 'phosphoribosyl-1-pyrophosphate (PRPP)
HPRT
hypoxanthine - - - - - -  Inosinate
(IMP)
HPRT APRT
guanxne Guanylate
(GMP)
Adenylate
(AMP)
dGTP dATP
DNA DNA
Figure 3.1. Simplified scheme of purine metabolism
Solid lines = de novo biosynthesis 
Broken liness = salvage pathway
adenosine
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guanine
SH
6 -thioguanine
Fig.3.2. The structure of guanine and its toxic analogue 6- 
thioguanine. Both compounds are substrates for the enzyme 
HPRT
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dihydrofolate reductase involved in the synthesis of inosine monophosphate 
and hence blocks de novo synthesis of purines. However in wild-type cells, 
purines can be obtained via the salvage pathway using the hypoxanthine 
provided and thus are able to grow. Since the synthesis of thymidine 
monophosphate is also blocked by aminopterin, the presence of thymidine is 
required to provide a source for pyrimidine nucleotides. Cells deficient in 
HPRT cannot grow in HAT medium since de novo synthesis is blocked and 
they are unable to utilise hypoxanthine.
One important advantage of studying mutation at the hprt locus is that 
this gene is located on the X-chromosome of both human and many animal 
species (Chinault and Caskey, 1984), such that the hprt gene is hemizygous in 
male cells and functionally hemizygous in female cells, due to inactivation of 
the gene on the second X-chromosome (Liskay and Evans, 1980). Thus the 
6-TG resistant phenotype results from one-step mutation affecting only one 
allele, and mutants can be selected in cells of any type and in many different 
mammalian species. The hprt gene is therefore not only useful for the study 
of mutation in cultured cells but also for assessing chemically induced 
mutation in laboratory animals (Jones et al., 1987), and for monitoring human 
populations that may be exposed to mutagenic agents (Albertini et al., 1982). 
In contrast, the analysis of genes coding for other purine or pyrimidine salvage 
enzymes which are located on autosomes, are limited by the availability of 
hemizygous or heterozygous cell lines and are restricted to the analysis of in 
vitro mutation.
One limitation of using an X-chromosome linked gene is that if genetic 
damage extends beyond the target locus into adjacent genes required for cell
99
survival, then cell death will occur since no second gene copy exists to supply 
the essential function (Chu, 1971). However the hprt locus is large, 34 kb in 
hamster cells, and might be expected to detect larger deletions within the 
gene, than for example the aprt gene which is only 2.5 kb. For clastogen- 
induced damage, the size of the target gene will only be relevant for the 
detection of mutant frequencies if the chemical causes intragenic alterations 
(less than 34 kb for the hamster hprt gene), as well as damage affecting 
hundreds of kilobases of the chromosome.
The hprt gene has also been studied extensively in humans since 
deficiency of the enzyme is responsible for an inherited X-linked group of 
disorders (Seegmiller et al., 1967). Patients with HPRT deficiency are unable 
to metabolise intracellular hypoxanthine to IMP, but instead it is lost from the 
cells and converted to uric acid by xanthine oxidase in the liver. In patients 
with partial HPRT deficiency this excessive production of uric acid leads to 
hyper uricaemia and gouty arthritis (Kelley et al., 1969). Total HPRT 
deficiency results in a severe disease of the central nervous system (CNS), 
Lesch-Nyhan syndrome (Lesch and Nyhan, 1964), characterised by hyper- 
uricaemia, spasticity, mental retardation and compulsive self-mutilation. 
Dysfunction of the CNS in Lesch-Nyhan patients is thought to be related to 
abnormal development of the dopaminergic neurons caused by purine 
imbalances (Goldstein et al., 1985).
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3.2. The HPRT assay in V79 cells
3.2.1. Introduction
Chinese hamster lung (V79) cells are used to detect mutations in selectable 
genes, including the hprt locus (Chu and Mailing, 1968). This cell line has a 
rapid growth rate with a doubling time of 12-16 h, a high cloning efficiency 
and a stable karyotype of 22 ± 1 chromosomes (Bradley et al., 1981; Nestmann 
et al., 1991). Although CHO cells are more popular for mutagen testing than 
V79 cells, the latter are more commonly used when molecular analysis of the 
mutants is to be studied since the cells are monosomic for the X-chromosome 
(Brown and Thacker, 1984). Nestmann et al. (1991) reported that 
approximately 520 HPRT assays per year were carried out using CHO 
compared with 380 with V79.
One disadvantage with both of these cell lines is that spontaneous 
mutant frequencies are low and thus large numbers of cells must be treated 
to allow statistical analysis of induced mutant frequencies (Arlett et al., 1989). 
Since V79 is a fibroblast cell fine growing as monolayers this involves a large 
number of culture dishes which may present technical difficulties. In addition 
metabolic co-operation between mutant and non-mutant cells at high cell 
densities has been reported to result in a decline in the recovery of m utant 
clones (Arlett et al., 1975; Bradley et al., 1981). These problems may be 
overcome by using suspension-adapted cell lines (Li and Shimizu, 1983) and 
may result in a higher mutagenic response than the standard assay. However, 
Moore et al. (1991b) found that a suspension culture was no better than a 
monolayer culture in detecting chemicals that exhibited a genotoxic effect 
through clastogenic mechanisms in the CHO/HPRT mutation assay. In the
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present investigation, mutation induction by EMS and MMC was studied in a 
standard V79/HPRT assay, using monolayer cultures. These were carried out 
to provide mutant and non-mutant clones for molecular analysis, so that the 
types of DNA damage induced in a standard HPRT assay could be investigated.
3.2.2. Results
The results for EMS as regards survival and 6-TG resistance are given in 
Tables 3.1 and 3.2 respectively and plotted against EMS concentration in 
Figure 3.3. Survival was estimated immediately after treatm ent as 
recommended by Arlett and Cole (1990) which in general yields a higher 
estimate of survival than methods based on relative total growth (Clive and 
Spector, 1975). As can be seen in Table 3.1 survival, calculated as the 
percentage of control, ranged from 78.8% at 100 /xg/ml EMS to 30.8% at 
1000 /xg/ml EMS. A dose-dependent increase in cytotoxicity was seen for EMS 
within these concentrations (Fig.3.3.)
The V79 cells had recovered from the cytotoxic effects of EMS by the 
time of selection for 6-TG resistance when the cloning efficiencies for treated 
cultures were comparable to those of untreated cells (Table 3.2). This is 
important for accurate determination of mutant frequency (Cole et al., 1990). 
A dose-related increase in resistance to 6-TG was seen in EMS-treated cultures 
(Table 3.2, Fig.3.3).
The survival data for MMC treatment is given in Table 3.3. As with 
EMS, a dose-dependent decrease in survival was seen for MMC, from 100% of 
control values at 0.0625 /xg/ml MMC to 17% at 0.5 /xg/ml. Cytotoxic effects of 
MMC had disappeared by six days after mutagen treatment (Table 3.4) when
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cells were selected for HPRT mutants. Although MMC did produce a dose- 
related increase in mutant frequency, this chemical was far less effective than 
EMS in inducing 6-TG resistance over a dose range giving comparable survival 
(Fig.3.3).
In these experiments the spontaneous mutant frequency was low, 6.4 
and 6.1 mutants/106 cells, which is one disadvantage in using the V79 cell line. 
For both spontaneous and chemically-induced mutants the 6-TG resistant 
phenotype was stable over many subcultures in the absence of the selective 
agent.
To compare the mutagenic effects of EMS and MMC, two different 
methods reported in the literature were used. Bradley et al. (1981) calculated 
mutagenic potency to compare mutation induction by different chemicals and 
different genetic markers.
Mutagenic potency (D10C) is defined as the concentration (/xM) of a 
compound that yields a mutant frequency 10 x higher than the spontaneous 
frequency.
D10C = 10 CD/Y 
where Y = mutants/106 survivors at dose D (/xM)
C = spontaneous mutants/106 survivors 
D10C is calculated for the highest and lowest doses giving an increase in 
mutants > 3 x spontaneous mutants, and averaged.
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EMS conc. 
(fj g/ml) Colonies/dish
Mean no. 
colonies % survival
% survival 
of control
1000 59,66,62 62.3 31.2 30.8
40,46,48 44.7 22.3
500 101,109,111 107 53.5 62.1
96,119,111 108.7 54.3
200 122,148,133 134.7 67.3 75.8
122,114,149 128.3 64.2
100 149,152,137 146 73.0 78.8
129,147,107 127.7 63.8
0 148,149,148 148.3 74.15 100
149,222,225 198. 6 99.3
Table 3.1. Survival of V79 cells immediately post-treatment with EMS
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EMS conc. Mean no. % plating Mutants freq.
(pg/ml) Colonies/dish colonies efficiency (cols/106 cells)
1000 65,62,54,67,73 64.2 69.0 930
64,65,84,58,80 70.2 77.8 902
500 35,43,47,44,42 42.0 76.8 547
49,47,49,42,38 45.0 85.7 525
200 17,14,8,13,17 13.8 95.2 145
22,9,20,19,26 19.2 80.7 237
100 14,9,9,6,7 9.0 91.0 98
10,12,17,12,10 12.2 86.2 141
0 0,1,1,0,0 0.4 62.5 6.4
0,0,0,0,0 0 103.5 0
Table 3.2. The induction of 6-TG resistant mutants in V79 cells by EMS
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MMC conc. 
(fu g/ml) Colonies/dish
Mean no. 
colonies % survival
% survival 
of control
in•o 31/26,32 30 15 17
31,36/36 34 17
0.25 135/111/95 114 57 57
117/85/82 95 48
0.125 177/153/129 153 77 80
138/146/137 140 70
0.0625 219/195,187 200 100 108
226,228,234 196 98
0 169,170,185 175 88 100
257,162,150 190 95
Table 3.3. Survival of V79 cells immediately post treatment with MMC
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MMC conc. 
(pg/ml) Colonies/dish
Mean no. 
colonies
% plating 
efficiency
Mutant free 
(cols/106 cell
0.5 4,3,3,4,1 3.0 74 40.5
1,5,0,1,1 1.6 72 22.2
0.25 1,1,2,0,1 1.0 79 12.7
0,2,2,2,1 1.4 66 21.2
0.125 0,0,1,0,1 0.4 69 5.8
1,0,1,2,1 1.2 64 15.6
0.0625 0,1,2,1,4 1.6 82 19.5
2,1,0,0,0 0.6 72 8.3
0 0,0,0,0,0 0 68 0
0,0,0,1,1 0.4 66 6.1
Table 3.4. The induction of 6-TG resistant mutants in V79 cells by MMC
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Thus, for EMS: 
at 1000 fjg/ml (8 mM)
10 x 8000 x 3.2
Dloc = -------  = 279 fjM
916
and at 100 fjg/ml (800 //M))
10 x 800 x 3.2
D10C = -------------------  = 214//M
119.5
thus averaged,
279 + 214 
Dioc = -------------------  = 246.5 fjM
For MMC,
at 0.5 jjg/m  1 (1.5 jl/M),
10 x 1.5 x 3.1 
D10C = = 1.49 /vM
31.35
and at 0.062 jJg/ml (0.19 //M),
10 x 0.19 x 3.1 
D10c = = 0.42 fjM
13.9
thus averaged,
1.49 + 0.42
D ioc ~  =  1 -0  fjM
2
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On this basis, MMC would appear 250 times more potent a mutagen, 
than EMS. This method does not however take into account the toxicity of 
the chemical. An alternative method used by Jensen and Thilly (1986) is 
based on the arithmetic relationship between cell killing and gene mutation. 
Lethal hits are calculated at -In (survival). The plots of EMS- and MMC- 
induced mutation against the number of lethal hits for V79 in the present 
study are given in Fig.3.4. From these graphs, EMS induces a mutant fraction 
of 860 x 10‘6 for each lethal event, whilst MMC induces a mutant fraction of 
17 x 106 per lethal hit. Jensen and Thilly have estimated the portion of the 
hprt gene sequence that, if altered, would result in 6-TG resistance mutants 
is about 1000 bp (exons and regulatory sequences). Thus to convert events per 
gene to events per cell, the ratio of base pairs per cell (3 x 109) to base pairs 
per gene (1 x 103) may be used.
Therefore for EMS:
(860 x 10'6)(3 x 109)
(1 x 103)
= 2580 detectable mutations occur per lethal event on a cellular basis.
For MMC:
(27 x 10'6)(3 x 109)
(1 x 103)
= 81 detectable mutations occur per lethal event on a cellular basis.
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Figure 3.4. Comparison of mutant fractions induced by EMS and MMC to the 
number of lethal events in V7 9 cells
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Thus, when comparing the chemicals as regard gene mutation relative \ 
to cell killing, EMS is 32 x more potent than MMC.
3.2.3. Discussion
In this study the ability of EMS and MMC to induce mutation at the hprt locus 
of V79 cells was examined. The monofunctional alkylating agent, EMS, caused 
a high frequency of mutants resistant to 6-TG, which was as expected since 
EMS is recommended for use as a positive control, giving a well defined 
response in the HPRT assay (Nestmann et al.> 1991). The level of mutants 
obtained was in close agreement with published studies using similar doses of 
EMS and 5 /xg/ml 6-TG as the selective agent, for example van Zeeland and 
Simons (1976), and O’Donovan (1990), although in this latter study EMS was 
far less cytotoxic. This variability in cytotoxicity may be due to strain 
differences between the V79 culture lines, since a similar protocol to that of 
O’Donovan was used in the present study.
In contrast to EMS, MMC was a poor inducer of mutations at the hprt 
locus of V79 cells, and was cytotoxic at much lower concentrations. Since 
Vijayalaxmi and Evans (1984) have reported that in tissue culture medium the 
biological half-life of EMS is 5.3 h and that of MMC is "many hours", the 
difference seen in mutation frequencies is unlikely to be due to significantly 
different rates of chemical decay during the 3 h exposure period. Nishi et al. 
(1984) found similar levels of mutants and survival to those reported here 
after MMC treatment of V79 cells using 1.67 ^g/ml 6-TG as the selective 
agent.
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Although the bifunctional alkylating activity is thought to be responsible 
for the lethal effects and chromosome breaking ability of MMC (Tomasz et al., 
1988), the gene mutagenic effect of MMC has been attributed to DNA- 
monoadducts which appear to occur at least 10 times more frequently than 
DNA crosslinking (Teng et al., 1989). The participation of monoadducts in 
gene mutations has been shown by Carrano et al. (1979) and Nishi et al. (1984) 
using MMC and decarbamoyl mitomycin C (DCMMC) which, due to the lack 
of a carbamoyl group at the CIO position in the latter compound cannot cross­
link DNA. Both MMC and DCMMC were found to induce similar mutant 
frequencies in the HPRT assay implying that the monoadducts are primarily 
responsible for the mutagenic response.
The precise nature of the monoadducts that lead to MMC-induced gene 
mutations are as yet unknown. Singh and Gupta (1983) detected no increase 
in ouabain resistance (OuaR) in CHO cells exposed to MMC. It has been 
suggested by van Zeeland (1988) that in general mutation at the Na+/K + 
ATPase locus is most likely to be due to apurinic sites, since a poor correlation 
is found between 0 6-alkylguanine and OuaR. It is possible therefore that 
0 6-guanine MMC monoadducts are responsible for the gene mutations induced 
by MMC. Furthermore the poor mutagenic response obtained may be due to 
the large size of the MMC-monoadduct, which may be more efficiently 
removed by repair processes, than the smaller lesions produced by agents such 
as EMS (Carrano et al., 1979), or may result in lesions that are more readily 
converted to other types of DNA damage rather than to the type of mutations 
that can be detected at the hprt locus.
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The HPRT assay measures forward mutations in a non-essential gene, 
provided the alteration causes a loss in activity of the normal HPRT enzyme. 
In theory, the assay should therefore be capable of detecting a range of 
mutational events including both single base changes and larger damage 
(Gupta and Singh, 1982). Also, the large size of the hprt gene (>34kb in the 
hamster) would be expected to permit the. detection of larger deletions than, 
for example, the aprt gene (2.5kb). However there do appear to be limitations 
in the detection of mutants at loci located on hemizygous chromosomes 
(Yandell et al., 1986). Although intragenic mutations, including deletions of 
the entire hprt sequence are recoverable, mutations involving not only the hprt 
locus but also essential genes adjacent on the X-chromosome, would lead to 
cell death. In addition, repair pathways such as those involved in 
recombination or gene conversion, require a second homologous chromosome 
to act as a template, and therefore such pathways could not function at 
hemizygous loci (Liber et al., 1989a).
These factors could explain the difference seen in the mutagenic 
response of EMS and MMC at the hprt locus. Whilst EMS is a potent point 
mutagen, and hence causes intragenic mutations, many of the lesions caused 
by MMC may result in large multilocus deletions which are not compatible 
with viability at the hemizygous hprt locus. The molecular nature of the 
HPRT mutants induced by EMS and MMC is discussed later in this thesis.
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3.3. The HPRT assay for somatic mutations in humans
3.3.1. Introduction
The examination of peripheral blood lymphocytes for genetic damage is 
frequently used to assess human exposure to occupational and environmental 
factors that may pose a carcinogenic hazard. Two assays have been developed 
for the analysis of in vivo gene mutations using cloned T-lymphocytes: HPRT 
assay and HLA (histocompatibility antigen) assay. The HLA system has the 
advantage in that it selects mutants at an autosomal locus (Turner et al., 
1988), but is technically more difficult to perform. The HPRT assay, although 
probably limited by the spectrum of mutational damage that can be detected 
at a X-chromosome-linked gene, is the most commonly used method for 
monitoring human populations for gene mutations in somatic cells.
The frequency of HPRT mutants has been studied in apparently healthy 
individuals (Trainer et al., 1984; Albertini, 1985; Henderson et al., 1986; Tates 
et al., 1991) and indicates a large variability in mutant frequency. This may 
in part be due to experimental factors (Featherstone et al., 1987; Cole et al., 
1988) and in part due to donor factors such as age, sex and life-style habits 
(Trainer et al., 1984; Cole et al., 1988; Tates et al., 1991; Branda et al., 1993). 
Furthermore Cole et al. (1988) reported variation in mutant frequency when 
repeat samples were obtained from the same donor, and therefore suggested 
that the assay is probably not suitable for studying mutation in single 
individuals. However, it is suggested that at the population level the HPRT 
assay may be used to investigate donor factors, and to examine groups that 
may be genetically more susceptible, such as those having DNA repair or 
cancer-prone syndromes (Cole et al., 1990a).
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The HPRT assay has also been used to investigate the effect on mutant 
frequency of occupational or medical exposure to cancer-inducing agents. 
These have included ionising radiation (Messing and Bradley, 1985; Seifert et 
al., 1987; Hakoda et al., 1988) and cytotoxic drugs (Chrysostomou et al., 1984; 
Dempsey et al., 1985; Hiittner et al., 1990). Most human exposure investigated 
to date has been to high concentrations of cytotoxic agents administered to 
cancer patients, which have shown a 3- to 5-fold increase in 6-TG resistant 
colonies. Morley (1990) has therefore suggested that at the lower levels of 
environmental mutagens more likely to be encountered by human populations, 
the HPRT assay is unlikely to be sufficiently sensitive for monitoring 
exposure, and would require the study of exposed and control groups 
containing several hundred individuals to predict mutagenicity. One reason 
for this low sensitivity may be natural selection against 6-TG resistant 
lymphocytes which has been shown to occur in vivo (Dempsey et al., 1983), 
since in females heterozygous for Lesch-Nyhan syndrome only 1-9% of 
lymphocytes exhibit the 6-TG resistant phenotype, rather than the 50% 
expected. Alternatively, Ammenheuser et al. (1988) have suggested that the 
small increases in HPRT mutants detected may be due to the antitumour 
agents tested also being potent clastogens, which induce multilocus alterations 
not viable at the X-chromosome-linked hprt locus.
The present study was undertaken to investigate the ability of the 
HPRT assay to detect in vivo somatic mutations in human peripheral blood 
lymphocytes. The degree of variability in mutant frequency of lymphocytes 
from normal healthy adults, and the contribution of donor factors to this 
variability was examined.
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3.3.2. Results
Blood samples were obtained from 24 male and 24 female volunteers belonging 
to an amateur sports and social club. Each individual completed a 
questionnaire designed to obtain details of past and present health status and 
life style which might be relevant to the interpretation of the results. No 
subject reported exposure to mutagens either occupationally or medically, 
other than occasional diagnostic X-rays. Assays were performed on coded 
samples. These results have been reported by Davies et al. (1992).
The statistical analysis was performed by Dr D.P. Lovell.
Mutation data were not obtained from seven individuals because there 
was either little or no growth in the non-selected wells. Data were available 
from 41 individuals as well as information on age, sex, smoking, alcohol and 
caffeine intake and in the case of females, whether using a contraceptive pill 
or not. The HPRT mutant frequencies for these 41 individuals are given in 
Table 3.5
Statistical analysis was first performed using univariate statistics; linear 
regression and analysis of variance. There was a highly significant linear 
regression (P< 0.001) of mutant frequency with age, with an increased 
frequency of 0.09/106 for each year of age (Fig.3.5). However, two men with 
high mutant frequencies (Nos. 3M and 28M) may have a disproportionate 
effect on this rate of increase. No significant differences in mutant frequencies 
were found between the various categories of smoking (Fig.3.6.) (non-smokers 
= 2.44/106; ex-smokers >5 y = 2.89/106; ex-smokers <5 y = 4.28/106; smokers 
= 2.15/106; F (3,37) = 1.17, NS), or between the sexes (male = 3.03/106, 
female = 2.55/106; F (1,39) = 0.02, NS). There was no relationship between
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Donor Age
Smoking
category
Plating efficiency Mutant frequency
Po %PE Po MF/106 cells
10 M 23 NS 49/96 33.63 462/469 2.24
11 M 23 NS 53/96 29.70 477/480 1.06
12 M 30 NS 34/96 51.90 468/480 2.44
24 M 43 NS 32/96 54.93 365/378 3.19
25 M 28 NS 39/96 45.04 459/480 4.97
26 M 43 NS 60/96 23.50 477/480 1.33
34 M 28 NS 51/96 31.63 478/480 0.66
42 M 34 NS 39/96 45.04 468/480 2.81
2 M 49 ExS (>5y) 49/96 33.63 466/480 4.40
21 M 41 ExS (>5y) 48/96 34.66 470/480 3.04
22 M 41 ExS (>5y) 41/96 42.54 469/480 2.72
27 M 51 ExS (>5y) 51/96 31.63 474/480 1.99
3 M 50 ExS (<5y) 57/96 26.06 452/480 11.53
23 M 24 ExS (<5y) 52/96 30.66 472/480 2.74
28 M 60 ExS (<5y) 45/96 37.88 444/480 10.29
44 M 25 ExS (<5y) 55/96 27.85 478/480 0.75
4 M 44 S 49/96 33.63 474/480 1.87
29 M 55 S 45/96 37.88 471/480 2.50
36 M 25 S 53/96 29.70 477/480 1.06
37 M 28 S 57/96 26.06 477/480 1.20
43 M 22 S 62/96 21.86 478/480 0.96
5 F 49 NS 48/96 34.66 464/480 4.89
8 F 52 NS 50/96 32.96 463/468 1.65
13 F 34 NS 51/96 31.63 468/480 4.00
15 F 23 NS 37/96 47.67 471/480 1.99
20 F 23 NS 39/96 45.04 476/480 0.93
31 F 33 NS 47/96 35.71 475/480 1.47
32 F 52 NS 46/96 36.79 467/480 3.73
40 F 27 NS 39/96 45.04 461/480 4.48
48 F 24 NS 47/96 35.71 476/480 1.17
49 F 23 NS 60/96 23.50 478/480 0.89
33 F 35 ExS (>5y) 74/96 13.01 476/480 3.22
47 F 52 ExS (<5y) 56/96 26.96 475/480 1.94
14 F 42 ExS (<5y) 67/96 17.98 463/466 1.80
30 F 31 ExS (<5y) 58/96 25.20 475/480 2.08
41 F 24 ExS (<5y) 7/96 130.92 448/480 2.63
46 F 51 ExS (<5y) 44/96 39.01 471/480 2.43
7 F 55 S 43/96 40.16 454/467 3.52
17 F 20 S 62/96 21.86 479/480 0.48
18 F 36 S 48/96 34.66 464/480 4.89
38 F 26 S 37/96 47.67 467/480 2.88
M, male; F, female; NS, non-smoker; S, smoker; ExS, ex-smoker.
Plating Po is the number of negative wells/No. of wells plated for non-
selective plates.
Mutant Po is the number of negative wells/No. of wells plated for
selective plates.
Efficiency % PE = -Ln (plating Po)
----------------  x 100
2 *
Mutant frequency = PE in selective medium
PE in non-selective medium 
-Ln (Mutant Po) x 100/(2 x 104) *
Efficiency % PE 
* Number of mononuclear cells/well 
Table 3.5. Individual data for donors
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alcohol (Fig.3.7.), or caffeine containing drinks (coffee/tea) intake (Fig.3.8.) and \ 
mutant frequency. A significant difference was seen between females using 
the contraceptive pill or not (users = 1.67/106, non-users 3.14/106; F (1,18) 
= 7.73, P<0.05) (Fig.3. 9). This result should, however, be interpreted with 
caution as the women reporting contraceptive pill usage were also younger 
(20-35 y) than non-users (24-56 y). Age and pill usage may therefore be 
confounded in this study.
Significant variability in mutant frequency was found among different 
weeks of sampling (F (5,35) = 2.66/106, p<0.05) with a trend for decreasing 
incidence with increasing week number (ranging from 5.18/106 in week 1 to 
1.72/106 in week 6). As experimental factors were rigorously controlled it is 
unlikely that such factors contributed to these differences, however, it is 
possible that the age of the volunteers sampled each week may have affected 
the variability seen, for example the age range in week 1 was 36 to 55 and in 
week 6, 23 to 28. There was an increase in mutant frequency with age in all 
six weeks, in some cases these increases were statistically significant. An 
analysis of the pooled regression line showed it to be highly significant, but 
that there were no significant differences between the regression lines for the 
individual weeks. No significant differences in mutant frequency were found 
between the different pre-selection incubation periods (20 h = 2.69/106, 
40 h = 2.90/106, F (1,39) = 0.51, NS).
None of the factors investigated in this study appeared to affect plating 
efficiency in any of the statistical analyses carried out on the PE values. 
Plating efficiency was relatively high, a mean of 36.5 from the 41 individuals
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Figure 3.7. The effect of alcohol intake on mutant frequency
o, female; a, male.
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Figure 3.8. The effect of tea and coffee consumption on mutant frequency
o, female; male.
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Figure 3.9. The effect of contraceptive pill on mutant frequency
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where cultures were adequate. There was no significant correlation between \ 
mutant frequency and plating efficiencies (r(39) = 0.070). Three individuals 
had values very distinct from the others, two men (i.d. nos. 3M and 28M) had 
mutant frequencies greater than 10/106 (11.53/106 and 10.29/106 respectively) 
while one women (41 F) had a plating efficiency of 130.92 (this volunteer was 
diabetic and was prescribed insulin). If these three individuals are excluded 
from the correlation, the value becomes (r(36) = 0.378) which is significant at 
P<0.05. However, whilst this may be statistically significant, there is still a 
indication of a considerable spread of results and the finding may be of limited 
relevance. These calculations used the 'raw' plating efficiencies and mutant 
frequencies. Similar results were obtained on the log transformed data.
Stepwise multiple regression identified two factors which appeared to 
be responsible for 'explained' variation in the 41 individuals where mutant 
frequency data were available. These were, as found previously using the 
univariate analysis of variance, age and week of sampling. No other factors 
help improve the fit to the observed data. These two factors accounted for 
34% of the variation. The two men noted previously to have high mutation 
frequencies (nos. 3M and 28M) were again identified as possible outliers. As 
these two individuals were among the older subjects (50 and 60 years old, 
respectively) they may have a disproportionate effect on the age relationship.
3.3.3. Discussion
Monitoring human exposure to genotoxic agents has been used to assess 
occupational and environmental hazards, and many methods have been 
developed for this purpose. These have included cytogenetic studies (Galloway
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et al., 1986), gene mutation assays (Jensen et al., 1990), DNA and protein 
adduct formation (Watson, 1987; Periera and Chang, 1981) and the detection 
of mutagenic fractions in body fluids (Venitt, 1987). Such methods are useful 
to determine exposure to genotoxins, although as pointed out by Ashby (1988), 
cannot be used to predict an increased risk of cancer, but must be interpreted 
with the available evidence from epidemiology, animal and in vitro studies. 
Assays which measure mutation at selectable genes of blood cells are the only 
methods available at present for detecting somatic cell mutations, and thus 
may be particularly relevant in monitoring for carcinogen exposure. Of the 
assays of this type, mutation at the hprt locus has been the most frequently 
employed for human surveillance studies. One advantage in the use of the 
hprt gene is that results may be compared with those obtained in the in vitro 
mammalian cell HPRT assay. In addition, since the 6-TG resistant 
lymphocytes may be cloned, mutants can be characterised to determine the 
molecular mechanisms responsible for the mutant phenotype. In this respect 
however, the HLA assay may result in the recovery of a broader spectrum of 
mutations (Turner et al., 1988; Grist et al., 1992). Unfortunately time did not 
permit investigation into the nature of the DNA alterations in the present 
study.
The background frequencies of HPRT mutants were determined, since 
normal individuals have been shown to vary considerably in their lymphocyte 
mutant frequency (Trainer et al., 1984; Seifert et al., 1987; Cole et al., 1988). 
In the present study mutant frequency varied from 0.48/106 to 11.53/106 cells 
for 41 individuals for whom plating efficiency of the unselected lymphocyte 
population was adequate.
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In agreement with the results of others (Vijayalaxmi and Evans, 1984; 
Henderson et al., 1986) no significant difference in mutant frequency was 
found between the sexes. In contrast, a significantly higher level of SCEs have 
been found in females rather than males (Soper et al., 1984; Margolin and 
Shelby, 1985; Dewdney et al., 1986) and the incidence of chromosome 
aberrations is reported to be greater in females (Hedner et al., 1982; Anderson 
et al., 1988). However, the degree of mitogen-induced blastogenesis and the 
proliferation rate of lymphocytes has been reported to be higher in males than 
in females (Anderson et al., 1988).
An age-related increase in mutant frequency of 0.09/106 cells with each 
year of age was found in this study, where the age range was 20-60 years. An 
increase in mutant frequency of 0.24/106 cells per year (age range 19-74), has 
been reported by Vijayalaxmi and Evans (1984), 0.07/107 (age range 0-86) by 
Trainer et al. (1984), and 0.04/106 (age range 23-56) by Cole et al. (1988). 
Conflicting results were obtained by Strauss and Albertini (1979) and Bradley 
and Messing (1989) who found no age-related increase. Soper et al. (1984) 
reported that SCEs increase with age, but Dewdney et al. (1986) found no age- 
related effect on SCEs, and the same group reported no increase with age in 
chromosome aberrations (Anderson et al., 1988). Examination of the data 
shown in Fig.3.3. suggests that if the two older men with mutant frequency 
values of greater than 10 per 106 cells are excluded, then the age effect is 
restricted to individuals under the age of 30, particularly females. Although 
the data may be viewed as suggesting an increase with age which is dependent 
upon both age and sex, further studies involving much larger groups would be
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necessary to test this hypothesis. No age effect was seen by Sala-Trepat et al.
(1990) who studied 31 breast cancer patients.
No difference in mutant frequency was observed with alcohol intake 
(range 2-70 units/week) or tobacco usage. A lack of effect of smoking has also 
been reported by Albertini et al. (1988), Tompa and Sapi (1989) and Branda et 
al. (1993). In contrast Cole et al. (1988) found a highly significant increase in 
mutant frequency for smokers and an increase was also seen by Tates et al.
(1991) although it was not significant. Although Vrieling et al. (1992) found 
a significant increase in mutant frequency in smokers, interestingly the type 
of DNA damage did not vary between smokers and non-smokers. Bradley and 
Messing (1989) observed that, although smokers and non-smokers in a control 
group has similar mutant frequencies, smoking appeared to have a synergistic 
effect on occupational exposure to low doses of radiation. No significant 
differences in mutant frequencies were seen for exposure to X-rays (0 to 3 
diagnostic X-rays within the previous 12 months) or for coffee and tea intake 
(range 0 to 12 cups/day). Coffee intake has been reported to affect SCEs in 
Korean women living in an industrial environment (Shim et al., 1989). The 
apparently lower mutant frequency seen in females using the contraceptive pill 
compared to non-users, was probably due to the age differences between the 
two groups. An increased incidence of SCEs in contraceptive pill users has 
been reported by Balakrishna Murthy and Prema (1979), although no effect 
on chromosome aberrations, mitogen-induced blastogenesis or proliferation 
rate index was seen by Anderson et al. (1988).
In summary, a significant increase in mutant frequency with age was 
observed in this study. Other factors such as sex, smoking and drinking
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habits, tea/coffee drinking, or X-ray exposure had no effect. The lower mutant 
frequency seen with contraceptive pill usage was confounded by the difference 
in age between users and non-users. This study provides further information 
on HPRT mutant frequency to add to an historical database of control 
individuals.
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CHAPTER 4
CHROMOSOME ABERRATION IN V79 CELLS
4.1. Introduction
Since both gene and chromosome mutations are implicated in the process of 
carcinogenesis, chromosome aberrations are regarded as a suitable 
complementary genetic end point to specific-gene mutations for estimating the 
carcinogenic potential of chemicals. Tests for chromosome aberrations detect 
damage to the chromosome structure, in cells that have been blocked at 
metaphase by agents that interfere with the spindle apparatus. This damage 
results in breaks in the chromosomes which, due to mistakes in the repair 
process, are either left unrepaired or the DNA is inaccurately rejoined to 
produce abnormal configurations.
Agents that cause chromosome breakage have been divided into 2 main 
types: S-independent and S-dependent. Ionising radiation and radiomimetric 
chemicals are able to directly break the DNA backbone, and intercalating 
agents can distort the DNA helix to such an extent that breaks occur. These 
agents are S-independent and cause chromosome-type aberrations when the 
cells are treated in the Gx phase of the cell cycle. When treated in S phase a 
mixture of both chromosome-type and chromatid-type aberrations are seen, 
and only chromatid-type when the cells are treated in G2 phase. Most 
chemicals however are S-dependent, producing lesions in the DNA, which in 
S-phase interfere with normal DNA replication, resulting in chromatid-type 
aberrations.
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Indirect mechanisms that result in chromosome breakage have also 
been reported. Chemicals that effect specific chromosomal proteins such as 
DNA topoisomerase II and the peripheral proteins (PI proteins and 
perichromin) may result in chromosome stickiness, causing chromosome 
aberrations (Gaulden, 1987). Such changes are thought to induce chromosome 
breakage during movement of the chromatid during anaphase, as the result 
of mutations in the structural genes for the proteins, or by the direct action 
on the proteins by the chemicals. Such events are not easily distinguishable 
in metaphase preparation for the analysis of chromosome aberrations. 
Chromosome aberrations induced by formaldehyde and hypertonic culture 
medium have been suggested to be primarily due to the chromosome 
stickiness (Dowd et al., 1986; Gaulden, 1986). Chromosome stickiness was not 
found to be a mechanism in the formation of chromosome aberrations after 
treatment with MMC (Ferguson et al., 1985).
A second indirect mechanism by which chromosome breakage may occur 
involves chemically-induced changes in the methylation state of DNA (Smith, 
1991). Methylation of cytosine is thought to play an important role in 
stabilizing inactive chromatin domains by allowing the binding to specific 
proteins that prevent decondensing of the DNA. Changes in DNA methylation 
patterns have been associated with the early stages of carcinogenesis (Goelz 
et al., 1985). Changes in the DNA involving guanosines of CG dinucleotide 
pairs by deletion, substitution or unusual base pairing, that may provide weak 
sites for breakage during chromosome condensation are stabilized by a DNA 
methyltransferase, which methylates the cytosine of the CG pair. Thus 
chemical damage that causes a defect in the methylation system would result
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in an increased susceptibility to chromosome breakage, and it is thought also 
to result in an increase in recombinational events.
In contrast to breakage that results from the direct action of chemicals 
on DNA, both of the indirect mechanisms described are unlikely to induce 
chromosome aberrations that are apparent at the first metaphase after 
chemical treatment. Chromosome aberration tests usually examine changes 
at the first metaphase after chemical treatment of the cells since many of the 
damaged cells may not survive mitosis. Chemicals are more likely to cause cell 
death if they predominantly induce breaks and unstable aberrations such as 
dicentrics, rings, acentric fragments and asymmetrical rearrangements 
(Carrano, 1973). This is due to the prevention of cell division or to unequal 
segregation of the chromosomes, or loss of acentric fragments at division. 
Stable aberrations, such as balanced translocations, inversions and symmetrical 
rearrangements, will survive mitosis. However, many stable aberrations, for 
example reciprocal translocations and inversions together with small deletions 
of less than 106 base pairs cannot be detected in standard tests for 
chromosome aberrations (Radman et al., 1982). The gross events detected in 
the assays are assumed to indicate that these more subtle changes have also 
occurred after chemical treatment (Scott et al., 1990).
The clastogenicity of both EMS and MMC has been previously reported 
in the literature, with MMC inducing aberrations at much lower 
concentrations than those required for EMS. For example Ishidate et al. 
(1988) found the lowest effective concentration of MMC caused aberrations in 
Chinese hamster lung cells was 0.04 jug/ml, whereas for EMS it was 
500 jug/ml. However differences in sensitivities between cell lines and even
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between clones of the same cell line have been reported (Kirkland, 1992) and 
differences in protocols, particularly treatment times, make comparisons 
between the published results difficult.
The present study was undertaken to determine the extent to which 
chromosomal events, induced by EMS or MMC, contribute to the genotoxicity 
of these chemicals. Chromosome aberrations were scored at similar 
concentrations of the chemicals to those previously used for the HPRT 
mutation assay in the same, V79 cell line, in order to assess the possible role 
of chromosomal mutations on the recovery of gene mutations at a hemizygous 
locus. A higher concentration of EMS (2 mg/ml) was also included to ensure 
a positive response with this chemical.
4.2. R esults
Chromosome aberrations were scored in V79 cells after a 3 hour treatment 
with either EMS or MMC, and sampling times of 8 hr, 24 hr and 48 hr from 
the start of treatment. All types of structural aberrations were recorded 
including gaps; the aberration totals and the percentage of damaged cells were 
presented to include and exclude gaps, since their significance is uncertain 
(Scott et al., 1990).
No response was seen with EMS when the cells were scored at 8 hr 
from the start of treatment. However, at 24 hr a positive response was 
observed at concentrations of 1000 and 2000 fig/m l EMS (Table 4.1), consisting 
almost exclusively of chromatid breaks and interchanges (Fig.4.1). The 
number of gaps, predominantly of the chromatid-type, had also increased at 
the higher concentration of EMS. By 48 hr the number of aberrations was
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declining with aberrations only detectable at 2000 /-ig/ml, suggesting that the 
damaged cells had not survived more than the first 2 to 3 metaphases. Those 
detectable at 48 hr may have been due to an extensive cell-cycle delay in these 
cells; the number of chromosome breaks had increased slightly at 48 hr in cells 
treated with 2000 /xg/ml EMS (Table 4.1).
Like EMS, MMC did not induce an increase in aberrations at 8 hr, but 
the yield had increased by 24 hr in a dose-related manner (Table 4.2). Again, 
most aberrations were chromatid breaks and exchanges, although the numbers 
of chromosome-type events, both breaks and exchanges, were also elevated at 
0.5 pcg/ml MMC. The incidence of gaps increased, but less than seen with 
EMS. Many cells had multiple aberrations at the highest dose of MMC, and 
these included complex chromatid interchanges involving between 3 and 5 
centromeres (Fig.4.1). By 48 hr the number of aberrations observed had 
decreased considerably, with only cells treated with 0.5 fig/m l MMC showing 
a response, when compared to the number of aberrations seen in untreated 
control cultures (Table 4.2). Most of the damaged cells contained only a single 
chromosome aberration at 48 hr; cells containing multiple aberrations would 
be extremely unlikely to survive mitosis.
Using the method described by Jensen and Thilly (1986) to express 
chromosomal damage in terms of the toxicity of EMS or MMC, the number of 
aberrations observed was plotted against lethal hits, calculated as -ln(survival). 
As can be seen in Figure 4.2 this gave values of 20 x 10'2 induced aberrations 
per lethal hit for EMS, and 115 x 10‘2 for MMC. Thus relative to lethal 
damage, MMC is far more potent than EMS at inducing clastogenic events.
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Figure 4.2. Comparison of chromosome aberrations induced by EMS and MMC 
to the number of lethal hits in V79 cells
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4.3. D iscussion
Both EMS and MMC induced chromosome aberrations in V79 cells in this 
study, and for both compounds the highest yield of aberrations was obtained 
at a harvest time of 24 h from the start of treatment. For many compounds 
a harvest time of between 17 and 21 h has been suggested to be optimal for 
detecting aberrations in CHO cells (Bean et al., 1992), although the optimal 
time varied with each concentration of the chemical used. Lower doses of a 
compound would be expected to produce less cell-cycle delay than higher doses. 
However, Armstrong et al. (1992) concluded that even weakly clastogenic 
chemicals could be detected at a single sampling time of 24 h from the start 
of treatment. The results shown here are in agreement with this, since for 
both EMS and MMC the number of aberrant cells was declining at the later 
harvest time of 48 h. Bean et al. (1992) also reported that for a diverse range 
of chemicals the frequency of aberrant cells declined rapidly to reach near 
control values by 30 h.
In this study EMS caused an increase in aberrations at 2000 and 
1000 fig/m l but not at 500 /xg/ml EMS. At the higher concentration many of 
the damaged cells contained two or more aberrations. It was particularly 
noticed that gaps were rarely seen as the only damage to a cell, but the reason 
for this was unknown. When gaps were excluded, EMS induced mainly 
chromatid-type breaks and exchanges, although a small number of 
chromosome-type breaks and exchanges were also seen in cells treated with 
2000 fig/ml EMS.
At a harvest time of 24 h MMC induced aberrations at all concentrations 
tested, in a dose-related manner. Although again mainly chromatid-type
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breaks and exchanges were observed, an increase in chromosome-type 
alterations (breaks and exchanges) was seen at the highest concentration, 
0.5 fig/ml. The number of gaps had also increased, but to a lesser extent than 
with EMS. Many of the cells had multiple damage, which often included 
complex chromatid exchanges. Scott et al. (1991) reported that the detection 
of cells with multiple damage requires a delayed harvest time (24 h) and may 
be caused by indirect as well as direct mechanisms. A similar result in CHO 
cells treated with MMC was seen by Armstrong et al. (1992) who also observed 
many cells with multiple damage at 24 h from the start of treatment.
Ishidate et al. (1988) suggested that chemicals which induce exchange- 
type aberrations are more likely to be rodent carcinogens, since deletions are 
usually lethal to the cell. However, it is also recognised that agents which 
produce gross chromosomal deletions visible under the light microscope will 
also induce submicroscopic deletions (Scott et al., 1990). As has been 
previously discussed, such deletions have been implicated in the carcinogenic 
process, particularly in the inactivation of tumour suppressor genes. Although 
relatively little information is available concerning genetic alteration in tumour 
suppressor genes in experimentally-induced rodent cancers (see, for example, 
Lilleberg et al., 1992) it is likely that deletion events will be shown to be 
important in at least some chemically-induced rodent cancers.
The purpose of this study was to determine if EMS and MMC induced 
chromosomal events which might explain the difference in the abilities of the 
two chemicals to induce gene mutations in the HPRT assay. Indeed, at the 
highest concentrations tested in the HPRT system, MMC induced chromosome 
aberrations in a much higher proportion of cells than did EMS: 82% aberrant
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cells at 0.5 /xg/ml MMC compared with 25% aberrant cells at 1000 /ig/ml EMS. 
Thus, in the HPRT assay it is likely that the poor efficiency with which MMC 
induced mutation was due to the induction of structural alterations involving 
both the hprt gene and other essential genes on the X-chromosome.
141
CHAPTER 5
THE L5178Y TK+/  MUTATION ASSAY
5.1. Introduction
The ability of most mammalian cells to synthesis purine and pyrimidine 
nucleotides by both de novo and salvage pathways is used, in a similar way to 
that already described for HPRT mutants, to select for mutants deficient in 
the enzyme thymidine kinase (TK). Using the salvage pathway, thymidine 
derived from degraded DNA or supplied in the culture medium, is 
phosphorylated to thymidine 5’-monophosphate (TMP) in the presence of TK 
(Fig.5.1). Selection of TK mutants is possible by adding toxic thymidine 
analogues, such as bromodeoxyuridine (BrdU) or trifluorothymidine (TFT) to 
the culture medium (Fig.5.2). Cells proficient in the enzyme (TK+) will 
incorporate the analogue into their DNA and will die; TFT is the preferred 
selective agent since BrdU requires 2-3 cells divisions before cell death occurs 
(Clive et al., 1983). In contrast, cells lacking the TK enzyme will survive this 
treatment since the analogue is not phosphorylated and therefore cannot be 
incorporated into the DNA
Wild-type TK+ cells are selected by growth in HAT media. Biosynthesis 
via the de novo pathway uses the enzyme thymidylate synthetase (TS) to 
catalyse the conversion of deoxyuridine monophosphate (dUMP) to TMP 
(Fig.5.1). This enzyme is inhibited by folic acid analogues such as aminopterin, 
but cells having a functional salvage pathway can utilise exogenously added
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Figure 5.1. Simplified scheme of pyrimidine metabolism
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Figure 5.2. The structure of thymidine and its toxic analogues. All are 
substrates for the enzyme, thymidine kinase
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thymidine to synthesise TMP. Cells deficient in TK cannot grow since they 
have no functional salvage pathway and do novo synthesis is blocked.
Although the tk gene is located on an autosome, chromosome 11 in the 
mouse, the L5178Y-3.7.2C cell line is heterozygous for this locus (tk+/'). These 
heterozygotes have been shown to have about 50% of the thymidine kinase 
enzyme activity of the original, homozygous (tk+/+) cells (Clive et al., 1983). 
Since only one functional allele is present, a single-step mutation results in the 
TFT-resistant phenotype.
Mutants at the tk locus show a bimodal distribution in the sizes of 
colony isolated: large colonies showing a normal growth rate, and small 
colonies which have a slower rate of growth than wild-type cells. Clive et al. 
(1979) suggested that these sizes represented 2 genetic classes of mutations; 
large-colony mutants were due to intragenic mutations affecting only the tk 
gene, whereas small-colony mutants represented multilocus mutations 
involving the tk locus and adjacent genes which affected growth rate, even 
when present on the homologous chromosome. Since small-sized colonies were 
not normally observed in non-selected cultures of mutagen-treated cells, Clive 
et al. (1979) concluded that the slow-growth characteristic was not due to 
secondary mutations occurring independently of the mutation affecting the tk 
gene.
Hozier et al. (1982) have reported a heteromorphism in the centromeric 
region of chromosome 11 which allows distinction of the tk* and tk' 
chromosomes. Cytogenetic studies using banding techniques have 
demonstrated that visible alterations are often associated with the small-size 
TK mutant phenotype. In contrast, no visible alterations in the
145
chromosome 11 carrying the functional tk gene could be detected for large- 
colony TK mutants (Moore et al., 1985). Analysis of chromosome aberrations 
and small-colony mutants induced by 34 chemicals showed no simple 
correlation between these two endpoints (Moore and Doerr, 1990), which was 
suggested to be due to the different subpopulations of chromosome damage 
evaluated by the two assays. One important difference is that in the TK 
system, the chromosomal damage represents events which are compatible with 
cell viability. Slow-growing TK mutants may also be the result of mitotic 
recombination or gene conversion, events which are often not discernable by 
gross chromosome analysis (Moore and Doerr, 1990).
The mouse lymphoma L5178Y-3.7.2C cell line grows rapidly in 
suspension media with a generation time of 10-12 hours, a high cloning 
efficiency, and a stable, near-diploid number of chromosomes (40 ± 1). Besides 
mutation at the tk locus, this cell line has been used to study other gene- 
mutation endpoints, namely 6-TGR and OuaR (Cole and Arlett,1984) and for 
assessing chromosome damage using the micronucleus assay (Cole et al., 
1990b). The ability of L5178Y cells to grow in suspension means that large 
numbers of cells can be treated and maintained. An additional advantage is 
the shorter expression time required for TFT resistance (2 days), as compared 
to 6 TG resistance (6 days), and subsequent savings in time and cost.
However, this shorter expression time may, in certain circumstances, be 
disadvantageous; if a high level of growth inhibition occurs with the test 
compound, the cells may not have recovered completely from the toxic effects 
during the normal 2 day expression period. A decrease in cell survival with no 
concurrent increase in mutants results in what is known as "the distilled water
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effect", and may result in an erroneous estimate of mutant frequency at high1 
toxic doses of chemical (Green and Muriel, 1976). The TK assay, in common 
with other in vitro tests that measure chromosome damage, also appears to 
be susceptible to chemicals that produce conditions of physiological stress in 
the culture medium, for example, high osmolarity, extreme pH (Scott et al., 
1991) which can lead to artifactual increases in mutant frequency.
In situations where a mammalian cell mutation assay is required by 
regulatory authorities, the TK assay has, in recent years, become the most 
recommended test system. Nestmann et al. (1991) reported that 50% of tests 
for mammalian gene mutagens were conducted in the L5178Y TK+/* assay.
The present study investigates mutation at the tk locus of mouse 
lymphoma cells induced by EMS or MMC. The ability of these two chemicals 
to induce the large- or small-colony TKR phenotype and their relative 
frequency was used to compare the apparent capacity to induce intragenic 
mutations or larger, intergenic damage.
5.2. Results
The experiments reported here were undertaken in collaboration with Dr B. J. 
Phillips (BIBRA).
Four mutation assays were carried out with EMS, and three assays with 
MMC, using the microtitre cloning technique described by Cole et al. (1983a). 
The plates were scored visually using an inverted microscope, and individual 
colonies were sized using an ocular micrometer. Colonies of 1 mm or above 
were classified as "large", and those of less than 1 mm as "small". Survival was
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measured immediately after mutagen treatment as recommended by Arlett\ 
and Cole (1990).
The dose range for EMS was selected from preliminary experiments to 
give a similar survival rate as that previously observed for V79 cells. This 
proved to be similar concentrations of EMS for both cell types, although with 
L5178Y cells there was an initial shoulder to the curve, not seen with V79 cells 
(Fig.5.3). The results for survival following treatment with EMS are given in 
Table 5.1; in experiments where duplicate plates were used, plating efficiency 
and survival were calculated from the mean number of negative wells observed 
in the 2 plates. Survival was determined as a percentage of the control 
(untreated) cultures and showed a dose-dependent increase in cytotoxicity 
(Fig.5.3) ranging from 100% at 100 ^g/ml EMS to 27.9% at 1000 /xg/ml EMS 
(based on the results of 3 experiments).
The TFTr mutant frequencies induced by EMS are given in Table 5.2. 
A dose-related increase in mutant frequency at the tk locus was observed, 
which is illustrated in Figure 5.3 (based on the results of 4 experiments). 
Although each individual experiment showed an increase in the total number 
of mutants, the proportion of large- and small-sized colonies induced by EMS 
varied between experiments (Table 5.2). However, it was clear that EMS 
induced a dose-related increase in both sizes of mutant colonies.
To estimate the mutant frequency, plates were scored for the total 
number of negative wells and for the number of wells which did not contain 
large colonies. This allowed calculation of the total mutant frequency and 
large colony frequency; the proportion of small-colony mutants was then 
estimated by subtraction. This method however did not give a true value,
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Cone. EMS 
mg/ml Negative wells % PE (mean) % Survival
Experiment 1
0 21,34 63 .9 100
0.1 32,27 59.2 92.6
0.3 25,28 64.5 100.9
1.0 69,77 13.8 21.6
Experiment 2
0 11,2 150.9 100
0.25 3,7 152.9 101
0.5 9,11 113 .5 75.2
1.0 24,58 47.3 31.3
Experiment 3
0 10, 5 130.4 100
0.25 6 138.6 106.3
0.5 14 96.3 73.8
1.0 43 40.2 30.8
Table 5.1. Survival of L5178Y cells immediately post EMS treatment
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Cone. EMS 
mg/ml
Negative wells MF/106 survivors
Total Large % PE (mean) Total Large Small
Experiment 1 
0 91,90 94,95 173.3 17.0 4.5 12.5
90,88 95,91 193.6 19.6 8.2 11.4
0.1 74,77 85,85 228.2 49.7 26.7 23.0
79,74 88,86 193.6 58.6 25.4 33.2
0.3 66,54 81,68 147.7 159.1 85.8 73.3
54,63 67,81 103.9 238.3 125.3 113.0
1.00 47,41 70,62 75.9 514.0 246.8 167.2
55,49 72,72 53.4 574.2 269.4 304.8
Experiment 2 
0 86,83 86,83 138.6 46.0 46.0 0
90,87 93,88 173.3 23.6 17.0 6.6
0.25 66,66 75,76 96.3 194.5 124.7 69.8
59,61 72,74 96.3 244.0 142.2 101.8
0.5 53,50 62,59 76.0 409.7 333.7 76.0
45,48 57,55 63.4 517.7 425.1 146.6
1.0 57,54 67,65 19.5 1405.0 960.7 444.3
60,57 74,63 21.1 1173.1 799.8 373.9
Experiment 3 
0 90,93 96,96 138.6 17.3 0 17.3
0.25 59,66 73,82 113.1 189.7 94.7 95.1
0.5 33,32 56,53 118.4 457.4 239.1 218.3
1.0 26/87,31 53/87,60 43.5 1342.3 544.0 798.3
Experiment 4
0 77,82 81,86 159.4 64.5 43.7 20.8
75,84 83,84
0.1 60,69 70,82 145.1 137.0 80.5 56.5
0.3 26,42 37,63 147.3 352.3 221.4 130.9
1.0 12,14 28,34 55.9 1795 1011 784
Large = 1 mm or >; Small = < 1 mm.
Table 5.2. The Induction of TFT resistant mutants in L5178Y by EMS
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since not all wells received a single cell inoculum, and some wells were, 
observed to contain more than one colony. To investigate the true proportion 
of large and small mutants, individual colonies were sized and counted, and 
these figures used to calculate the percentage of each colony type. The results 
are illustrated in Figure 5.4. On this basis 35% of spontaneous mutant 
colonies were small and 65% large. The proportion of small-sized colonies was 
increased only slightly, to 41%, in EMS treated cultures.
The survival data for MMC-treated L5178Y cultures is given in 
Table 5.3. A clear, dose-related decrease in survival was observed, as shown 
in Figure 5.3 (based on the mean of 3 experiments). It was apparent that 
mouse lymphoma cells were more sensitive than Chinese hamster lung cells 
to the cytotoxic effect of MMC, since a concentration of 0.25 ^g/ml resulted in 
a decrease in survival to 17% of control values in L5178Y cultures, whereas 
0.5 (JLg/ml was required to reduce survival to this level in V79 cultures.
A dose-dependent increase in TFTR mutant frequency was observed for 
MMC (Table 5.4; Fig.5.3). In each of the 3 experiments more small- than 
large-sized colonies were apparent. The proportion of the two sizes of mutant, 
when individual colonies were taken into account, were 36% large and 64% 
small in MMC-treated cultures.
As shown in Figure 5.4 a definite bimodal distribution of colonies was 
seen for both spontaneous mutants and those induced by the two mutagens. 
In each case the division of the two size classes appeared to be at 
approximately 1 mm. Small-sized colonies were also occasionally observed in 
non-selective plates, but did not reflect this bimodal distribution.
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When the mutagenic effects of EMS and MMC at the tk locus were 
compared on the basis of mutagenic potency:
D10C EMS 3.3 mM
2.7 mM
2.7 mM
1.4 mM
(Exp 1) 
(Exp 2) 
(Exp 3) 
(Exp 4)
Mean D10C EMS = 2.5 mM
and, D10C MMC = 0.677 p M  
0.308 p M  
0.542 p M
(Exp 1) 
(Exp 2) 
(Exp 3)
Mean D10C MMC = 0.509 p M
Thus, MMC was 5000 times more potent a mutagen than EMS at the 
tk locus, compared with only 250 times more potent at the hprt locus of V79 
cells.
The EMS- and MMC-induced TK mutant frequency was plotted against 
the number of lethal events (-In survival), and these graphs (Fig.5.5) used to 
calculate mutant fraction in terms of toxicity on a cellular basis (Table 5.5). 
Using this method EMS was 1.9 times more potent than MMC, compared with 
32 times in the HPRT assay. For large colony mutants only, EMS was 2.4 
times more potent than MMC, and for small colony mutants, 1.3 times more 
potent than MMC when toxicity was taken into account (Table 5.5).
5.3. Discussion
The spectra of genetic damage induced by chemicals are known to differ, and 
the use of an assay inappropriate for the detection of particular types of 
damage, will result in only limited, or even false, information as to the
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Cone. MMC 
mg/ml Negative wells % PE (mean) % Survival
Experiment 1
0 2 193.56 100
0.062 11 108.32 56.0
0.125 22 73 .76 38.1
0 .25 51 31.63 16.3
0.5 93 1.59 0.8
1.0 96 0 0
Experiment 2
0 6 138.6 100
0.062 17 86.6 62.5
0.125 24 69.3 50.0
0.25 63 21.1 15.2
Experiment 3
0 10.5 13 0.4 100
0 . 05 9 118 .4 90.8
0.1 17 86.6 66.4
0.25 59 24.3 18.6
Table 5.3. Survival of L5178Y cells immediately post MMC treatment
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Cone. MMC 
mg/ml
Negative wells
% PE (mean)
MF/10e survivors
Total Large Total Large Small
Experiment 1
0 78,77 83, 83 193 .6 55 .3 37.6 17.7
0.062 61, 62 81,79 113 .1 197.0 80.6 116 .4
0.125 41,49 73,76 78 .4 483.2 161.7 321.5
0.25 75, 70 91,91 27.8 505.0 96.2 408.8
Experiment 2
0 85, 87 93, 99 147.7 37.2 18.1 19.1
0.062 71, 67 80,83 67.3 245.4 121. 7 123 .7
0.125 65,61 85, 80 81.0 260.0 93 .6 166.4
0.25 67, 61 88,84 23.5 851.6 234.0 617.6
Experiment 3
0 77, 82 82,85 159.4 59.2 43 . 8 15 .4
0.05 72, 71 86, 81 102 .3 144.0 68.2 75.8
0.10 69,63 83, 84 81.5 229.9 85.6 144 .3
0.25 63, 57 82, 80 24.7 951.4 343 .9 607.5
Large = 1 mm or >; Small = < 1 mm.
Table 5.4. The induction of TFT resistant mutants in L5178Y cells by MMC
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Mutagen Experiment
Mutants/lethal
No.
hit
Total Large Small
EMS 1 1200 480 720
2 3480 2400 1020
3 3570 1440 1900
Average 2750 1440 1213
MMC 1 1080 480 600
2 1500 600 960
3 1860 720 1260
Average 1480 600 940
Ratio EMS:MMC 1.9 2.4 1.3 •
The values were obtained by plotting mutant frequency against -In (Day 0 
survival) (Fig.5.5) and used to calculate events per cell as:
Mutant frequency x 10'6 per lethal hit) (base pairs per cell)
(base pairs per gene)
= (MF x '6/lethal hit) (3 x 109)
(1 x 103)
Table 5.5. Mutagenicity expressed in terms of toxicity
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158
genotoxic status of a chemical. In the present study MMC was shown to give \ 
a strong positive response at the tk locus of L5178Y cells, whereas this 
chemical gives only a weak response in many assays for point-mutational, or 
intragenic, endpoints. An efficient inducer of point mutations, EMS is detected 
using point-mutational endpoints at comparable frequencies to those seen in 
the TK assay.
More small-colony TK mutants (64%) were observed with MMC than 
with EMS (41%), Clive et al. (1979) suggested that small-sized mutants could 
be due to chromosomal alterations involving both the tk locus and adjacent 
genes, which in the hemizygous state, affected cell growth. This was 
substantiated by Moore et al. (1985) who found, using the centromeric 
heteromorphism to identify the chromosome functional for the tk gene 
(chromosome lib ), that 59% of the small-sized colonies had abnormalities 
affecting this chromosome, visible using banding techniques. A modification 
of this technique, allowing analysis earlier in the clonal history of TK mutants, 
showed an even higher proportion, 93%, of small colonies to have chromosomal 
damage involving chromosome l ib  (Hozier et al., 1985). The higher number 
of abnormalities found in the latter study were due to the inclusion of 
dicentrics, potentially unstable chromosome rearrangements leading to 
karyotypic instability. These later resolve into an apparently normal 
karyotype, although not to reversion to the TFT-sensitive phenotype. As 
pointed out by Hozier et al. (1985) however, this higher proportion of small 
colonies showing chromosome l ib  abnormalities may have been due to the 
clastogenic specifity of the chemicals chosen for study.
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Recently, Moore et al. (1991a) have reported that the purine analogue,' 
2-amino-N6-hydroxyadenine (AHA), which induces mainly large colony mutants, 
also induced small-colonies in which only 10% showed alteration in banded 
karyotype analysis. It was suggested that these chromosomally-normal small­
sized mutants resulted from multi-gene point mutations affecting both the tk 
gene, and loci elsewhere in the genome affecting cell growth. Although this 
may somewhat limit the use of the TK assay in defining point mutagens and 
clastogens, it does emphasise the range of genetic events that maybe detected. 
Small colony mutants therefore appear to be due to intergenic mutations 
affecting the tk gene and linked genes on the same chromosome, multiple 
point mutations arising independently which affect the tk gene and other 
single loci elsewhere in the genome, and presumably intragenic tk mutations 
with chromosomal events not involving chromosome lib . The majority of 
small colonies would be expected to represent intergenic mutations of tk and 
linked genes (Clive et al., 1991).
The definition of large- and small-sized colonies varies between 
laboratories; this may depend on whether the soft agar or microtitre cloning 
method is used, and whether colonies are measured by eye or using an 
automatic colony counter. These size differences used to define small colonies 
may explain the variation in the proportion of small colonies exhibiting 
chromosomal abnormalities seen between laboratories as noted by Clive et al. 
(1991).
The slow-growth rate may be due to a gene-dosage effect, or to allelic 
differences in a growth gene adjacent to tk, whereby this gene when linked to 
the active tk allows normal growth, but if linked to the inactive tk permits
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only slow growth. The latter case appears to be the more likely explanation 
since Moore et al. (1985) have described a slow growing, small-sized mutant 
having two chromosomes 11a (carrying the inactive tk gene), but which had 
lost chromosome lib . Further evidence for this allelic difference was reported 
by Amundson and Liber (1991), using subclones of the human lymphoblastoid 
cell line, TK6 , which carried the active tk gene on alternate chromosomes 
(chromosomes 17a and 17b in the human). When the tk+ locus was carried on 
chromosome 17a, a reduced level of TFT-resistant mutants induced by X-rays 
was seen, which was due to a lack of small colonies.
A number of chromosomal events may result in the small-colony 
phenotype, including deletions, insertions and translocations (Moore et al., 
1985). Besides resulting from direct interaction of the chemical with DNA, 
chromosome damage may also occur due to indirect mechanisms, such as 
intercalation without covalent binding, or oxidative damage, which can induce 
recombinational events. Chemicals may also interact with non-DNA targets 
such as enzymes or the structural proteins of chromosomes (Casciano et al., 
1991). One such candidate is topoisomerase II, each dimer of which is a 
potential specific break site in DNA, and suggested by Clive (1989) to possibly 
be a preferred site for SCEs, mitotic recombination and gene conversion.
Mechanisms of genotoxicity which involve non-DNA target may be 
caused by chemicals for which there is no classical structural alert (Clive, 
1989) and would not be detected in bacterial assays since their chromosomes 
are DNA-only. Recombinational mechanisms induced by chemicals affecting 
DNA or non-DNA targets, require the presence of the homologous 
chromosome (Liber et al., 1989a), and thus cannot operate at hemizygous loci,
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such as hprt. However, at the autosomal tk locus, recombinational events are 
permitted. The importance of recombinational mechanisms resulting in the 
loss of a dominant allele in relation to tumour suppressor genes is discussed 
elsewhere in this thesis.
The TK assay therefore seems to be capable of detecting a wide range 
of mutational events including point mutations and intragenic rearrangements, 
chromosomal damage (deletions, inversions, translocation), and mitotic 
recombination and gene conversion. Further evidence that higher mutant 
frequencies are recovered at heterozygous loci, for chemicals that 
predominantly induce chromosomal mutations, has been obtained using 
different endpoints. Bradley et al. (1988) used X-ray induced mutation to 
compare mutant frequencies in aprt heterozygotes and homozygotes, and 
found a 100-fold increase in mutants using aprt+/' compared with aprt'/0 cell 
lines. Waldren et al. (1986) constructed a hybrid CHO cell line ALJ1, 
containing a single human chromosome 11, carrying 3 antigenic markers as 
selective endpoints. Since none of the genes on the human chromosome was 
essential for viability of the hamster cells, X-ray induced mutants, due to 
structural damage of the human chromosome, or even loss of the whole 
chromosome, were recoverable, resulting in a 200-fold increase in mutant 
frequency at the antigenic endpoint compared with HPRT mutant frequency 
in normal CHO cell lines. Unlike the TK assay however, neither of the two 
endpoints described exhibited a bimodal distribution of size in the mutant 
colonies.
In the present study therefore it is probable that the higher mutant 
frequency seen with the clastogen, MMC, at the tk locus compared with the
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frequency at the hprt gene, is due to the recovery of TK mutants that have 
sustained chromosomal damage at the heterozygous tk locus. The small colony 
TK mutants induced by EMS may have arisen due to chromosomal 
abnormalities or to multi-gene point mutations. The molecular analysis of 
these mutants as described later will give further insight into the actual DNA 
damage sustained by large- and small-colony TK mutants.
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CHAPTER 6 
MOLECULAR ANALYSIS OF MUTANTS
6.1. The hprt gene
The hprt gene is located on the X-chromosome in a variety of mammals 
including man, mouse and hamster (Chinault and Caskey, 1984). This 
facilitates nucleic acid analysis since male derived cell lines have no second 
copy of the gene to mask the identification, by molecular techniques, of altered 
DNA fragments arising as the result of mutation. Deaven and Petersen (1973) 
have found CHO cells to contain only one X-chromosome, which have led to 
this female hamster ovary cell line to also be used for molecular studies of 
HPRT mutants.
The hprt gene extends to 36 kb in the hamster (Rossiter et al., 1991) 
and sequences coding for the enzyme are divided into 9 exons, separated by 8 
intron regions (Chinault and Caskey, 1984). The full structure of the hamster 
gene has recently been published (Rossiter et al., 1991), and is comparable to 
that of the mouse and human, which show remarkable similarity in length of 
exons, and in the sequences at intron/exon junctions, although differences in 
intron regions exist (Stout and Caskey, 1985). The structure of the hprt gene 
for these three species is given in Fig.6.1. In all three species the hprt coding 
region is 654 nucleotides long, and flanked by sequences which are transcribed 
into hprt mRNA, but are not translated into the HPRT protein. The 5’- 
untranslated sequence is about 100 nucleotides, and the 3’-untranslated
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region varies from 470 to 570 nucleotides according to the species (Stout and 
Caskey, 1985). Homology between all three species is about 95% in coding 
regions and 80% in untranslated regions. Single nucleotide changes result in 
7 amino-acid differences, out of 217, between mouse and hamster HPRT 
proteins, and 7 differences also exist between the mouse and human (Chinault 
and Caskey, 1984). Most of these are conserved changes with respect to 
amino-acid class.
Besides the functional gene, regions on autosomes showing sequence 
homology to hprt have been detected; 4 such sequences exist in man (Patel et 
al., 1984) and one each for mouse (Melton et al., 1984b) and hamster (Fuscoe 
et al., 1983). These sequences are thought to represent processed, 
unexpressed psuedogenes derived from spliced ENA intermediates (Stout and 
Caskey, 1985).
"Housekeeping” genes, such as hprt, are expressed in all tissues, 
although often at different levels, and of those housekeeping genes 
characterised so far, all appear to share certain regulatory nucleic acid 
sequences, which differ from those of regulated genes (Stout and Caskey, 
1985). In common with other housekeeping genes such as dihydrofolate 
reductase and phosphoglycerate kinase (Beebee and Burke, 1988), hprt is 
lacking in TATA and CAAT boxes (Melton et al., 1986) but instead a G-C rich 
region exists (80% of the lOObp immediately flanking the 5’ end of the gene). 
Melton et al. (1986) have shown this G-C rich region to contain the hprt 
promoter sequences.
The expression of hprt is low in most cells, accounting for 0.005-0.01% 
of the total mRNA species (Melton et al., 1981), although higher levels are
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found in the central nervous system (0.02-0.04% of total mRNA). The size of 
the hprt mRNA is about 1.6 kb (Stout and Caskey, 1985).
The isolation of complimentary DNA (cDNA) probes for selectable genes 
has made possible the study of mutational changes at the DNA level. The 
cDNA for hamster hprt has been identified and cloned by Konecki et al. (1982) 
as a sequence of 1301 nucleotides, which includes the entire coding region (654 
nucleotides). The cell line used for the isolation of hprt mRNA was a 
spontaneous revertant of an EMS-induced HPRT misssense mutant, RJK159, 
found to over-produce hprt mRNA due to gene amplification. This mRNA 
acted as the template for cDNA synthesis, which was made double-stranded 
and cloned into pBR 322. This plasmid is designated pHPT12 .
In this study the range of molecular changes in HPRT deficient 
mutants, induced by EMS or MMC, or occurring spontaneously, was 
investigated using Southern and Northern blotting and ribonuclease A 
cleavage. Non-mutant (HPRT+) clones were also analysed to determine if 
mutations had occurred that did not lead to the 6-TG resistant phenotype.
6.1.1. Southern analysis o f HPRT mutants
Structural changes in genes can be identified by digestion of DNA with 
restriction enzymes, and comparison of the fragment patterns of mutant and 
non-mutant clones after Southern blotting (Southern, 1975). Occasionally loss 
or gain of a restriction site will be due to a base change within the recognition 
sequence, but most point mutations will be undetected by Southern analysis. 
In general, DNA fragment pattern changes will indicate that large alterations 
such as deletions or re-arrangements have occurred within the gene.
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6.1.1.1. Introduction
The molecular nature of HPRT mutants in cultured mammalian cells has been 
investigated by several groups, mainly using Southern blotting techniques to 
detect large scale alterations in the hprt gene after mutation induction by 
physical or chemical agents. Mutant clones having no detectable changes are 
presumed to arise by point mutations, and sequencing techniques are 
beginning to be used to confirm this.
Most studies have been concerned with the spectrum of mutation 
caused by ionising radiation, which appears to induce a high frequency of 
deletion mutants at the hprt locus. Fuscoe et al. (1986) found 2  total- and 2  
partial-deletions amongst 8 X-ray induced mutants of V79 cells examined by 
Southern blotting. Total gene deletions also accounted for about one half of 
the X-ray-induced mutants studied by Aghamohammadi et al. (1992). Analysis 
of 20 X-ray induced HPRT mutants of RJKO cells (a derivative of V79) by 
Chaudhry and Fox (1990) revealed 9 to have lost the entire hprt gene, and 
Vrieling et al. (1985) found similar results for 12 out of 19 X-ray induced 
mutants of V79 cells. Morgan et al. (1990) studied a total of 89 X-ray induced 
mutants of CHO cells and found 54 to have total deletions of the hprt gene, 
and 25 to have partial loss or re-arrangements. In 12 of the 15 mutants 
showing partial deletions the breakpoints were mapped to the 3’ half of the 
gene which Morgan et al. suggested may be more sensitive to the mutagenic 
effect of X-rays.
Similar results have been demonstrated for 7 -rays and a-particles 
(Thacker, 1986). Southern blotting of 7 -ray-induced HPRT mutants of V79 
cells detected 20 total- and 10 partial-deletions in a total of 43 mutants tested,
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whilst for a-particle-induced mutants this was 6 total- and 5 partial- out of 15 
mutants. Anon-random distribution of breakpoints was again observed for 14 
partial deletion mutants, with 8 of the 28 breakpoints occurring between exons 
4 and 5 (Thacker et al., 1990).
A comparable spectrum of radiation-induced mutations has also been 
observed in cultured human cells. Using a human lymphoblastoid cell line, 
TK6 , Liber et al. (1987) found 14 total- and 1 partial-deletions in a series of 28 
X-ray-induced mutants. Three anonymous sequence probes for regions linked 
to the hprt gene on the X-chromosome of TK6 cells were used by Whaley and 
Little (1990) to demonstrate that although between 30-40% of mutants 
induced by X-rays or iodine isotopes had lost the entire hprt gene, only 3-7% 
had also lost one of the linked markers, and none had lost all 3. Thus the 
deletions did not involve large regions of the chromosome.
As a more rapid method than Southern blotting of screening for 
deletions in Chinese hamster cell lines, Xu et al. (1989) used the polymerase 
chain reaction (PCR) to amplify exons 3 and 9 of the hprt gene, which could 
then be detected on agarose gels. Of 15 X-ray-induced mutants 5 had lost both 
exons, whilst 6 had deletions only of exon 9, suggesting that mutants occur 
more frequently at the 3’ end of the hprt gene. In contrast, none of 10 UV 
light-induced mutants had lost both exons, although four partial deletions 
were observed, 1 involving exon 3, and 3 occurring at exon 9. Other studies 
have shown, using Southern analysis, UV light to induce almost exclusively 
point mutations (Fuscoe et al., 1983; Nussbaum et al., 1983).
Few molecular studies have been reported for chemicals that are known 
clastogens. Chaudhry and Fox (1990) found that among 41 methyl
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methanesulphonate-induced mutants of RJKO cells, 17 had lost the entire hprt 
gene. When the Southern blots for mutants showing no alterations were 
reprobed with sequences specific for exons 3 and 9, no small deletions in 
these exons were observed. Liber et al. (1989) detected 6  total- and 8  partial- 
deletions among 30 formaldehyde-induced mutants of TK6 cells, and Koberle 
and Speit (1991) found 9 total- and 4 partial- deletions amount 30 bleomycin- 
induced mutants of V79 cells analysed by Southern blotting.
Southern analysis of mutants induced by other chemicals have 
suggested that the 6-TG resistant phenotype arose mainly by point-mutations. 
Compounds studied in Chinese hamster cell lines have included the 
diolepoxide of benzo(a)pyrene (King and Brookes, 1984), EMS (Stankowski et 
al., 1986; Thacker and Ganesh, 1989) and ICR191 (Stankowski et al., 1986). 
Similarly, no changes detectable by Southern blotting were found in HPRT 
mutants of a mouse lymphoma cell fine, GRSL 13-2, treated with ethylnitro- 
sourea (Vrieling et al., 1988), or in adult rat liver (ARL) epithelial cells treated 
with benzo(a)pyrene or aflatoxin B2 (Armel and Williams, 1988). In contrast, 
Huang et al. (1989) detected 12 total- and 3 partial-deletions in 16 mutants of 
CHO cells treated with either of two purine nucleoside analogues 
9-B-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) and 9-B-D-arabino- 
furanosyladenine (ara-A) known to be incorporated into DNA.
The spectrum of alterations reported to occur in spontaneous mutants 
has varied considerably, as shown in Table 6.1. In an effort to rationalise 
these differences, the concentration of 6-TG used to select mutants was noted, 
however, contrary to expectations, more stringent selection appeared to favour 
recovery of point-mutations rather than major deletions. This is surprising
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Cone. 6-TG 
(pg/ml)
Cell
line
% Mutations
Point Deletions Reference
10 V79 100 0 Koberle & Speit, 1991
5 V79 100 0 Fuscoe et al., 1986
2 V79 100 0 Chaudhry & Fox, 1990
(30-azaguanine) V79 90 10 Fuscoe et al., 1983
1.67 CHO 78 22 Stankowski et al., 1986
1 TK6 67 33 Crosby et al., 1988
0.5 TK6 64 36 Liber et al., 1989
1 V79 62 38 Thacker & Ganesh, 1989
1.67 V79 60 40 Xu et al., 1989
1 TK6 59 41 Gennett & Thilly, 1988
0.5 TK6 43 57 Whaley & Little, 1990
Table 6.1. The spectrum of changes in spontaneous HPRTmutants of 
cultured cells
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since Van Zeeland and Simons (1976) found that only mutants having less than 
2% of normal HPRT activity are able to survive in concentrations of 5 pg/m l 
or above of 6-TG. Sequence analysis of spontaneously occurring mutants by 
Zhang et al. (1992) showed the majority to be base pair substitutions, mainly 
transversions, which were distributed throughout the hprt gene. Splice site 
mutations were responsible for about 30% of the mutations and deletions 
accounted for 10% of the spontaneous mutants.
6 .1.1 .2 . Results
Independent clones of both non-mutant (HPRT+) and mutant (HPRT ) 
phenotypes were isolated after EMS or MMC treatment, or from untreated 
cultures. Cloning rings, secured with silicon grease were placed over well 
separated colonies, the isolated colonies were trypsinised and removed with a 
pasteur pipette into 175 cm2 flasks and grown in DMEM growth medium 
under 5% C02 in air, at 37 °C. The clones were expanded by culturing in 
DMEM growth medium until each clone had reached between 2 and 5 x 108 
cells (average 6 passages), when the phenotype of each clone was checked by 
growing in 6-TG or HAT medium as appropriate. The cells were then 
pelleted, washed in PBS(A) and frozen in aliquots at -70°C. Approximately 
0.5 x 108 cells from these pellets was used for the extraction of DNA. Clones 
surviving expansion, and from which high molecular weight DNA was obtained 
are listed in Table 6.2.
The purity and quantity of DNAs was assessed by checking 1 y\ aliquots 
in 0.8% mini-gels and by taking spectrophotometric readings. The optical 
densities, measured at wavelengths of 260 and 280 nm, gave ratios of between
Code No. Exp. No. Treatment Phenotype
EMS 1 1 1000 pg/ml EMS HPRT’
EMS 2 1 1000 pg/ml EMS HPRT"
EMS 3 1 1000 fj g/ml EMS HPRT"
EMS 4 1 1000 /vg/ml EMS HPRT"
EMS 5 1 1000 /jg/ml EMS HPRT"
EMS 7 1 1000 pg/ml EMS HPRT*
EMS 8 1 1000 pg/ml EMS HPRT"
EMS 9 1 1000 /vg/ml EMS HPRT"
EMS 10 1 1000 /'g/ml EMS HPRT"
EMS 11 1 1000 /'g/ml EMS HPRT+
EMS 12 1 1000 /'g/ml EMS HPRT +
EMS 13 1 1000 /'g/ml EMS HPRT+
EMS 14 1 1000 /'g/ml EMS HPRT +
EMS 15 1 1000 /'g/ml EMS HPRT +
MMC 2 2 0.5 /'g/ml MMC HPRT"
MMC 3 2 0.5 /'g/ml MMC HPRT'
MMC 6 2 0.5 /'g/ml MMC HPRT"
MMC 7 2 0.5 /'g/ml MMC HPRT"
MMC 10 2 0.5 /'g/ml MMC HPRT"
MMC 12 2 0.5 /'g/ml MMC HPRT"
MMC 13 2 0.5 /jg/ml MMC HPRT"
MMC 14 2 0.5 /'g/ml MMC HPRT"
MMC 15 2 0.5 /'g/ml MMC HPRT"
MMC 16 2 0.5 /'g/ml MMC HPRT"
MMC 17 2 0.5 /'g/ml MMC HPRT"
MMC 18 2 0.5 /'g/ml MMC HPRT"
MMC 25 2 0.5 /'g/mi MMC HPRT+
MMC 26 2 0.5 /'g/ml MMC HPRT+
MMC 27 2 0.5 /'g/ml MMC HPRT+
MMC 28 2 0.5 p g/ml MMC HPRT+
MMC 31 2 0.5 /'g/ml MMC HPRT+
MMC 34 2 0.5 /'g/ml MMC HPRT+
MMC 36 2 0.5 /'g/ml MMC HPRT+
MMC 37 2 0.5 /'g/ml MMC HPRT+
MMC 39 2 0.5 /'g/ml MMC HPRT+
MMC 40 2 0.5 /'g/ml MMC HPRT +
Table 6.2. Origin of clones used in Southern blot analysis to detect 
changes in hprt locus
continued....
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Exp. No. Treatment Phenotype
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
HPRT"
HPRT'
HPRT"
HPRT"
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
HPRT+
continued
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1.78 and 1.85, which indicated that the DNAs were uncontaminated by either 
RNA or protein species. For each DNA sample concentrations of 
approximately 2 mg/ml were obtained.
After extraction, the DNAs were subjected to restriction enzyme 
digestion and Southern blotting. Six restriction enzymes were used: EcoRI, 
Hind III, Bgl II, Kpn I, BamH I, Pst I. The normal restriction patterns for 
these enzymes, as seen with the DNA extracted from wild-type (HPRT+) V79 
cells, probed with the hamster hprt cDNA, are shown in Fig.6.2. Bands, 
reported in published studies to be due to the non-functional hprt pseudogene 
are shown where detected. However, in this study, they were often absent, 
probably due to the stringent post-hybridisation washing procedures used. 
Characterisation of pseudogene fragments for certain enzymes, is sometimes 
inconsistent. For example with the enzyme BamH I Fuscoe et al. (1983) 
identified the 18kb fragment as being of pseudogene origin, whilst Huang et 
al. (1989) assigned the pseudogene to the 23kb fragment and Kaden et al. 
(1989) identified both bands as being part of the functional hamster gene. 
During Southern blotting the DNA fragments were transferred to either 
Nytran (EMS-treated cells) or Genescreen plus (MMC- treated cells). 
Genescreen plus was used in the later experiments as it gave less background 
binding and slightly clearer DNA bands.
None of the 9 EMS-induced mutants analysed showed any changes in 
restriction patterns with the 6 enzymes used (Table 6.3). Similarly, four 
spontaneous mutants showed no alterations, nor were any changes seen in 
non-mutant clones from either EMS- or MMC-treated, or untreated cultures 
(Table 6.3.)
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Figure 6.2. Known fragment patterns with restriction enzymes at the
hyrt locus
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Treatment
No. of clones examined No. with changes
HPRT+ HPRT' HPRT+ HPRT'
None 12 4 0 0
EMS 5 9 0 0
MMC 10 12 0 4
Table 6.3. Southern blot analysis of treated and untreated V79 clones 
: number of clones with detectable changes in restriction
fragment pattern
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In contrast 4 out of 12 MMC-induced mutants showed changed 
detectable by Southern blotting. The details of these changes are given in 
Table 6.4. Examples of these changes are shown in Fig.6.3. Mutants MMC 14 
and 15 showed complete loss of all fragments with each of the six restriction 
enzymes, and thus mutation in these clones is due to total deletion of the hprt 
gene.
The two other mutants showing alterations detectable by Southern 
blotting are probably partial deletions. The recent publications by Morgan et 
al. (1990) and Thacker et al. (1990) have assigned the exon regions of the 
hamster hprt gene to particular fragments generated by certain restriction 
enzymes. Thus it is possible to map tentatively deletions involving part of the 
hprt gene.
Mutant MMC3 has lost the 17kb (exons 6-9) and 12.5kb (exons 2-4) 
fragments with EcoR I but has gained a 14.5kb band. The llk b  (exons 6-9) 
Hind III band is missing, and in its place a 22kb band is seen. With Pst I the 
7.7kb (exons 6-8) fragment is lost, and is replaced by a very faint band 
migrating to 4kb. The 23kb BamH I fragment containing exons 5-9 (Rossiter, 
et al., 1991) appears to be reduced to about 20kb. The 6 .6kb Kpn I fragment 
is also lost, but the location of exons is unknown for this enzyme. The 
changes in restriction patterns suggest that MMC3 may contain an intragenic 
deletion of about 3.5kb and involving at least exon 6 . Since the 1.5kb Bgl II 
fragment, to which exons 7 and 8 have been assigned, is still present the 
alteration does not appear to extend beyond exon 6 . Thacker et al. (1990) 
have located both exon 4 and exon 6 to bands of 4.3kb with Bgl II, so loss of 
exon 6 cannot be verified. The results with EcoR I and Hind III do not
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Nature
Restriction
enzyme Clone No .
of fragment change
Loss Gain
BamH I MMC 3 23kb 20kb
MMC 7 11.5kb -  •
MMC 14 Total -
MMC 15 Total -
Bgl II MMC 7 3. 4kb -
MMC 14 Total -
MMC 15 Total -
EcoR I MMC 3 17 & 12.5kb 14.5kb
MMC 7 8. 2kb -
MMC 14 Total -
MMC 15 Total -
Pst I MMC 3 7. 7kb 4 kb
MMC 14 Total -
MMC 15 Total -
Kpn I MMC 3 6. 6kb -
MMC 14 Total -
MMC 15 Total -
Hind III MMC 3 llkb 22kb
MMC, 14 Total -
MMC 15 Total
Table 6.4. Analysis of MMC-induced mutants with detectable chancres in 
restriction fragment pattern
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entirely agree with this interpretation, unless a loss of restriction sites for 
these two enzymes had occurred through gene rearrangement.
The fragment changes seen with mutant MMC7 are more difficult to 
interpret, since the 11.5kb BamH I fragment and 3.4kb Bgl II fragments have 
both been located to the hprt pseudogene. However, as mentioned earlier the 
assignment of BamH I bands to the pseudogene is somewhat confusing, and 
Kaden et al. (1989) have assigned this 11.5kb band to exon 1 of the functional 
gene. The 8.2kb fragment seen with EcoR I is not reported in most published 
studies; however this band is apparent in Southern blots of V79 cells analysed 
by Vrieling et al. (1985) and by Koberle and Speit (1991). Although it is 
probable that MMC7 contains a partial deletion, it is possible that this mutant 
arose due to a point mutation, and a co-incidental event has deleted the hprt 
pseudogene.
6 .1 .1.3. Discussion
Southern analysis of 9 EMS-induced and 4 spontaneous mutants showed no 
evidence of variation in the organisation of the hprt gene, which would be 
indicative of major gene alterations, such as deletions, insertions or 
translocations. Since however a change must have occurred to give rise to 6- 
TG resistance, it is probable that lesions such as point mutations or small 
deletions beyond the limits of detection by Southern analysis (<100bp) are 
responsible for the HPRT deficient phenotype. Similar results for EMS have 
been reported by Thacker (1986) and Stankowski et al. (1986).
Only a very limited number of spontaneous mutants were analysed in 
this study, since the spontaneous mutation rate was very low in the V79 cell
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line used, and the objective was to investigate the mutational events occurring 
in a standard mutation assay. Analysis of only 4 spontaneous mutants 
however does not allow any definite conclusions to be drawn as to the 
spectrum of mutations that could account of the HPRT deficient phenotype. 
The range of changes found in other studies (Table 6.1) could be due to: 
differences in the time allowed for fixation of pre-mutational lesions and the 
expression of mutation, the period of growth in 6 -TG, the concentration of the 
selective agent or differences in repair capacity between cell lines.
Certain cell lines have been reported to give rise to more deletion 
mutants at the hprt locus. Kaden et al. (1989) investigated the molecular basis 
of spontaneous HPRT mutants using a series of six Chinese hamster embryo 
fibroblast (CHEF) cell lines. Point mutations predominated in a control, non- 
tumorigenic cell line, whilst in 3 tumour-derived lines the majority of mutants 
had partial- or total-gene deletions. One tumour cell line gave a 25-fold 
increase in spontaneous mutants at the hprt locus, 90% of which carried point 
mutations; this cell line was presumed to have an alteration in a DNA 
replication or repair enzyme. The remaining tumour cell fine showed only a 
modest increase in deletional events (13%) above that seen in the control, non- 
tumorigenic cell line. Enzymic defects in DNA repair pathways were thought 
to be responsible for these differences in mutational events (Kaden et al., 
1989).
Molecular analysis of 12 MMC-induced mutants showed 4 to have 
detectable fragment changes; 2  had total deletions of the hprt gene, 1 had a 
partial deletion involving at least exon 6 , and 1 had a deletion of undetermined 
location. The remaining 8 mutants were presumptive point mutations. Large
182
deletions of the hprt locus have also been reported for methyl' 
methanesulphonate (Chaudhry and Fox, 1990), bleomycin (Koberle and Speit, 
1991) and ionising radiations (Thacker, 1986). As with MMC, these clastogenic 
agents induced point mutations as well as gene deletions. In this respect, the 
results of Huang et al. (1989) may be due to a different mechanism of 
mutation, since 15 out of 16 mutants induced by F-ara-A and ara-A were due 
to deletions. It is possible that these agents, besides inducing chromosome 
breakage, also inhibit the enzymes involved in its repair, as is known for 
another nucleoside analogue, ara-C, thus resulting in extremely high 
frequencies of deletional events.
Clastogenic agents, such as MMC in the present study, are extremely 
inefficient at inducing mutation at the hprt locus, and the percentage of 
deletions detected is unlikely to be representative of the total induced, since 
most will be several hundred kilobases long, and would result in cell death. 
Multilocus deletions that involve not only the hprt gene but also adjacent 
genes on the X-chromosome will only be recovered if they do not involve 
essential genes, since at hemizygous loci no second copy of the gene exists to 
provide the essential function. Species differences in the arrangement of the 
hprt gene on the chromosome may also be important, resulting in variations 
in the size of deletions that are recoverable in cell lines from different species.
No non-mutant clones, isolated after EMS or MMC treatment, or from 
untreated cells, showed any structural DNA changes detectable by Southern 
blotting. This is not surprising since these changes would be expected to be 
limited to small regions of the introns. Silent mutations resulting from base
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changes that do not alter protein function would not be detected by Southern 
analysis.
Most chemical mutagens induce both gene and chromosomal mutations. 
Obviously the most useful mutation assays are those capable of detecting both 
types of damage. Thacker and Ganesh (1989) have suggested that the HPRT 
assay is sensitive in detecting the mutagenic mechanisms of different DNA- 
damaging agents. However, the HPRT assay is very poor in detecting 
compounds that cause multilocus deletions, since the hemizygous nature of the 
gene results in the non-variability of the mutants. This study has shown that 
although the limited number of recoverable MMC-induced mutants at the hprt 
locus demonstrated a range of genetic damage, the percentage of deletion 
mutants was not consistent with the known potent chromosome-breaking 
ability of the compound. This was also shown for the clastogen, methyl 
methanesulphonate (Chaudhry and Fox, 1990), where only 17 out of 41 HPRT 
mutants analysed were due to large deletions at the hprt locus.
This study demonstrates that data on survival frequency must 
accompany the molecular analysis of chemically induced mutants, in order to 
assess the contribution of DNA damage to non-viability of the cells. 
Compounds which cause gross DNA damage cannot be assessed in assays in 
which such damage will lead to the non-viability of the mutants, and will give 
an inaccurate prediction of the predominant mechanisms by which a chemical 
induces mutation.
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6.1.2. Northern analysis o f HPRT mutants
Messenger RNA (mRNA) carries the genetic information coded by DNA in the 
nucleus to the ribosomal site of protein synthesis in the cytoplasm (MacLean, 
1989). The mRNA molecule produced from a gene can be altered by mutations 
in the coding regions of the DNA; nonsense and frameshift mutations may 
result in a non-functional mRNA, as for example in some forms of 
Mediterranean fi-thalassaemia where no fi-globin is produced (Orkin and 
Kazazian, 1984), or base-pair changes may result in an aberrant mRNA and 
the synthesis of an abnormal protein, as occurs for the p21 ras protein 
(Marshall, 1989). Major gene damage, such as large deletions, will result in no 
mRNA being produced, as for example in many cases of DMD (Davies and 
Read, 1988).
During processing of the precursor mRNA (hnRNA) intron sequences 
are normally spliced out of the transcript (Sharp, 1987). Thus most mutations 
in introns will not affect the mRNA. However changes in splice-site sequences 
at the intron/exon junctions can result in the "skipping" of one or more exons 
from the mRNA during processing; this has been observed in the Rb gene of 
patients with retinoblastoma (Yandell et al., 1989). The use of a cryptic splice 
site in an exon will lead to only part of an exon being lost from the mRNA; a 
change of this type has been described by Gibbs et al. (1990) in a Lesch-Nyhan 
patient resulting in 17 bases of exon 9 being deleted in the hprt mRNA. A 
number of mutations in the human hprt gene were found by Steingrimsdottir 
et al. (1992) to result in aberrant splicing of the hprt mRNA. Mutations 
affecting the splice acceptor sites of introns 3, 5 and 6 of the hprt gene 
resulted in loss of the downstream exon, whereas when the mutation occurred
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in the splice acceptor sites of introns 7 or 8  a cryptic site in the downstream 
exon was utilised.
Conversely, utilisation of a cryptic splice site in an intervening sequence 
will cause intron material to be incorporated into the mature mRNA. Splicing 
defects of this type have been found in certain forms of B-thalassaemia 
(Trisman et al., 1983), where loss of the donor splice site at the 
exon 1 /intron 1 junction and the utilisation of 3 cryptic splice sites within the 
first intron, create a mixture of variously spliced mRNAs from which no 
functional B-globin chains can be translated. Point mutations may introduce 
alternative cryptic donor- or acceptor-sites into exon or intron sequences. One 
such example occurs in the Mediterranean form of B+-thalassaemia 
(Weatherall, 1991) where a G->A transition in a intron region rich in 
pyrimidines produces an AG acceptor site. Competition between the cryptic 
and authentic splice sites results in a mixture of functional and non-functional 
mRNA, leading to an 80% deficiency in B-chain synthesis.
Regulation of protein synthesis is essential for the normal functioning 
of cellular processes (Ross, 1989). Over-production of a protein involved in cell 
proliferation can play a role in tumour development (Teich, 1986), and under­
production has been implicated in many human diseases including a and 
B-thalassaemia (Weatherall, 1991). Regulation of the gene product results 
both from the control of the rate of transcription from DNA into mRNA and 
from post-transcriptional mechanisms governing mRNA breakdown (Saini et 
al., 1990).
Mutations involving promoter or enhancer regions may significantly 
change the level of gene transcription. One of the most studied examples is
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the c-myc translocation in Burkitt’s lymphoma that places c-myc sequences 
under the control of powerful immunoglobulin promoters leading to the 
inappropriate expression of c-myc (Leder et al., 1986). Regulation of c-fos 
transcription has been shown to be altered by mutation at a site for 
transcription factor binding upstream of the c-fos gene (Verma and Sassone- 
Corsi, 1987).
Both the 5’- and 3-’ untranslated regions of mRNA have been implicated 
in the modulation of mRNA stability (Cleveland, 1989). Mutations in either 
of these two regions may affect the half-life of the mRNA by making the ends 
of the mRNA more, or less likely targets for nuclease attack, perhaps by 
changing molecular configuration (Ross, 1989; Saini et al., 1990). Changes in 
the 3’-untranslated regions of both c-myc and c-fos have been shown by 
Piechaczyk et al. (1988) to result in altered stability of the mRNAs.
Thus analysis of mRNA size and amount by Northern blotting will 
detect not only differences in the gene such as major deletions (that are 
apparent by Southern blotting), but will also indicate the presence of point- 
mutations affecting the level of transcription, processing or the stability of the 
mRNA molecule.
6.I.2.I. Introduction
The analysis of hprt mRNA has been used to provide information on the 
nature of mutations at the hprt locus, particularly those showing no structural 
changes on Southern blotting. These data are summarised in Table 6.5.
Using RNA dot blots and Northern analysis, Thacker and Ganesh (1989) 
studied 13 spontaneous HPRT mutants for which no large structural DNA
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changes were apparent. Approximately half, (7/13), had normal levels of 
mRNA, while 6 mutants had reduced levels ranging from < 10% to 80% when 
compared to mRNA from wild-type V79 cells. No spontaneous mutants were 
found to have changes in the size of the hprt mRNA. Liber et al. (1989) found 
similar results from 10 spontaneous mutants of TK6 cells, 4 mutants had 
normal mRNA levels, 5 had reduced levels and 1 produced no detectable hprt 
mRNA. One mutant with a reduced level also had a mRNA of reduced size, 
about 300 bases were missing from the message, although no changes in the 
DNA could be detected. This mutant was thought to have a base substitution 
affecting RNA processing. Liber et al. also studied 4 mutants carrying partial 
deletions in the hprt gene. Two mutants missing part of the 5’ region of the 
gene, and one which had lost material from the 3’ end of the gene produced 
no mRNA. The other mutant which appeared to have a 2kb deletion of either 
exons 7 and 8 , or part of exon 9, synthesised message of about 100 bases 
shorter than normal and of reduced amount (Liber et al., 1989).
In contrast, Chaudhiy and Fox (1990) found only 1 out of 6 spontaneous 
mutants, carrying presumptive point mutations, able to produce normal 
mRNA. The other 5 mutants showed no mRNA detectable by Northern 
blotting analysis, although a small amount of mRNA was demonstrated for one 
of these mutants by reverse transcriptase-PCR amplification.
Spontaneous mutants of a CHEF cell line studied by Kaden et al. (1989) 
using Northern blotting showed the majority (11/13) to have normal hprt 
mRNA, while 2/13 had reduced levels. Two tumour-derived CHEF cell lines 
gave similar results. Three other tumour-derived lines gave a higher 
proportion of mutants expressing reduced or no mRNA, although a smaller
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number of mutants were studied, since these lines had a much higher 
incidence of deletion mutants.
Northern blotting has also been used to study hprt in chemically-induced 
mutants (Table 6.5). Vrieling et al. (1988) using TK6 cells found 19/29 ENU- 
induced mutants to have normal mRNA levels, 5/29 to have reduced levels and 
5/29 to have no detectable hprt mRNA. It was supposed that reduced levels 
were due to mutations causing instability of the message rather than 
mutations in the promoter regions, since no enzyme activity could be detected. 
Mutations in the GC-rich promoter region were suggested by Vrieling et al. to 
be responsible for those mutants expressing no mRNA, since this region has 
a more open structure, and therefore greater accessibility, for the ultimate 
alkylating species of ENU.
A wide range of mRNA levels was found by Thacker and Ganesh (1989) 
in EMS-induced mutants; 33/46 has reduced or absent mRNA, and 13/46 had 
normal levels. One mutant had both a reduced level, and a reduction in size, 
which since this mutant was reversible to HPRT-proficiency, was thought to 
be probably due to a point-mutation in a splice-site. In a series of 11 BPDE- 
induced mutants, King and Brookes (1984) found 7 mutants to have normal 
and 4 to have reduced mRNA levels. Two of the latter also had about 300 
bases missing from the mRNA, which were attributed to point-mutations in 
splice sites and an increased rate of degradation of the truncated mRNA. 
Formaldehyde-induced HPRT mutants of TK6 cells (Liber et al., 1989) showed 
a range of mRNA levels; half of the 16 mutants studied had normal levels, 
while 3 had reduced levels and 3 expressed no hprt mRNA. Another mutant 
had a normal level of a reduced size mRNA, having about 100 bases missing.
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Treatment
Cell
line Total
Normal
amount
hprt mRNA
Reduced 
amount None
Reduced
size Reference
None V79 13+ 7 6** 0 0 Thacker & 
Ganesh (1989)
None TK6 10 4 5 1 1* Liber et al. 
(1989)
None CHEF 13 1 0 5 0 Kaden et al. 
(1989)
None RJKO 6 1 0 5 0 Chaudry & Fox 
(1990)
ENU TK6 29 19 5 5 0 Vrieling et al. 
(1988)
EMS V79 4 6+ 13 33** 0 1* Thacker & Ganesh 
(1989)
Forma1dehyde TK6 16 9 3 3 1 Liber et al. 
(1989)
BPDE V79 11 7 4 0 2* King & Brookes 
(1984)
MMS RJKO 7 2 2 3 0 Chaudhry & Fox 
(1990)
+, based on dot blotting and Northern analysis 
*, mutant also has reduced amount of mRNA 
**; may include mutants having no mRNA
Table 6.5. Northern analysis of HPRT mutants with normal Southern 
blots investigated in other studies
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One mutant, showing a normal Northern blot pattern, was found, on 
sequencing the cDNA, to be lacking exon 8 . Since this exon is only 77 bp it 
was possible that the deletion was present in the DNA, but not detected by 
Southern blotting.
Northern analysis of MMS-induced mutants by Chaudhry and Fox (1990) 
showed 2/7 mutants to have wild-type mRNA levels, 2/7 to have reduced 
levels and 3/7 to have no mRNA. However PCR amplification of cDNA of 22  
mutants detected normal mRNA levels in half, reduced levels in 3 and the 
mRNA was undetectable in 6 mutants. Two mutants had mRNA of reduced 
size. Sequencing of cDNA transcribed from hprt mRNA was used to study 
2 -cyanoethylene-oxide induced mutants by Recio et al. (1990) who found a 
large number of splice-site mutations (19/39) causing loss of single or multiple 
exons in the cDNA. Recio et al. suggested that this large proportion containing 
splicing aberrations may be due to the preference of cyanoethylene-oxide for 
mutation at AT base pairs and the fact that splice acceptor sites are AT-rich. 
It was suggested that since splice mutations are not so common with other 
chemicals, the occurrence may be due to the mutagenic specificity of the 
chemical.
6.I.2.2. Experimental
Total cytoplasmic RNA was isolated from approximately 2 x 108 cells per clone 
using the method of Krawetz et al. (1986). The concentration and purity of 
the RNA samples was determined spectrophotometrically. The amount of 
RNA extracted from each cell pellet varied from 1.5 to 2.74 mg/pellet. Each 
sample was further checked for the integrity of the RNA by running 2 /xg
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aliquots of each in non-denaturing 0 .8% agarose mini-gels. The presence of 
well-defined bands, visualised by ethidium bromide fluorescence, at 5.0 kb and 
1.9 kb representing the 28 S and 18 S ribosomal RNAs respectively, were used 
to confirm the quality of the samples.
Northern blots were prepared using 20 pg of RNA per well in 
denaturing, 1% agarose gels. One outside lane in each gel contained a 
molecular weight marker consisting of a 0.24-9.5 kb RNA ladder. After 
electrophoresis the RNA molecules were transferred onto Nytran membranes 
and hybridised to a radiolabelled hamster hprt cDNA probe. Autoradiography 
in the presence of intensifying screens was at -70 °C for 3 to 21 days.
Difficulty was often encountered in obtaining clear hprt mRNA bands 
on the autoradiographs after Northern blotting. This problem was thought to 
be due to either; a) inefficient transfer of RNA from the gel to the membrane; 
or b) incomplete binding of the RNA to the membrane.
To assess if efficient transfer had occurred, methods of visualising RNA 
in the gels both before and after blotting, and their effect on the efficiency of 
transfer were investigated. Although RNA is single-stranded the molecules do 
contain secondary structures caused by hydrogen bonding between 
complementary bases within hairpin loops (Lehrach et al., 1977). Secondary 
structure must be removed for successful electrophoretic separation of RNA 
species according to molecular size. This is commonly achieved using 
denaturing agents, such as formaldehyde, in the agarose which, after initial 
heat denaturation of the RNA, form adducts with the amino groups of guanine 
and uracil, this preventing hydrogen bands forming during electrophoresis 
(Gurney, 1984). However when formaldehyde gels are stained with ethidium
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bromide the denaturant gives a high background fluorescence, which coupled 
with the weak binding capacity of ethidium bromide to single-stranded nucleic 
acids, often leads to difficulties in visualising RNA.
The effect of RNA staining on the efficiency of transfer was studied 
using 20 pg aliquots of the same RNA sample. Each treatment was prepared 
in triplicate and electrophoresed in parallel in 1% agarose gels containing
2.2 M formaldehyde. The gels were cut up as appropriate to facilitate the 
various treatments.
Treatment of the gels was as follows:
a) Lanes 1-3, controls, no treatment
b) Lanes 4-6, gel soaked in 50 mM NaOH/10 mM NaCl for 45 min at room 
temperature, then neutralised in 0.1 M Tris-HCl, pH 7.5 for 45 mins.
c) Lanes 7-9, gel stained in 33 pg/ ml acridine orange in gel running buffer 
for 20  min at room temperature, then destained in buffer alone for 
40 mins (McMaster and Carmichael, 1977).
d) Lanes 10-12, 1 pg ethidium bromide (1 pi of a 1 mg/ml solution) was 
added to heat-denatured RNA samples prior to loading the wells and 
visualised under UV-light after electrophoresis.
All gels were washed in 10 x SSC before blotting overnight onto Nytran 
membranes and hybridising to a radiolabelled hprt probe. Autoradiography 
was carried out at -70 °C with intensifying screens for 3 days.
As shown in Fig.6.4 bands of comparable intensity were obtained after 
all treatments. Addition of ethidium bromide to the sample prior to 
electrophoresis, or acridine orange staining after electrophoresis did not 
compromise transfer or hybridisation of the RNA. Visualisation of the gels
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1 2 3 4  5 6 7 8 9 10 11 12
* *  «  * *
Lanes 1-3 ,  no t r e a t m e n t
Lanes 4 -6 ,  g e l  d en a tu re d  and n e u t r a l i s e d
Lanes 7 -9 ,  g e l  s t a i n e d  w i th  33 f j g/ ml  a c r i d i n e  orange
Lanes 10-12,  1 y g ethidum bromide added t o  w e l l s
F ig u re  6 .4 .  The e f f e c t  o f  s t a i n i n g  on t h e  e f f i c i e n c y  o f  RNA t r a n s f e r  
d u r in g  Nor thern  b l o t t i n g
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before and after blotting showed that transfer was complete. Although 
Maniatis et al. (1982) state that hydrolysis in NaOH will improve transfer of 
high molecular weight RNA, in this study it had no effect on transfer. Since 
the addition of ethidium bromide to the wells was simple and allowed staining 
of RNA without background fluorescence from the gels, this method was used 
to check the efficiency of RNA transfer in all subsequent Northern blotting 
experiments.
It was apparent however that transfer was not the cause of the poor 
hybridisation to the probe which sometimes occurred (Fig.6.5A), and this was 
further investigated. Maniatis et al. (1982) state that the pH of the 
formaldehyde solution should be greater than 4.0. Since the pH of the 
formaldehyde stock in the laboratory was found to be 2 .8 , an aliquot of this 
solution was deionised in a mixed base resin until the pH was above 4.0. 
Separate denaturing gels were prepared using formaldehyde solutions at 
pH 2.8 or 4.0, and Northern blotting and hybridisation to a hprt probe was 
carried out using identical RNA samples. No difference in the efficiency of 
RNA transfer to the membranes was seen at either pH. However, as shown 
in Fig.6.5 the pH of the formaldehyde had a critical effect on the hybridisation 
capacity. Using formaldehyde at pH 4.0 in the gel, subsequent hybridisation 
gave clear, well-defined hprt mRNA bands whereas formaldehyde at pH 2.8 
resulted in only background hybridisation. Fourney et al. (1988) have reported 
that using formaldehyde at a concentration of 0.66 M instead of the normal
2.2 M in the gels results in better binding of the RNA to the nylon membrane. 
It is possible that the pH of the formaldehyde solution also affects RNA 
binding; at the lower pH binding may be incomplete resulting in loss of the
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F igu re  6 .5 .  The e f f e c t  of  pH of formaldehyde on h y b r i d i s a t i o n  o f  th e  
h p r t  probe to  RNA samples
A. Gels p r e p a re d  w i th  u n t r e a t e d  formaldehyde (pH 2.8)
B. Gels  p re p a re d  w i th  d e i o n i s e d  formaldehyde (pH 4.0)
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RNA during hybridisation or washing procedures. All subsequent Northern 
blots used deionised formaldehyde.
After hybridisation and autoradiography the hprt probe was removed 
from the blots. To check the equal loading of RNA in each well the 
membranes were reprobed with a 1.15 kb Pst I fragment of pAM91, containing 
the mouse skeletal actin cDNA. Since actin is unrelated to hprt and would 
therefore be unaffected by the mutational status of the clones, comparison of 
the hprt/actin signal could be used to determine differences in hprt mRNA 
levels between lanes.
Total cellular RNA from each independent HPRT+ and HPRT' clone 
listed in Table 6.2 was used for Northern blotting experiments. A large 
variation in hprt mRNA levels was found in the chemically-induced HPRT 
mutants (Table 6 .6), which when compared with the intensity of actin mRNA 
was not due to unequal loading of the RNA samples (Fig.6 .6).
No hprt mRNA was detectable for 4 MMC-treated mutants which had 
been shown by Southern blotting to have total- or partial-deletions of the hprt 
gene (Fig.6 .6). Three MMC-induced mutants had much reduced amounts and 
5 MMC mutants had normal levels when compared to the hprt mRNA of 
untreated wild-type cells (Table 6 .6).
Of the nine EMS-induced mutants analysed, 8 had normal hprt mRNA 
levels, and one had a reduced amount. The 4 spontaneous mutants had 
normal levels of mRNA. No mutants showed any variation in the size of the 
hprt mRNA.
Northern analysis of RNA from non-mutant clones also showed 
differences between untreated cells and cells exposed to either EMS or MMC
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hprt
a)
2 3 6 7 10  12  13  14 15 16  17  18
? t !!»
actin ►
b)
hprt ►
acting l . l
c)
• • •
hprt^
4 5  4 6  4 7  4 8  4 9  5 0  5 2  5 3  5 4  5 5  5 6  5 7
acting
(a)
(b)
MMC-treated mutan ts  ( 2 , 3 , 6 , 7 , 1 0 , 1 2 - 1 8 )  
MMC-treated non-mutan ts  ( 2 5 - 2 9 ,3 1 , 3 4 ,3 6 , 3 7 ,3 9 ) ,  
u n t r e a t e d  mutants  (41,42) and (c) u n t r e a t e d  non ­
mutan ts  (wild type ) (45-50 ,52-57)
B lo t s  were r e p ro b ed  w i th  a c t i n  cDNA
;. Examples of  N or the rn  b l o t t i n g  o f  RNA samples of  HPRT* and 
HPRT~ c lo n e s ,  a f t e r  h y b r i d i s a t i o n  w i th  32P - l a b e l l e d  ham ste r
h p r t  cDNA and a u t o ra d io g ra p h y
hprt mRNA
Increased Normal Reduced Reduced
Treatment Phenotype Total amount amount amount Size size
None HPRT' 4 0 4 0 0 0
EMS HPRT' 9 0 8 1 0 0
MMC HPRT' 12 0 5 3 4* 0
None HPRT+ 12 0 12 0 0 0
EMS HPRT+ 5 4 1 0 0 0
MMC HPRT+ 10 10 0 0 0 0
*, all these mutants had total or partial deletions of the hprt gene
Table 6.6. Northern analysis of HPRT mutant and non-mutant clones
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(Table 6 .6). Twelve untreated clones of HPRT+ phenotype had hprt mRNA of 
normal size and equal amounts. However, an increased level of mRNA was 
seen for 4/5 EMS-treated clones and 10/10 MMC-treated clones that were of 
HPRT+ phenotype and grew in HAT medium (Fig.6 .6). The remaining EMS- 
treated clone had a normal level of mRNA.
6.I.2.3. Discussion
Northern analysis of hprt mRNA was used to further characterise HPRT 
mutants, occurring either spontaneously or arising after exposure to EMS or 
MMC.
Four spontaneous mutants had mRNA that was indistinguishable in size 
and amount to that of untreated wild-type cells. These mutants presumably 
had base-pair changes in the coding regions of DNA causing missense 
mutations which resulted in the synthesis of an aberrant mRNA and the 
production of an inactive protein. Changes of this type also predominated in 
the EMS-induced mutants and in the majority of MMC-induced mutants 
showing no structural changes detectable by Southern analysis.
As was expected, the 2 MMC-induced mutants carrying total deletions 
of the hprt gene did not produce any mRNA, nor did 2 MMC-mutants with 
partial deletions of the gene. Mutants with deletions in the 5’ end of the gene 
would be unlikely to produce any mRNA, however a truncated message might 
be produced by mutants carrying intragenic deletions, or deletions of the 3’ 
region of the DNA. The partial deletions in the 2 mutants in this study were 
thought to be located within the gene, and one, MMC 3, was shown to include 
a deletion of exon 6 . However, mRNA was undetectable in both these clones,
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even in Northern blots using 60 pg total RNA, instead of the normal 20 /xg. 
Liber et al. (1989) found only 1 out of 6 3’-partial deletions produced mRNA, 
which they suggested might be due to the elimination of sequences involving 
post-transcriptional modification resulting in an unstable message that was too 
short-lived to be detected. In contrast, Recio et al. (1990) found a mutant 
lacking exons 3-6 in the DNA produced a mRNA, although of much reduced 
size. It is apparent from the study of Kaden et al. (1989) using tumour derived 
cell lines that partial deletion mutants may have a complex pattern of mRNA 
expression. For example, although 1 mutant with a deletion of exons 2-4 
produced no mRNA, another with a deletion of exons 2-6 produced a mRNA 
of larger size than normal, and a further mutant with an insertion in exon 7 
had no detectable mRNA (Recio et al., 1990).
No mutants carrying point-mutations and producing no mRNA were 
found in the present study, although such mutants have been described by 
others (Chaudhry and Fox, 1990; Liber et al., 1989; Vrieling et al., 1988). 
These mutants would either be due to base-pair changes in promoter regions 
affecting transcription, or mutations in the untranslated regions of the gene 
causing greatly increased instability of the mRNA Thacker (1985) has 
proposed that housekeeping genes maybe particularly susceptible to alkylation 
damage in promoter regions because of the high proportion of GC-sequences 
in this area. However in all published investigations total loss of mRNA 
expression formed only a small proportion of the total changes found in mRNA 
(Table 6.5). This is probably because of the target size of the promoter region 
relative to the total size of the gene; it is possible that had more mutants been 
analysed in this study non-expression mutants would have been included.
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The mutants with reduced levels of hprt mRNA , 3/12 MMC-induced 
and 1/9 EMS-induced mutants, were probably due to point mutations in the 
untranslated regions of the gene, resulting in increased instability of the 
mRNA. Although reduced levels could also be due to mutations in regulatory 
regions such mutants would be unlikely to survive the stringent conditions of 
mutant selection used, since some normal HPRT enzyme would still be 
produced. Van Zeeland and Simons (1976) have reported that only mutants 
having less than 2 % of the wild-type enzyme are able to grow in the presence 
of 5 pg/m l 6 -TG.
No mutants were detected that had an mRNA of an abnormal size, 
which could be due to point mutations in splice-sites. Similarly Thacker and 
Ganesh (1989) found only 1 out of 31 EMS-induced mutants to have an mRNA 
of reduced size. It has been suggested by Recio et al. (1990) that mutations 
at splice-sites may depend on the mutagenic specificity of the chemical 
mutagen. They found that whilst 2-cyanoethylene oxide was a potent inducer 
of splicing defects (17/39 were splice site mutations), formaldehyde induced 
few mutants (1/16) with aberrant splicing (Liber et al., 1989). Since splice- 
acceptor sequences are AT-rich, this region may be particularly susceptible to 
2 -cyanoethylene oxide mutagenesis, as this compound exhibits a preference for 
AT base pairs in AT-rich sequences. In contrast no specific DNA sequences 
which are particularly prone to formaldehyde mutagenesis have been noted.
No other studies have been reported that investigate the effect of 
chemical treatment on cultured cells retaining the HPRT-proficient phenotype. 
The high number of EMS- and MMC-treated HPRT+ clones isolated in this 
study that had a raised mRNA level may be due to a growth advantage
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conferred by an increase in enzyme activity. Southern blotting analysis had 
shown no evidence of DNA amplification in these clones. Thacker and Ganesh
(1989) found increases of up to 140% in hprt mRNA in 4 spontaneous and 1 
EMS-induced mutants but presumably these cells synthesised an abnormal 
protein for the mutant phenotype to occur. A single base substitution, G-*A 
at position -117, in the foetal A7 -globin gene from certain patients with 
hereditary persistence of foetal haemoglobin has been reported by Rixon and 
Gelinas (1988) to increase the mRNA 1.4 fold, resulting in the continued 
expression of foetal y-globin genes into adulthood. Mutations at other sites in 
the promoter regions did not affect transcription.
It is unlikely that the increase in hprt mRNA seen in non-mutant clones 
is due to extrinsic regulatory factors stimulated by the mutagen treatment, 
since such effects would be transient, and the clones had been grown up for 
some time without the presence of the chemical. It therefore seems most 
likely that mutations had occurred in the promoter region of the gene which 
had up-regulated gene expression.
The analysis of hprt mRNA has shown that EMS and MMC induced 
changes in both the coding and non-coding regions of the gene. These point 
mutations may lead to either the production of an inactive protein, or affect 
the rate of turnover of the mRNA such that little or no protein is produced. 
Furthermore cells treated with either alkylating agent may acquire mutations 
that do not result in the mutant phenotype.
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6.1.3. Screening for point mutations in the hprt  gene
The detection of point mutations of unknown location in a large number of 
heterogenous samples proved somewhat of a problem. As discussed earlier, 
Southern blotting will only detect point mutations that result in the loss or 
gain of a restriction site, and Northern blotting gives only an indication of the 
possible region of the gene in which the mutation might occur. Determination 
of the nucleotide sequence is the defini tive technique to characterise base-pair 
changes, but it is impractical to sequence long stretches of DNA from a large 
number of clones. Where mutations are at specific known locations, synthetic 
oligonucleotides, homologous to the mutant or wild-type sequence, can be used 
as differential hybridisation probes. This method is frequently used for the 
detection of mutations at codons 12 and 61 of the ras oncogene (Verlaan de 
Vries et al., 1986).
Where the location of the mutation is unknown methods must be simple 
enough to allow screening of the entire gene. Unfortunately most screens do 
not detect 100% of all possible alterations. Current methods for the detection 
of unknown mutations have been reviewed by Cotton (1989) and Rossiter and 
Caskey (1990). Most methods are based on either differences in 
electrophoretic mobility between heteroduplexes and homoduplexes under 
denaturing conditions, or the enzymic or chemical cleavage at mismatched 
bases in heteroduplexes.
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6.1.3.1. Introduction
Few studies have reported the screening of the hprt gene of cultured cells, 
mutated by chemical agents, for point mutations. Recio et al. (1990) found 18 
different sites for point mutation, 6 of which occurred in exon 8, by polymerase 
chain reaction (PCR) amplification and sequencing of the hprt cDNA of 
2-cyanoethylene oxide induced mutants of TK6 cells. Two mutations occurred 
at each of 3 of the 18 sites. Both AT and GC base pairs were implicated in the 
changes, which consisted of transitions and transversions. In contrast, 
sequence analysis of cDNAs of formaldehyde-induced mutants showed 4 out 
of 6 to be AT -> CG transversions at position 704 in exon 8 (Liber et al., 1989). 
Analysis of the cDNA, transcribed from mRNA, instead of the genomic DNA 
reduced the size to be sequenced from >34kb to 700bp and allowed study of 
the entire coding region from those mutants that still produced an mRNA 
The use of an automatic DNA sequencer also greatly facilitated the analysis.
Other studies using manual sequencing methods, have looked at a 
smaller number of mutants, or have been limited to single exons. Vrieling et 
al. (1988) sequenced the cDNA of 3 mutants of ENU-treated mouse lymphoma 
cells. One contained an AT -* GC transition in exon 4, the second an AT -» TA 
transversion in exon 8, and the third resulted from abnormal processing, 
probably due to a mutation in the 3’ splice site of intron 1. Base changes were 
detected in only 6 out of 10 cDNAs sequenced by Chaundry and Fox (1990). 
Two MMS-induced mutants carried the same GC -» AT transition at position 
425 in exon 6, and 1 EMS-induced and 1 X-ray-induced mutant had the same 
TA -» CG transition at position 404 in exon 6. One MMS-induced mutant had
205
a TA -> AT transversion in exon 2, and 1 X-ray-induced mutant had a 7bp ' 
deletion in exon 1.
A different approach was chosen by Carriello et al. (1990), who used 
denaturing gradient gel electrophoresis (DGGE) to detect mutants in a mass 
culture treated with N-methyl-N’nitro-nitrosoguanidine (MNNG) or ICR-191. 
Mutant and wild-type DNAs were separated by their different electrophoretic 
mobilities as wild-type/mutant heteroduplexes. Isolated mutant bands were 
then subjected to PCR amplification of exon 3 and the exon sequenced. The 
same sequence was indicated as a mutational hotspot for both chemicals. Nine 
out of 29 ICR-191-induced mutants showed an insertion of either G or C in a 
GGGGGG sequence at positions 292-297, and 3/32 MNNG-induced mutants 
had a GC AT transition at positions 293 or 294. This same technique was 
used to screen exon 3 for point mutations induced by UV-light (Keohavong et 
al., 1991). Five mutational hotspots were located, including GC -> AT 
transitions at positions 293 and 294.
The effect of depletion of 0 6-methyltransferase on the spectrum of point 
mutations induced by MNNG in a human fibroblast cell fine was studied by 
Lukash et al. (1991). Sequencing of mutant cDNAs showed that GC -> AT 
transitions predominated. In the presence of the repair enzyme 70% of the 
base-pair changes were located in the 3’ half of the gene, while in cells 
depleted of 06-methyltransferase 60% were located in the 5’ half of the gene. 
Furthermore, 40% of the total point mutations in repair deficient cells were 
found at a GGGGGG sequence in exon 3, but only 3 (12%) were found at this 
run of six-G base pairs in 06-methyltransferase proficient cells. Mattano et al.
(1990) also reported this same sequence to be an important site for mutations
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induced by 2 ’-deoxyadenosine and 2’-deoxyguanosine; 9 of the 20 mutations \ 
studied involved changes in this GGGGGG sequence.
These studies show that at least one hotspot for mutation occurs in the 
hprt gene of human cell lines, at a GGGGGG sequence in exon 3. Mutations 
at this sequence have also been found by Gibbs et al. (1989) in lymphocytes 
from Lesch-Nyhan patients. The involvement of such a sequence as a 
mutational hotspot is not surprising, since a run of guanines might be expected 
to form hairpin loops in the DNA molecule. This would make the sequence 
both more accessible to alkylating agents that show a preference for guanines, 
and cause strand slippage during DNA replication, which participates in 
frameshift mutations involving single base additions and deletions (Ghosal and 
Saedler, 1978).
When the present study was undertaken PCR was still in the early 
stages of development, and sequences at the intron/exon junctions had not 
been determined for the design of primers allowing amplification of entire 
exons. Sequencing of hprt cDNAs was therefore not a practical proposition for 
the detection of point mutations in a large number of mutants.
Instead, a method based on the ability of the enzyme RNase A to cleave 
single nucleotide mismatches in RNArRNA hybrids (Winter et al., 1985) was 
used in an attempt to detect base-pair alterations in EMS- and MMC-induced 
mutants. This method uses mRNA as the source of sequence information, 
rather than the genomic DNA. Only mutations represented in the mRNA can 
be detected, but as Northern blotting had already shown that most of the 
mutations were of this type, RNase A cleavage was considered appropriate for 
this study.
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When mRNA is hybridised to a radiolabelled antisense RNA probe, that 
is an RNA synthesised to contain sequences complementary to the mRNA of 
interest, the non-hybridised regions caused by mismatches in the mRNA: 
antisense RNA heteroduplex will be recognised as single-stranded and cleaved 
by the enzyme RNaseA (Fig.6.7). The fragments produced can then be 
analysed by denaturing polyacrylamide gel electrophoresis to determine the 
nature and location of the mutation.
RNase A cleavage analysis was used by Gibbs and Caskey (1987) to 
locate point mutations in the hprt gene of patients with Lesch-Nyhan 
syndrome. The mutations in 5 out of 14 patients were identified by this 
method. Davidson et al. (1988) found two alterations in the hprt DNA after 
sequencing the cDNA of a Lesch-Nyhan patient and used RNase A cleavage to 
determine which mutation was responsible for HPRT deficiency, and which 
was a cloning artifact. The efficiency of cleavage depends on the particular 
mismatch; only 4 of the possible 12 single-base mismatches are 100% cleaved 
using RNase A (Lopez-Galindez et al., 1988), although other mismatches are 
cleaved to a certain extent. However, with consideration of these limitations, 
this method was thought to be a useful screen for determining the location of 
base-pair changes, and possible hotspots for mutation in the hprt gene in the 
present study.
6.1.3.2. Results
Cloning the hamster hprt cDNA into a transcription vector
As the first step, the hamster hprt cDNA to be used as a radiolabelled
riboprobe, had to be inserted into a plasmid vector carrying the promoter for
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bacteriophage RNA polymerase. The system chosen carried two such 
promoters; plasmid vector pSPT18 has the promoters for SP6 and T7 RNA 
polymerases located on either side of a multiple cloning site (Fig.6 .8), such that 
an insert cloned within this site may be transcribed using either promoter. If 
the cDNA is inserted in the correct orientation, normal mRNA will be 
transcribed using SP6 RNA polymerase, and antisense RNA is transcribed 
using T7 RNA polymerase.
The hamster hprt cDNA was isolated from the plasmid, pHPT12, as a 
141 lbp fragment which also included about lOObp of the vector sequence, 
using the enzyme Hpa II. This fragment was purified by electrophoresis in a 
0 .8% low melting point agarose gel and extraction of the appropriate band. 
Since Hpa II results in a cut producing 3’ recessed ends, and a blunt-ended 
molecule was required, the ends were filled in using the Klenow fragment of 
DNA polymerase I (Fig.6.9).
The transcription vector, pSPT18, was cleaved with Sma I at its 
recognition site within the polylinker region to produce a blunt-ended molecule 
(Fig.6.9). To prevent religation of the cut ends the vector was treated with 
alkaline phosphatase which removes the phosphate group at the 5’-terminus 
of the DNA molecule.
The final step in producing the recombinant DNA was the insertion of 
hprt cDNA insert into the pST18 host vector using T4 ligase (Fig.6.9). 
Appropriate aliquots of the DNA ligation mixtures were introduced into 
competent E. coli cells, strain TB1, by the process of transformation. As this 
system did not contain any markers, such as antibiotic resistance or 
B-galactosidase activity, which could be used to select transformants, all
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colonies isolated after the transformation process were screened for th e . 
required recombinant clone. Fifty colonies were grown up, and the plasmid 
DNA extracted and linearized with the restriction enzyme, BamH I, which 
produces a single cut in the polylinker site. The sizes of the DNA molecules 
were estimated after separation by gel electrophoresis in 0 .8% agarose.
Two clones were found to carry plasmids of the correct length (4515bp) 
to be the recombinant molecule. The presence of the recombinant plasmid 
and the orientation of the inserts was determined by cleaving the extracted 
plasmids singly with Pst I, Hind III or Hpa II. The fragments were separated 
by gel electrophoresis, blotted onto Nytran membrane and hybridised to a 
radiolabelled hprt cDNA probe. The results are shown in Fig. 6.10.
Of the two clones tested, one, clone 27, carried the hprt cDNA insert in 
the "conventional" orientation, and the other, clone 12 , carried the insert in 
the "opposite" orientation (Fig.6.11). Thus antisense hprt RNA could be 
transcribed from clone 27 using the T7 promoter, and from clone 12 using the 
SP6 promoter.
In vitro transcription o f antisense hprt cDNA
Briefly, in vitro transcription of RNA consisted of incubation of the cDNA 
template, linearised downstream of the cDNA to produce "run-off transcripts, 
in the presence of the four ribonucleotide triphosphates (rNTPs) and the 
phage RNA polymerase, in a buffer system (Melton et al., 1984a). To produce 
uniformly radioactive transcripts, one of the rNTPs is labelled, usually with 
[32P] CTP at a specific activity of 400-800 Ci/mmol. In order to produce high 
specific activity transcripts, the unlabelled rNTPs are used at 500 pM, the
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Lane 1, Clone 12
Lane 2, Clone 12
Lane 3, Clone 12
Lane 4, Clone 27
Lane 5, Clone 27
Lane 6, Clone 27
Lane 7, pSPT 18,
Lane 8, pSPT 18,
Lane 9, pSPT 18,
P s t  I d ig e s t  
Hind I I I  d ig e s t  
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P s t  I d ig e s t  
Hind I I I  d ig e s t  
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Hpa I I  d ig e s t
F ig u re  6 .1 0 .  C o n f irm a tio n  o f  th e  p re se n c e  o f  h p r t  in  th e  recom binan t 
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optimal concentration for the RNA polymerase, but the labelled rNTP is used 
at only 6-12 pM. Following transcription the DNA template was removed by 
DNase treatment, and the RNA transcripts purified by phenol extraction and 
several precipitations in ethanol to remove unincorporated nucleotides. The 
transcript size was determined by electrophoresis in 5% polyacrylamide/urea 
denaturing gels and visualised by autoradiography.
After several attempts to synthesise the antisense hprt RNA it was clear 
that the transcription process was not as simple as it appeared from the 
literature. The average length of the transcripts produced was only 50bp, 
instead of the 1400bp full-length transcripts expected when the plasmid was 
cut downstream of the hprt sequence, using either EcoRI for transcription 
from the SP6 promoter, or BamH I for transcription from the T7 promoter. 
This occurred with both promoters and with the cDNA in either orientation. 
Obviously transcription had initiated but the reaction could not then continue.
To determine precisely what length of transcript could be transcribed, 
the plasmids were cut with the restriction enzymes Fok I and Nde I to give 
templates of less than the full-length cDNA. As these enzymes also cut 
upstream of the promoters, unnecessary plasmid vector DNA was removed, 
thus eliminating the possibility of transcription proceeding in the wrong 
direction (Melton et al., 1984a). The results are shown in Fig.6.12. The 
autoradiograph shows that the highest number of complete transcripts was 
generated from a 173bp template, followed by a 535bp template. The 926bp 
and 1285bp template producing mainly incomplete transcripts.
Krieg and Melton (1987) have suggested that most problems in 
obtaining complete transcripts are due either to limitations of the
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F ig u re  6 . 1 2 .  The e f f e c t  o f  fragm ent le n g th  on t r a n s c r i p t i o n
R e s t r i c t i o n  enzymes were used  to  p roduce  DNA f rag m e n ts  o f  
known s i z e s .  The t r a n s c r i p t s  were s e l e c t e d  by  
p o ly a c ry la m id e  g e l  e l e c t r o p h o r e s i s  and a u to ra d io g ra p h e d .
Lane 1 : Clone 12, EcoR I d i g e s t (1468 bp) w i th  SP6
Lane 2 : Clone 27, EcoR I d i g e s t (1468 bp) w i th  SP6
Lane 3 : Clone 12, BamH I d i g e s t (1442 bp) w i th  T7
Lane 4 : Clone 27, BamH I d i g e s t (1442 bp) w i th  T7
Lane 5 : Clone 12, Fok I d i g e s t (535 bp) w i th  T7
Lane 6 : Clone 27, Fok I d i g e s t (926 bp) w i th  T7
Lane 7 : Clone 12 , Nde I d i g e s t (173 bp) w i th  T7
Lane 8 : Clone 27 , Nde I d i g e s t (1285 bp) w i th  T7
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concentration of the radiolabelled rNTP, or to terminator sequences that exist 
in the cDNA template. As termination signals are reported to be often 
overcome by increasing the rNTP concentration (Krieg and Melton, 1987), the 
effect of rNTP concentration was investigated.
In order to transcribe RNA of a high specific activity it is not economic 
to use radiolabelled rNTP at the optimal concentration for the RNA 
polymerase. Instead, the three unlabelled rNTPs are used at 500 //M (the 
saturating concentration), and the radiolabelled CTP at 6 //M. To study the 
effect of rNTP concentration [a-32P] CTP was supplemented with either 10 or 
50 jjM of unlabelled CTP in the transcription reaction. As shown in Fig.6.13 
increasing the CTP level resulted in an increase of transcripts of the correct 
length. Antisense RNA was therefore synthesised using both labelled and 
unlabelled CTP in the reaction mixture to give a total concentration of the 
nucleotide of 18 //M.
RNase A  cleavage analysis
Annealing of the antisense RNA probe to the hprt mRNA was performed in a 
liquid hybridisation system, using 100 //g total RNA extracted from mutant or 
non-mutant clones. Digestion of non-hybridised regions with RNase A was 
carried out, before separating the fragments by electrophoresis, in 5% 
polyacrylamide/urea gels.
No clear indication of cleavage due to mismatches was obtained; up to 
20  different fragments were detected and there was no evidence of differences 
between mutant and non-mutant RNA samples (data not shown).
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Figure 6.13. The effect of CTP concentration on the production of 
complete RNA transcripts
Lane 1 : ; Clone 12, Ava II digest (783 bp) using T7, 12.4 pM CTP
Lane 2 : ; Clone 12, Ava II digest (783 bp) using T7, 22.4 /xM CTP
Lane 3
i
: Clone 12, Ava II digest (783 bp) using T7, 62.4 pM CTP
Lane 4 : Clone 27, Fok I digest (926 bp) using T7, 12.5 pU CTP
Lane 5 : Clone 27, Fok I digest (926 bp) using T7, 22.5 pH CTP
Lane 6 : Clone 27, Fok I digest (926 bp) using T7, 62.5 pH CTP
Lane 7 :;Clone 12, Nde I digest (1285 bp) using T7, 12.5 pH CTP
Lane 8 :|Clone 12, Nde I digest (1285 bp) using T7, 22.5 /xM CTP
Lane 9 : Clone 12, Nde I digest (1285 bp) using T7, 62.5 /xM CTP
Lane 10 : Clone 27, BamH I digest (1422 bp) using T7, 12.5 pM. CTP
Lane 11 : Clone 27, BamH I digest (1422 bp) using T7, 22.5 /xM CTP
Lane 12 : Clone 27, BamH I digest (1422 bp) using T7, 62.5 pM. CTP
Lane 13 : | Clone 12, Ava II digest (697 bp) using SP6, 12.5 /xM CTP
Lane 14 : Clone 12, Ava II digest (697 bp) using SP6, 22.5 pH CTP
Lane 15 : Clone
/
12, Ava II digest (697 bp) using SP6, 62.5 pH CTP
Lane 16 : ! pAT 153, Hinf I digest (molecular weight markers)
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6.I.3.3. Discussion
The approach used to screen for point mutations was unsuccessful, and it was 
therefore decided to abandon the screening for point mutations. Myers et al.
(1988), using RNA:DNA hybrids, also found that screening regions longer than 
lOObp by RNase A cleavage resulted in random digestion at perfectly-matched 
positions. The reason for this is unclear.
In molecular biology new techniques are constantly becoming available, 
although simple screens for point mutations are still limited. Since the start 
of this study PCR methods have rapidly progressed, such that PCR 
amplification of individual exons and direct sequencing of the PCR products 
would be the method of choice today. However, this method would still be 
somewhat impractical for screening the whole hprt gene in a large number of 
samples, and perhaps could be limited initially to the sequencing of exon 3, 
which has been implicated by others (Cariello et al., 1990; Lukash et aZ., 1991) 
to be a mutational hotspot.
6.2. The tk gene
The tk gene is located on an autosome, chromosome 11 in the mouse (Kozak 
and Ruddle, 1977), chromosome 7 in the hamster (Stallings et al., 1983) and 
chromosome 17 in the human (Yandell et al., 1986). Thus, two copies of the 
tk gene are present in the genome. Significant homology of tk nucleotide 
sequences exists between vertebrates, including human, lemur, tree shrew, 
rat, mouse and chicken (Bradshaw and Deininger, 1984). The mouse, hamster 
and chicken tk genes show marked similarity in exon size (Fig.6.14) (Lin et al., 
1985; Lewis, 1986), although the chicken tk gene differs from that of the other
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two species in being only 3kb in length. This difference is due to intron sizes,1 
which total about lOkb in the mouse and hamster, but are only lkb in the 
chicken (Merrill et al., 1984).
In the mouse, the tk gene is llk b  in length, and is divided into 7 exons 
separated by 6 intervening intron sequences (Lin et al., 1985). There is an 
open reading frame of 699bp which codes for 233 amino acids in the TK 
protein. This region is flanked by a 5’ untranslated sequence of at least 32bp, 
and a 3’ untranslated sequence of 422bp (Lin et al., 1985). The human tk gene
fMcnH?
codes for 234 amino acids (Bradshaw and Deininger, 1984), one extra than the 
mouse, and there are 29 differences in the amino acids coded. The mouse 
shows 86% conservation with the tk coding nucleotide sequence of the human, 
and the hamster 90% compared to the human.
The presence of ^ -related sequences in the genomes of several different 
mouse strains, which probably represent pseudogenes, have also been 
demonstrated. This was confirmed using mouse LTK cells, which contain no 
functional tk sequences, but do carry ^ -related sequences for which no mRNA 
was expressed (Lin et al., 1985).
The promoter region of the tk gene has not been as extensively studied 
as that of the hprt gene. In the hamster a CAT box sequence has been 
identified, together with a TTTTAAA sequence which resembled the TATAA 
box element (Lewis, 1986). However, since GC-rich sequences also exist, in 
common with other "housekeeping" genes, the TATA box may not be required 
for transcription of the tk gene. Expression of the tk gene is associated with 
DNA replication, being most active during the S-phase of the cell cycle, and 
declining rapidly during the G2-phase. In terminally differentiated cells TK
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activity ceases (Bradshaw and Deininger, 1985). The mouse tk mRNA is about; 
1 .2kb and is expressed at low levels even in actively growing cells.
The cDNA for mouse tk has been characterised and cloned by Lin et al. 
(1985), who isolated a nearly full-length cytosolic tk cDNA from a library 
prepared using the mRNA of mouse L-cells. The plasmid was designated 
pMtk4 and contains a sequence of 1156 nucleotides which is the functional 
mouse tk cDNA In addition, Lin et al. screened a cosmid library to isolate a 
clone, pMtk 116, containing over llk b  of sequence which hybridised to the tk 
cDNA, and therefore corresponded to the entire functional tk genomic DNA 
This cosmid is useful in identifying pseudogene sequences amongst fragments 
generated by restriction enzymes.
6 .2 .1 . Southern analysis o f TK mutants
6.2.1.1. Introduction
Southern blotting analysis of TK mutants has been facilitated by the 
identification of restriction fragments length polymorphisms (RFLPs), which 
allow the functional and non-functional tk alleles to be distinguished. The 
mouse lymphoma, L5178Y.3.7.2C, cell line is heterozygous for a Nco I RFLP 
at the tk locus; this polymorphic site is located downstream from the 3’ end of 
the tk coding region and is unlikely to affect the function of the tk gene 
(Applegate and Hozier, 1987). When digested with Nco I, the functional tk 
gene is cut into 3 fragments:2 fragments each of 4.1 kb, which contain exons 
1-3 and exon 4, and a fragment of 6.3 kb which contains exons 5-7 and the 3’ 
intergenic region (Fig.6.15). The non-functional allele is cut by Nco I to give 
the same 4.1 kb bands, but an additional Nco I site results in the 6.3 kb band
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being divided into two, to give fragments of 4.8 kb and 1.5 kb (Fig.6.15). The, 
1.5 kb band does not contain any exon material and thus this fragment is not 
seen on Southern blots hybridised to tk cDNA probe (Applegate and Hozier, 
1987).
Since the 6.3 kb Nco I fragment, containing exons 5-7 represents 71% 
of the coding sequence of the tk gene, analysis of alterations in the Nco I 
polymorphism is useful for detecting changes that lead to inactivation of the 
functional tk allele. Loss of the 6.3 kb band, when unaccompanied by changes 
in the fragment patterns of other restriction enzymes, indicates loss of the 
entire functional tk gene. Intragenic rearrangements within the gene will 
result in new fragment patterns, but unless the 6.3 kb Nco I is also altered it 
cannot be confirmed that the change involves the functional tk gene. 
However, it is assumed that this would be the most likely explanation since 
a change in the functional gene must have occurred to produce the TFTP* 
phenotype. In mutants where no changes can be detected by restriction 
enzyme digestion, the mutations are presumed to be to point mutations.
Applegate et al. (1990) studied 51 large-colony and 48 small-colony TK 
mutants induced by ionising radiation or by chemical mutagens, EMS, MMS, 
methotrexate, bleomycin and pyrimethamine. Only one clone, a large-sized, 
bleomycin-induced mutant, showed a change in restriction fragments indicative 
of a partial detection. Of the other large colony mutants examined, only 13 of 
17 EMS-induced, and 5 of 28 bleomycin-induced mutants had retained the 
6.3 kb Nco I band. All 5 methotrexate large colonies, and the single 
pyrimethamine large colony studied had lost the 6.3 kb Nco I fragment. Of
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the 48 small colony mutants examined all except one had lost the 6.3 kb band,' 
whatever means of mutation induction was used.
Furthermore, Applegate et al. (1990) investigated amplification of the 
non-functional tk allele in 10 mutants which had lost the active tk copy, by 
comparing the densities of bands from Hind III or Nco I/Hind III digests 
hybridised first to the tk cDNA probe, and then after reprobing with a-actin 
or histine 3.2 specific sequences. Loss of the tk+ allele should result in a 50% 
reduction in the intensity of ^ -specific bands relative to actin or histine band 
intensity. However, it was found that several of the 10 mutants studied 
appeared to have two or more copies of the tk' allele. Applegate et al. 
concluded that loss of the functional tk allele, followed by somatic 
recombination, including mitotic recombination and gene conversion, was 
probably the most likely explanation for the apparent increase in copy number 
of the non-functional tk sequences.
Southern blotting was also used by Clive et al. (1990) to investigate 
changes in restriction fragment patterns in TK mutants of L5178Y cells 
induced by 10 different chemicals: AHA, EMS, MMS, 2 -acetylaminofluorene, 
methotrexate, caffeine, methapyrilene,4-(9-acridinylannno)-methanesulpho-m- 
anisidate, hycanthone methanesulphonate and procarbazine. The majority of 
both large- and small-sized mutants induced by AHA had retained the 6.3 kb 
Nco I fragment, as had the majority of large colony EMS mutants. Both of 
these compounds induced mainly large colonies, 70% of AHA, and 60% of EMS 
mutants. The other eight mutagens induced mainly small-sized mutants, the 
majority of which had lost the tk+ allele, as had a high proportion of large- 
colony mutants induced by these chemicals. Some of these compounds had
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been shown to be negative or only weakly positive at the hprt locus (Clive et\ 
al. 1990).
Changes in restriction fragments after induction of TK mouse lymphoma 
mutants by cigarette smoke condensates were investigated by Cobb et al.
(1989). No differences were found in restriction fragment patterns generated 
by Hind III between mutant and wild-type colonies, however all 61 small-sized 
and 22 of 25 large-sized mutants had lost the 6.3 kb band when digested with 
Nco I.
Analysis of spontaneous mutants by Clive et al. (1990) showed that the 
majority had lost the polymorphic fragment associated with the tk+ gene. 
Twenty out of 29 large-, and 27 out of 29 small-sized mutants from solvent- 
treated cultures were lacking the 6.3 kb band. When corrected for the number 
of mutants obtained in the assay, Clive et al. estimated that 83% of 
spontaneous mutants arose by deletion of the functional tk gene. A somewhat 
confusing result was obtained by Cobb et al. (1989), who found 4 out of 5 large- 
colony mutants, but none out of 9 small-colony mutants had lost the 6.3 kb 
band in control cultures treated with the solvent dimethylsulphoxide. These 
cultures also contained S9 mix, which has been reported by Myhr and Mayo 
(1987) to be both cytotoxic and mutagenic to L5178Y cells, inducing mainly 
small-sized colonies. The mutants described by Cobb et al. many therefore not 
be true spontaneous mutants, but result from mutagenic compounds present 
in the S9 mix.
Restriction mapping of the tk gene in human TK6 cells has revealed this 
cell line also carries an RLFP, a polymorphic Sac I site 4.2 kb downstream of 
the tk coding sequence. A 14.8 kb Sac I fragment is associated with the tk+
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allele (Yandell et al., 1986). In addition polymorphic markers have been, 
located in other genes on the same chromosome. An Xho I polymorphism 
within the c-erb Al gene, sited proximal to tk on the long arm of 
chromosome 17, can be used to detect large-scale changes that extend beyond 
the tk locus. Non-disjunction, leading to loss of the whole chromosome, can 
be detected by a Pst I polymorphism within the sequence of the short arm of 
chromosome 17 which hybridises to the D1752 probe (Little, 1989).
These polymorphic markers were used for Yandell et al. (1990) to 
determine the scale of changes affecting the tk gene in TK6 mutants. When 
the tk gene was analysed in mutants induced by MMC, X-rays or UV-light, the 
tk+ allele was lost in 28%, 66% and 40% of the large-sized mutants respectively. 
The tk* gene was found to be rearranged in 7% of MMC- and 7% of 
UV-induced large colonies. Between 7% and 25% of large-colonies with a 
structurally normal tk* allele had lost the c-erb A l locus, and of those which 
had lost the functional tk gene, 25% MMC, 39% X-ray and 33% UV-mutants 
had also lost the c-erbAl gene.
Analysis of small-colony mutants induced by MMC showed only 3% to 
have a structurally normal tk+ allele, and of the 97% that had lost the 14.8 kb 
Sac I fragment associated with the tk* allele, 45% were also lacking the 
c-erbAl gene. It was therefore apparent that a significant number of TK 
mutants of TK6 cells have deletions involving a large region of 
chromosome 17, which are not normally associated with cytogenically 
detectable changes. Non-disjunction appeared to be a relatively rare event, 
since only 5 out of 300 mutants studied had lost the D1752 marker as well as 
the tk and c-erbAl loci (Yandell et al. (1990). A similar high proportion of
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mutants that had lost both the tk and c-erbAl genes was found by Kronenberg 
and Little (1989) after induction with densely ionising radiation (fast neutrons 
and accelerated argon ions).
An assay system was developed by Benjamin et al. (1991) using a human 
cell line to demonstrate the involvement of recombinational events in 
mutation at the tk locus. In this system ICR-191 was used to induce TK 7 
mutants which had different frameshift mutations in each allele, one in exon 4 
and the other in exon 7. Reversion to the TK+ phenotype could only occur by 
interallelic recombination, gene conversion or a frame-restoring point 
mutation. Molecular analysis, using RFLPs, SSCP and sequencing of the tk 
gene and polymorphic marker genes (D17521, D17S4, D17S24) on the long arm 
of chromosome 17, was performed to determine the events leading to 
reversion to the TK+ phenotype. Two revertants were studied, one of which 
was due to a single recombinational event with breakpoints outside the tk 
gene, and subsequent mismatch repair of the exon 7 mutation, and the other 
involved crossing over between exons 4 and 7. Spontaneous recombination at 
the tk locus in this human cell line was estimated to occur at a frequency of 
about 10 '9.
When spontaneous TK mutants of TK6 cells were analysed by Yandell 
et al. (1990), 70% of large colonies had lost the tk* allele, and 39% of these had 
also lost the c-erbAl gene. In slow-growing colonies 97% had lost the tk* 
allele, of which the c-erbAl gene was missing in 53%.
In the present study cultures of L5178Y cells, untreated and treated 
with EMS or MMC, were analysed for changes in the tk locus detectable by
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Southern blotting. Both wild-type and TK mutant isolates were examined to' 
determine the changes leading to the TK' phenotype.
6.2.I.2. Results
Colonies growing in plating efficiency or mutation plates were sized using an 
ocular micrometer, and individual wells were identified which contained a 
single colony of an appropriate size. Each colony was transferred to a separate 
culture flask and the cells allowed to grow, using progressively larger cultures, 
until approximately 5 x 108 cells were obtained. During this growth phase the 
TFTR and TFTS phenotypes were checked as appropriate. The pelleted cells 
were frozen in aliquots at -70 °C. Approximately 1 x 108 cells were used for the 
extraction of DNA. Wherever possible at least 10 clones of each size class, 
large and small, for both untreated and EMS- or MMC-treated cultures were 
used for Southern blotting analysis. However, it was not possible to isolate 
sufficient small-sized non-mutant clones for EMS-treated or untreated 
cultures. The types and numbers of clones examined are given in Table 6.7.
The purity of the DNAs was assessed, and their concentrations 
estimated by running 1 fA aliquots of each DNA sample in 0.8% mini-gels, and 
by taking spectrophotometric readings. The optical densities, measured at 
wavelengths of 260 and 280 nm, gave ratios of between 1.76 and 1.96 which 
indicated that the samples were free from contamination by either protein, or 
solvents used in the extraction process. Normally between 1 and 2 mg DNA 
was obtained after extraction.
The DNA samples were subjected to restriction enzyme digestion and 
Southern blotting. Since little information was available from the literature
231
Treatment Phenotype Colony size N o . examined
None TK+ Large 10
Small 5
TK' Large 10
Small 10
1 mg/ml EMS TK+ Large 10
Small 8
TK' Large 10
Small 12
0.25 /xg/ml MMC TK+ Large 10
Small 10
TK' Large 12
Small 14
Table 6.7. Clones used in blotting- analysis of detect chancres in the tk 
locus
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as to which enzymes, besides Nco I, would be most useful for detecting 
alterations in the tk gene, 11 different restriction enzymes were appraised for 
their ability to cleave the mouse tk gene. The enzymes were chosen from 
those already available in the laboratory, and were selected to include a range 
having recognition sites of 4, 5 or 6 nucletodies in length. The enzymes 
studied were: Kpn I, Sau3A I, Ava II, Bgl II, Ava I, Hinf I, Hae II, Hpa II, 
BamH I, Taq I and Pst I. These enzymes, together with Nco I and Hind III, 
which have been described previously by Applegate et al. (1990) to detect 
changes in the tk gene, were used to digest DNA isolated from a TFTR mutant 
and a TFTS non-mutant of L5178Y cells. The sizes of fragments produced by 
these enzymes is given in Table 6 .8 . At this stage neither the cosmid, 
pM tkll6 , nor LTK' cells, which are entirely deficient of tk pseudogenes, were 
available for the detection of tk-like sequences. Therefore, for most of the 
enzymes in Table 6.8 the fragments correlating to pseudogene sequences could 
not be identified. Where pseudogene bands were later detected for certain 
enzymes, these are shown in the Table.
Three enzymes Ava I, BamH I and Kpn I, which all gave bands that 
totalled more than llkb  for each enzyme, and therefore assumed to span the 
entire tk gene, were selected for further study. These enzymes, together with 
Hind III and Nco I, were used to study structural changes in the tk gene in the 
DNA samples.
No wild-type isolates, from either untreated or mutagen-treated cultures 
showed changes in the fragment patterns with any of the restriction enzymes 
studied. When DNA from mutant clones was digested with the enzymes Ava I, 
BamH I and Kpn I identical banding patterns were obtained to those observed
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Enzyme Cleavage site Size of tk-specific bands (kb)
Kpn I GGTACC >23,8.2*,5.0,1.5*
Sau3A I GATC 3.0,1.8,1.4
Ava II GG (A/T) CC 2.1,1.7,1.5,0.9
Bgl II AGATCT >23,8.2,5.3,4.0
Ava I C (C/T) c g (A/G) g >23,6.6,4.2*,1.4*
Hinf I GANTC 2.5,1.8,1.45,1.05,-0.95,0.75
Hae III (A/G)g c g c (c /t ) 1.3,1.05,0.8
Hpa II CCGG >23,12,10.5,6.0
BamH I GGATCC 12*,8.2,6.0,4.2,3.1
Taq I TCGA >24,5.2,4.0,3.4,2.5,2.7
Pst I CTGCAG 6.3,4.0,3.1,1.7
Nco I CCATGG 6.3,5.5*,4.8,4.1,2.1*
Hind III AAGCTT 20,10*,5.0,3.8*
* Denotes tk-pseudogene sequences (determined for the 5 enzymes
shown)
Table 6.8. Restriction endonuclease fracrments identified in mouse genomic 
DNA by the mouse tk cDNA probe, pMtk 4
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with DNA from wild-type clones, and to that obtained with pM tk ll6 , which 
carries the entire tk genomic sequence. Digestion with Hind III showed no 
detectable change in the fragment pattern of the tk gene in all except one 
DNA sample. This exception was a spontaneous mutant which showed the 
presence of an extra band of about 8kb. An additional fragment of 8kb was 
also seen for this spontaneous mutant when DNA was digested with Nco I.
However, cleavage of the DNA samples with the enzyme Nco I revealed 
that many mutants had lost the 6.3kb band, examples of which are shown in 
Fig.6.16. Of the spontaneous mutants 7 out of 10 large, and 9 out of 10 small 
colonies had lost this fragment (Table 6.9). These figures were corrected for 
the proportion of large (65%) and small (35%) colonies representing the 
average distribution of the two sizes of spontaneous TK mutants observed in 
the mutation assays. On this basis 77% of the total mutants would be 
expected to have lost the 6.3kb Nco I fragment representative of the function 
tk allele, 45% of which would be large colony mutants, and 32% small colony 
mutants (Table 6.10).
Ethyl methanesulphonate induced a somewhat different spectrum, with 
only 1 out of 10 large-sized and 6 out of 12 small-sized mutants having lost the 
6.3kb Nco I fragment (Table 6.9.). The relative proportions of EMS-induced 
mutants lacking the active tk gene were 6% colonies and 2 0 % small colonies 
(Table 6.10) calculated on an average distribution of 59% large- and 41% small­
sized colonies in the mutation assays. Overall, 26% of the mutants induced by 
EMS would be expected to have lost the functional tk allele.
In contrast to EMS, analysis of MMC-induced mutants showed that the 
majority had lost the active tk gene, 11 out of 12 large colonies and all 14 small
F i g u r e
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Treatment Phenotype
No . large colonies No. small colonies
+ band* - band* + band* - band*
None TK+ 10 0 5 0
EMS TK+ 10 0 8 0
MMC TK+ 10 0 10 0
None TK' 3 7 1 9
EMS TK' 9 1 6 6
MMC TK' 1 11 0 14
+band, 6.3kb Nco I band present 
-band, 6.3kb Nco I band absent
Table 6.9. Southern blotting analysis of Nco I digested DNA from L5178Y 
clones
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Treatment
% Mutants large 
colonies*
% Mutants small 
colonies*
% Mutants 
missing band+band -band +band -band
None 20 45 3 32 77
EMS 53 6 21 20 26
MMC 3 33 0 64 97
+ band, 6.3kb Nco I fragment present 
- band, 6.3kb Nco I fragment absent
* based on the results shown in Table 6.8. and corrected for the
proportion of large and small colonies seen in the mutation assays.
Table 6.10. Mutational spectra seen at the tk locus of L5178Y cells
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colonies studied had lost the 6.3kb Nco I band (Table 6.9). As shown in 
Table 6.10, when corrected for the relative proportions (36% large, 64% small) 
obtained in the mutation assays, 33% Would be large colonies and 64% small 
colonies. A total of 97% of TK mutants induced by MMC would result from 
the loss of the functional copy of the tk gene.
6.2.I.3. Discussion
The RFLP, identified with the enzyme Nco I, which distinguishes the 
functional and non-functional tk alleles in the L5178Y cell line, has been used 
to study loss of the active gene. A total of 68  DNA samples were analysed, 
from both spontaneous and chemically-induced mutants, 48 of which had lost 
the 6.3kb Nco I fragment. Since no changes were seen in the fragment 
patterns with 4 other restriction enzymes, apart from a single DNA sample, 
it is concluded that TFT resistance in these mutants was due to loss of the 
entire functional tk gene.
The fraction of mutants that had lost the tk+ allele varied according to 
the treatment, and agreed with the known mode of action of these chemical 
mutagens in modifying DNA. Mutants obtained after treatment with EMS, 
which induces mainly point mutations involving GO*AT transitions (Singer, 
1975), had lost the tk+ allele in only 1 /1 0  large-sized, and 6 /1 2  small-sized 
colonies. The majority, 9/10, of large colony mutants induced by EMS were 
thus probably due to point mutations within the functional tk gene, resulting 
in a loss of, or inactivation of, the protein product. The single large-sized 
mutant in which the tk+ allele was detected was probably due to a deletion 
which may have been multigenic but which did not involve genes that affected
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the growth rate. Similarly, multigenic mutations were responsible for the 
6 /1 2  small-sized mutants where the tk+ allele was lost, but in this case the 
damage involved genes that affected cell growth. It is possible that some of 
these small colony mutants had sustained damage at the chromosome level, 
which would be visible cytogenically, although this was not examined.
Small colony mutants induced by EMS that retained the tk* allele are 
likely to have arisen by multiple point mutations with one event inactivating 
the tk* gene, and separate events occurring elsewhere in the genome which 
affected growth genes. Such mutants have previously been described after 
treatment with EMS or AHA by Moore et al. (1991a) and Clive et al. (1991).
It was estimated, after allowing for the fraction of colonies that were 
slow-growing in the mutation assays, that 21% of TK mutants induced by EMS 
were probably due to multiple point mutations. This percentage was higher 
than that observed by Clive et al. (1991) who found only 13% of EMS-induced 
mutants in this class. This difference may be due to differences in the 
definition of small colony size. In the present study "small" was defined as 
those colonies of less than 1 mm, whereas Clive et al defined "small" as less 
than 0.6 mm. Also, sizing the clones by eye in this study allowed the inclusion 
of colonies outside the detection capability (0.3 mm) of the Artek 880 colony 
counter used by Clive et al. The total number of mutants induced by EMS 
that had lost the tk* gene was estimated to be 26%, compared to the 41% 
reported by Clive et al. (1991). However, both studies demonstrated the point 
mutational action of EMS, since the majority of mutants induced was 
consistent with small intragenic lesions, which in the present study were
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beyond the limits of detection by Southern blotting using 5 restriction, 
enzymes.
Treatment of cells with MMC, resulted in a very different spectrum of 
genetic damage, characteristic of the ability of this chemical to cause DNA 
strand breakage (Teng et al,. 1989) which may result in deletion mutants, 
either directly or indirectly via repair mechanisms. All 14 small, and 1 1 /1 2  
large colony mutants had lost the function tk allele after treatment with MMC. 
The large-sized mutants were likely to have lost several kilobases of DNA, 
including at least the llk b  representing the tk* gene, and perhaps involving 
adjacent genes that did not include genes essential for normal growth.
The small-sized mutants induced by MMC that have lost the tk* allele, 
have probably lost an even larger section of the chromosome, including genes 
affecting growth rate. This may have occurred via a variety of mechanisms 
that lead to homozygosity, including major deletions and recombination 
between the homologous chromosomes. Although recombinational events 
were not examined in this study, reports indicate that it is a common event 
in both rodent and human cell lines. Mitotic recombination has been described 
at the aprt locus in CHO cells (Ward et al., 1990) and in a human 
lymphoblastoid, H853 cell line (Klinedinst and Drinkwater, 1991), and at the 
tk locus in mouse L5178Y cells (Applegate et al., 1990) and human TK6 cells 
(Yandell et al., 1990). Since MMC is known to cause an increase in mitotic 
recombination (Turner et al., 1988) as a mechanism for the repair of DNA 
breakage, it is likely that the small colony mutants induced by MMC will 
include a proportion that have undergone recombinational events. A total of 
97% of the MMC-induced mutants seen in the mutation assays were estimated
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to have lost the tk* allele; Clive et al. (1990) found similar percentages for 
chemicals known to be clastogens.
The majority of spontaneous mutants also appeared to occur through 
loss of the tk* allele. An estimated 77% of the total mutants obtained in the 
mutation assays are likely to have lost the functional tk allele, which is very 
close to the 83% estimation by Clive et al. (1990).
In summary, the TK mouse lymphoma assay has the ability to identify 
chemicals that induce genetic damage by a wide range of mechanisms, many 
of which would not be detected at hemizygous loci. In the present study, 
molecular analysis demonstrated that multilocus events were responsible for 
the majority of mutants induced by MMC, and were also common events in 
both spontaneous mutants and those induced by EMS.
6.2.2. Northern analysis o f TK mutants 
6.2.2.I. Introduction
Very little has been published on the analysis of tk mRNA. In an abstract of 
a poster presentation, Applegate et al. (1987) reported that TK mutants of 
L5178Y 3.7.2C cells produced a tk mRNA indistinguishable from that of non­
mutant clones, despite the absence of TK enzyme activity in the m utant cells. 
This, they suggested, was due to the constitutive expression of an abnormal 
tk mRNA from the tk allele of the heterozygous cell line.
In the present study, Northern blotting was used to analyse RNA from 
mutant and non-mutant clones, untreated or treated with EMS or MMC.
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6.2.2.2. Experimental
Total cytoplasmic RNA was extracted from approximately 2 x 108 cells per 
clone by the method of Krawetz et al. (1986). The concentration and purity 
of the RNA samples were determined spectrophotometrically. Optical 
densities, measured at wavelengths of 260 and 280 nm, gave ratios of between 
1.78 and 2.05; the RNA concentrations were in the range of 2.0 to 3.06 mg per 
sample. The integrity of the samples were confirmed by running aliquots in 
non-denaturing 0.8% agarose mini-gels; well-defined bands at 5.0 kb and 1.9 kb, 
representing the 28S and 18S ribosomal fragments respectively, showed that 
the RNA samples were not degraded.
Northern blotting was carried out using 20 jjg of each RNA sample and 
electrophoresis in denaturing, 1% agarose gels. The RNA molecules were 
transferred to Genescreen Plus membrane and hybridised to the radiolabelled 
mouse tk cDNA probe. The presence of tk RNA/cDNA hybrids was detected 
by autoradiography, after exposure for 3 to 21 days in presence of intensifying 
screens at -70 °C. Equal loading of the RNA samples was assessed by 
reprobing of the membrane with the mouse skeletal actin cDNA.
Total cellular RNA from each independent TK+ and TK' clone, treated 
or untreated, as described in Table 6.7 were subjected to Northern analysis. 
For each sample a single band of about 1.0 kb was detectable; no difference in 
the intensity of bands from mutant or non-mutant samples were observed 
when compared with the relative intensities of the actin mRNA. Examples of 
the Northern blots are shown in Fig. 6.17.
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A) MMC-treated TK+ c lo n es
B) MMC-treated TK' c lo n e s  which have l o s t  th e  6 .3  kb
NCo I fragm ent
F ig u re  6 .1 7 .  N orthern  b l o t t i n g  o f  RNA from TK'1' and TK' c l o n e s , p ro b ed
w ith  th e  mouse t k  cDNA
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6.2.2.3. Discussion
Northern blotting detected no differences in the size or amount of tk mRNA 
between RNA samples isolated from TK mutants and those from non-mutant 
clones. In all a total of 68 mutant and 53 wild-type clones were analysed. 
Since it had previously been demonstrated, by Southern blotting, that the 
entire tk+ allele was lacking in 48 of the mutants, it was assumed that the tk 
mRNA band seen resulted from transcription of the tk' allele.
No functional tk mRNA would be expected to be produced in mutants 
that had lost the tk+ allele, so it was somewhat surprising that no difference 
was seen in the intensity of the mRNA bands between total deletion mutants 
and wild-type clones. Although in some cases recombinational events may 
have resulted in duplication of the tk' allele, and therefore a possible increase 
in the production of an abnormal tk mRNA, it is unlikely that this had 
occurred in all of the deletion mutants. Perhaps transcription from the tk' 
gene was increased by some mechanism in an attempt to compensate for the 
decrease in gene dosage.
Similarly, the constant levels of tk mRNA made it impossible to identify 
mutants, carrying point mutations or micro-deletions, that affected 
transcription or mRNA stability. Such mutants would result in a reduction or 
total lack of mRNA associated with the tk+ gene. No mutants were detected 
that had a mRNA of an abnormal size, which would have been seen as an 
extra band on the blots. This would have been indicative of mutations that 
affected splice sites at the intron/exon junctions.
Northern analysis of TK mutants, occurring spontaneously or induced 
by EMS or MMC, proved uninformative in identifying mutations that affected
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the tk mRNA, since no differences were observed between the mRNAs of, 
mutant and wild-type cells.
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CHAPTER 7
CONCLUDING DISCUSSION
Two commonly used mammalian cell mutation assays, which measure 
mutation at different loci, were compared for their ability to respond to 
genotoxic chemicals. The assay that measures mutation at the X-linked hprt 
gene, which is hemizygous in the male-derived V79 cell line, has the advantage 
that only one copy of the gene is present in each cell thus facilitating 
molecular analysis of the mutants. In contrast, tk is heterozygous, the cells 
containing one functional tk allele and one structurally normal, but non­
functional allele on the homologous chromosome 11. Molecular analysis of the 
tk mutants for structural changes is made possible by a RFLP distinguishing 
the functional and non-functional alleles.
Two genotoxic chemicals were studied: EMS and MMC, both of which 
are direct-acting alkylating agents that are known to differ in their biological 
activity. Ethyl methanesulphonate, which exhibits low cytotoxicity, induces 
a high level of point mutations which appear to be correlated with the 
formation of 0 6-ethylguanine and the consequent mispairing to give G-*A 
transitions upon DNA replication (Heflich et al., 1982). Mitomycin C besides 
forming monoadducts can also crosslink DNA, and it is this latter ability which 
results in the strong cytotoxicity of the chemical and to the induction of the 
much higher frequency of chromosome breakage events compared to point 
mutations at similar chemical concentrations (Tomasz et al., 1988). This was 
demonstrated in the present study by a test for chromosome aberrations in
247
V79 cells in which MMC was shown to induce considerably more chromosomal 
damage than did EMS, when cells were treated at concentrations of both 
chemicals that gave approximately equivalent levels of cytotoxicity.
In the HPRT assay, EMS induced far more mutants than did MMC at 
similar levels of cytotoxicity. Relative to toxicity EMS was 32 times more 
mutagenic than MMC at the hprt locus of V79 cells. However when the same 
concentrations of the two chemicals were used to induce mutation at the tk 
locus of L5178Y cells, both EMS and MMC induced high numbers of mutants. 
Mutagenicity calculated in terms of toxicity showed EMS to be only 1.9 times 
more potent than MMC at the tk locus.
It is apparent therefore, that the type of damage induced by EMS differs 
to that caused by MMC, and that the majority of genetic lesions induced by 
MMC cannot be recovered as mutants at the hprt locus. In contrast, the tk 
locus was shown to be responsive to the types of genetic lesions induced by 
both EMS and MMC. Furthermore TK mutants showed a bimodal distribution 
of colony sizes, as previously described by Clive et al. (1979), in which the 
relative numbers of large- and small-sized colonies induced is dependent on the 
mutagen under test. In the present study MMC induced a much higher 
proportion of small colony mutants than did EMS. This colony size 
distribution was not observed for either compound in the HPRT assay.
Molecular analysis was used to investigate the types of genetic lesions 
resulting in the HPRT and TK mutant phenotypes. Southern blotting of 
HPRT mutants, either spontaneous or induced by EMS, showed that no 
detectable structural changes had occurred in the hprt gene. Structural 
changes were, however, seen in four out of 12 mutants induced by MMC, two
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of which were total deletions of the hprt gene, and two partial deletions which\ 
were probably intragenic with both breakpoints within the hprt gene. 
Northern blotting indicated that the majority of structurally normal mutants, 
from all sources, also had normal mRNA, and probably carried point-mutations 
or small deletions in the coding region of the gene leading to the production 
of an inactive enzyme. A minority of mutants, 1/9 EMS-induced and 3/12 
MMC-induced, were found to have reduced levels of hprt mRNA, which was 
probably due to point mutations in the untranslocated regions of the gene 
resulting in an mRNA of greatly increased instability.
The restriction enzyme Ncol, which distinguishes the function and non­
functional tk alleles in the L5178Y cell line, was used in Southern analysis of 
both large- and small-sized TK mutants. Since four other restriction enzymes 
showed no changes in fragment pattern, apart from a single DNA sample, it 
was assumed that loss of the informative Ncol fragment indicated a deletion 
of the entire functional tk gene. Of the spontaneous mutants the tk+ allele 
was deleted in the majority of both large and small colonies, as had also 
occurred in the majority of large colonies and all of the small colonies induced 
with MMC. For EMS-induced mutants the majority of large colonies and half 
of the small colonies had retained the tk* allele, indicating that the TK‘ 
phenotype was due to point mutations in these colonies.
Thus the tk locus appears to be responsive to many types of genetic 
events leading to mutation in this gene. Based on the classification of tk'/' 
mutants suggested by Clive et al. (1991) the mutational mechanisms at the tk 
gene, induced by EMS and MMC, in the present study included:
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large colony mutants carrying intragenic mutations consisting of 
point mutations or alterations of less than lOObp;
large colony mutants carrying multigenic mutations, which 
include loss of the tk gene and perhaps adjacent genes, but in 
which the deletion does not extend into genes essential for cell 
growth;
small colony mutants carrying multigenic mutations of greater 
size than described above, in which the deletion extends into an 
essential growth gene on chromosome 11. Some of these 
mutants may have visible chromosomal aberrations in the region 
of the tk* gene (Hozier et al., 1983; Moore et al., 1985), but this 
was not investigated in the present study;
small colony mutants carrying complex intragenic mutations or 
small deletions inactivating the tk gene, and other, independent 
mutations that have affected a gene required for normal growth; 
these additional mutations need not be confined to 
chromosome 11 .
Thus it can be concluded that EMS is predominantly a point mutagen, 
inducing mutations at both the hprt and tk loci, and capable of inducing 
multiple point mutations. In addition EMS also induces larger scale
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alterations detected only at the tk locus, the majority of which involve multiple, 
loci including genes essential for growth.
As seen by the poor response at the hprt locus, MMC induces relatively 
few point mutations; this was endorsed by molecular analysis of tk mutants 
which showed only one out of 12 large colony mutants was due to point 
mutations. This chemical, however, does induce considerable large scale 
damage, as seen at the tk locus, the majority of which extends beyond tk into 
growth genes on chromosome 11. At the hprt gene only one third of the 
MMC-induced mutants examined showed structural damage: two partial 
deletions and two deletions of the entire gene. That no partial deletions were 
detected at the tk locus may be due perhaps to the greater number of total 
gene deletions produced, such that the latter were more likely to be selected 
for molecular analysis. Alternatively, it might suggest that a "hot-spot" for 
chromosome breakage occurs up- or down-stream of the tk gene; deletion 
break points have been reported to cluster within a lOObp region of the aprt 
gene in Chinese hamster cells (Meuth, 1990), and a non-random distribution 
of deletion break points have also been observed in the hprt gene of human, 
TK6 , cells (Gennett and Thilly, 1988) and Chinese hamster cells (Xu et al., 
1989).
Thus, the data presented here agree with other published studies (Clive 
et al., 1979; Evans et al., 1986; Liber et al., 1989a) in showing that the chemical 
induction of mutation at different loci in mammalian cells may result in 
differences in the mutant frequency observed. Furthermore this study has 
shown that this difference in mutant frequency is due to the types of genetic 
damage that may lead to the mutant phenotype. Intragenic changes, ranging
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from point mutations to loss of the entire gene, can be recovered as viable, 
mutants at both the hprt and tk loci, and thus chemicals such as EMS, that 
induce mainly this type of DNA alteration will induce similar mutant 
frequencies at both loci. However, for chemicals such as MMC that induce a 
high proportion of much larger, multilocus deletions relative to point 
mutations, where the deletions extends into genes essential for cell viability, 
mutants can be recovered at the tk, but not at the hprt locus.
This difference in response to mutagenic mechanisms is due to the 
position of the selectable genes in the genome. Since hprt is situated at the 
X-chromosome no homologous chromosome exists to provide the essential 
function of genes that may be lost along with hprt in multilocus deletions and 
the cells will die. In contrast, selectable genes such as tk are situated on 
autosomes and hence the homologous chromosome is present to provide the 
necessary function if essential DNA sequences are deleted (Yandell et al., 
1986). This is supported by the studies of tk in mouse lymphoma cells 
(Applegate et al., 1990; Clive et al., 1990) and in human lymphoblastoid (TK6 ) 
cells (Liber et al., 1989a; Yandell et al., 1990), in other selectable heterogenous 
loci such as aprt*/' (Adair, 1987) and in other systems using hybrids that 
contain the integrated gpt gene from E. coli (Stankowski et al., 1986) or 
contain a complete human chromosome where the mutants for antigenic 
markers can be selected (Waldren et al., 1986).
The presence of homologous sequences are also required for mutagenic 
mechanisms, such as gene conversion and mitotic recombination, which again 
are events that lead to homozygosity. Interchromosomal recombination has 
been shown to occur in a human cell line containing two different mutant tk
genes on chromosome 17 (Benjamin et al., 1991) and in the L5178Y cell line, 
loss of the tk* allele accompanied by duplication of the remaining tk' gene has 
been demonstrated (Applegate et al., 1990).
It is also apparent that the range of genetic events detected by a 
particular assay, even using heterozygous cell-lines, depends on the cells used 
and the relative position of any essential genes, that might themselves be 
heterozygous, to the selectable gene. In the event of such a heterozygous 
essential gene the size of any deletion that would be tolerated would be 
dependent on its distance from the target gene (Liber et al., 1989a). Thus, the 
lower mutant frequencies observed at the tk locus of TK6 cells when compared 
to those of L5178Y cells has been attributed to the relatively frequent 
occurrence of heterozygosity in human cells. Cell lines derived from rodent 
inbred strains are reported to be mainly homozygous (+/ +) for most genes 
(Little, 1989). This difference in the response of human cells compared to 
rodent cells has been observed at the tk gene (Liber et al., 1989a) and the HLA 
and glyoxylase I loci (Kavathas et al., 1980).
Response to mutation at the hprt gene of human lymphocytes in vivo 
was also studied, and showed an age related increase in mutant frequency in 
agreement with other investigators (Trainer et al., 1984; Vijayalaxmi and 
Evans, 1984; Cole et al., 1988). However, a wide variability of mutant 
frequency was found, and it has been suggested (Morley, 1990) that to detect 
exposure to environmental mutagens several hundred exposed and non­
exposed individuals would have to be studied. In addition, chemicals which 
predominantly caused large scale damage would not be detected at the 
functionally heterozygous hprt locus, this has been illustrated in cancer
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patients administered high doses of cytotoxic drugs which have resulted in 
only a 3- to 5-fold increase in hprt mutant frequency (Ammenhauser et al.,
1988).
That higher mutation rates would be possible in vivo at autosomal loci 
has been demonstrated by Hakoda et al. (1990) who studied lymphocytes from 
Japanese patients heterozygous for the aprt gene {aprt */'). In this group the 
frequency of mutation of aprt was between 10-100  times higher than the 
frequencies reported for hprt. Study of the HLA-A locus in human 
lymphocytes by Turner et al. (1988) showed that the majority of in vivo 
mutations involved deletion of the selected HLA-A allele. Many of these 
mutants resulted from complex events involving reduplication of the 
unselected allele, including mutants that had undergone recombination 
between the two chromosomes 6 on which the HLA-A locus is situated. 
Approximately one third of the mutations were due to mitotic recombination 
which was found to increase with age, and there was significant variations in 
the frequency of recombination between individuals, suggesting the possibility 
of genetic differences (Morley, 1991).
In view of this evidence and that observed at the hprt and tk genes in 
the in vitro mammalian cell assays with different chemicals, it appears that 
the in vivo HPRT lymphocyte assay is likely to be limited in its ability to 
detect exposure to environmental carcinogens. In particular, this assay is 
unlikely to detect exposure to chemicals that induce mainly large scale 
damage, such as multilocus deletions and recombinational events. However, 
the HPRT lymphocyte assay does show sensitivity to intragenic mutagens and
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may be used to assess genetic damage by chemicals that primarily cause point, 
mutations and intragenic alterations (Rossi et al., 1992; Vrieling et al., 1992).
Both dominant and recessive mutations are important in the 
development of many human cancers. One of the most studied examples is 
colon cancer, which has been shown to be a highly complex process involving 
both oncogenes and tumour suppressor genes (Vogelstein, 1991). The study 
of colorectal cancer is facilitated by the ease with which the various stages of 
development can be obtained, from aberrant crypt foci and very small 
adenomas to large metastatic carcinomas. Furthermore, since several 
inherited syndromes exist predisposing to colon tumours, both inherited and 
somatic mutations involved in the development of the cancer can be studied.
Losses of specific chromosome regions are frequently seen in colon 
cancer and RFLPs have been used to distinguish the two heterozygous 
chromosomes in normal and tumour samples. This has allowed identification 
of allelic deletions or loss of heterozygosity and duplication of the remaining 
allele (Vogelstein et al., 1989). Thus a somatic or inherited mutation in a 
tumour suppressor gene, followed by loss of the normal allele by deletion or 
recombination, can be detected in tumour tissue.
To date four tumour suppressor genes have been identified which, when 
mutated, appear to participate in the development of many human colorectal 
cancers (Vogelstein, 1991). These are the APC gene (adenomatous polyposis 
coli), MMC gene (mutated in colon cancer) both on chromosome 5, DDC gene 
(deleted in colon cancer), on chromosome 18, and the p53 gene on 
chromosome 17. In addition, specific mutations of the Ki-ras oncogene, in 
particular mutations at codons 12 and 13 also appear frequently in colorectal
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cancer (Fearon, 1992). Thus both mutational activation of oncogenes and 
mutational inactivation of tumour suppressor genes occur in colorectal cancers, 
and several mechanisms for genetic damage appear to be involved.
Other examples where diverse mechanisms of genetic alteration lead to 
the inactivation of tumour suppressor genes have also emerged. In particular 
the p53 and RB  genes have been found to be deleted, rearranged, point- 
mutated or reduced to homozygosity in a number of different types of human 
cancer (Goodrich and Lee, 1990; Levine et al., 1991; Vogelstein and Kinzler,
1992). This diverse range of genetic alterations also extends to other 
candidate tumour suppressor genes that have been observed in human 
tumours including neuroblastoma involving chromosome 13 (Weith et al.,
1989), Wilm’s tumour involving chromosome 11 (Haber and Housman, 1992) 
and small cell lung carcinoma involving chromosome 3 (LaForgia et al., 1991).
The L5178Y tk*/' assay appears to detect both the point mutations, 
deletions and rearrangements associated with the activation of oncogenes, and 
the often more complex alterations associated with the inactivation of tumour 
suppressor genes. Therefore, the possibility exists for the definition of in vitro 
mammalian cell assays which detect the whole spectrum of genetic damage 
that has been observed in human cancers. Hemizygous genes, such as hprt, 
may be more limited in the range of alterations that may be detected. At the 
present time the L5178Y tk*/' assay appears better able to detect chemicals 
that are potential human carcinogens, because it can detect those lesions 
missed by tests for point mutations and which are also undetected by the 
chromosome aberration assay. It does however, still remain to be resolved 
whether certain regions of the chromosomes are more susceptible to damage
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than others. For example differences exist in the properties of Giemsa-light 
and Giemsa-dark chromosomal bands, such as GC-rich regions, fragile sites, 
early replication, that may result in differences in susceptibility of these 
sequences to various forms of mutational lesions (Hozier, 1991). Further 
research is needed to ascertain whether a housekeeping gene such as tk is 
more or less susceptible to genetic damage than, for example, a gene involved 
in the control of cell growth or differentiation.
It is somewhat surprising that the L5178Y tk+/' assay is not universally 
preferred to the hprt assay for the preliminary screening for chemical 
carcinogens. Although the mouse lymphoma assay is recommended in the 
EEC where a mammalian cell mutagenicity assay is required (Kirkland, 1992), 
and the US Office of Pesticide Programs recommend the TK assay, or HPRT 
assay plus chromosome aberration test (Auletta et al., 1993), only 50% of 
laboratories were found to routinely use the TK assay (Nestmann et al., 1991). 
A recent survey by the Centre for Medicines Research found that only 29% of 
laboratories in the EEC, 9% in Japan and 30% in the US, used the mouse 
lymphoma assay for the genotoxicity testing of pharmaceuticals (Purves et al.,
1993). In each case the HPRT assay was preferred due to the lower levels of 
positive results, although it was admitted that the results did not significantly 
add additional information to that from other routine tests.
The use of heterozygous selectable genes, such as tk, with information 
on the small and large colony phenotype, allows better characterisation of 
genotoxic chemicals than assays using hemizygous genes. Additional 
information by molecular analysis of the mutants can be used to determine the 
mutagenic mechanism involved in the reaction of the chemical with the DNA.
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The types of genetic lesions induced by a chemical at the tk locus ', 
compared with those lesions found in tumours of rodents treated with the 
same chemical, would also provide evidence for the capability of the in vitro 
assay to predict carcinogen potential and perhaps reduce the number of rodent 
bioassays performed. With the use of molecular biology the carcinogenic 
potential of the chemical can then be evaluated by comparison of the DNA 
damage obtained in the mammalian cell assay with the types of genetic lesions 
known to be important in human cancers.
258
REFERENCES
Adair, G.M. (1987). Analysis of mutation at the Chinese hamster aprt locus. 
In: Mammalian Cell Mutagenesis, Banbury Report No.28. Ed. M.M. Moore, 
D.M. de Marini, F.J. de Serres and K.R. Tindell. Publ. Cold Spring Harbor 
Laboratory, pp:3-14.
Aghamohammadi, S.Z., Morris, T., Stevens, D.L. and Thacker, J. (1992). Rapid 
screening for deletion mutations in the hprt gene using the polymerase chain 
reaction :X-ray and a-particle mutant spectra. Mutat. Res., 259. 1-7.
Albertini, R.J. (1985). Somatic gene mutation in vivo as indicated by the 
6-thioguanine-resistant T-lymphocytes in human blood. Mutat. Res. 150, 
411-422.
Albertini, R.J., Castle, K.L. and Borcherding, W.R. (1982). T-cell cloning to 
detect the mutant 6-thioguanine-resistant lymphocytes present in human 
peripheral blood. Proc. Natl. Acad. Sci. (USA), 79, 6617-6621.
Albertini, R.J., O’Neill, J.P., Nicklas, J.A., Heintz, N.H. and Kelleher, P.C. 
(1985). Alterations of the hprt gene in human in vivo derived 6-thioguanine- 
resistant T-lymphocytes. Nature, 316, 369-371.
Albertini, R.J., Sullivan, L.M., Berman, J.K., Greene, C.J., Stewart, J.A., 
Silveira, J.M. and O’Neill, J.P. (1988). Mutagenicity monitoring in humans 
by autoradiographic assay for mutant T lymphocytes. Mutat. Res. 204, 
481-492.
Alitalo, K. and Schwab, M. (1986). Oncogene application in tumour cells. In: 
Advances in Cancer Research Vol.47. Ed. G. Klein and S. Weinhouse, 
pp.235-281.
Ames, B.N. (1983). Dietary carcinogens and anticarcinogens. Science, 121. 
1256-1263.
Ames, B.N. and Gold, L.S. (1990). Chemical carcinogenesis : Too many rodent 
carcinogens. Proc. Natl. Acad. Sci. USA, 87, 7772-7776.
Ames, B.N., Profet, M. and Gold, L.S. (1990). Dietary pesticides (99.99% all 
natural). Proc. Natl. Acad. Sci. USA 87, 7777-7781.
Ammenheuser, M.M., Ward, Jr. J.B., Whorton, E.B., Killian, J.M. and Legator, 
M.S. (1988). Elevated frequencies of 6-thioguanine-resistant lymphocytes in 
multiple scherosis patients treated with cyclophosphamide : a prospective 
study. Mutat. Res. 204, 509-520.
Amundson, S.A. and Liber, H.L. (1991). A comparison of induced mutation at 
homologous alleles of the TK locus in human cells. Mutat. Res. 247. 19-27.
259
Anderson, D., Jenkinson, P.C., Dewdney, R.S., Francis, A.J., Godbert, P. and 
Butterworth, K.R. (1988). Chromosome aberrations, mitogen-induced 
blastogenesis and proliferative rate index in peripheral lymphocytes from 106 
control individuals of the UK population. Mutat. Res. 204. 407-420.
Applegate, M., Broder, C., Wadhams, A., Kasweck, K , Hozier, J., Moore, M., 
Clive, D. and Burrell, D. (1987). In situ and molecular analysis of mutation 
at the TK locus in mouse L5178Y TK+/' 3.7.2C cells. Environ. Mutagen, 9, 
Supplement 8, 5.
Applegate, M.L. and Hozier, J.C. (1987). On the complexity of mutagenic 
events at the mouse lymphoma tk locus. In: Banbury Report 28. 
Mammalian Cell Mutagenesis, Ed. M.M. Moore, D.M. DeMarini, F.J. de 
Serres and KR. Tindall. Cold Spring Harbor Laboratory, pp.213-224.
Applegate, M.L., Moore, M.M., Broder, C.B., Burrell, A., Juhn, G., Kasweck, 
KL., Lin, P.-F., Wadhams, A. and Hozier, J.C. (1990). Molecular dissection 
of mutations at the heterozygous thymidine kinase locus in mouse lymphoma 
cells. Proc. Natl. Acad. Sci. (USA), 87, 51-55.
Arlett, C.F. and Cole, J. (1986). Mutation studies in cells established from 
human cancer-prone syndromes. In: Genetic Toxicology of Environmental 
Chemicals, Part A  : Basic Principles and Mechanisms of Action. Ed. C. 
Ramel, B. Lambert and J. Magnussson. Alan R. Liss, N.Y. pp.237-244.
Arlett, C.F. and Cole, J. (1988). The role of mammalian cell mutation assays 
in mutagenicity and carcinogenicity testing. Mutagenesis, 3, 455-458.
Arlett, C.F. and Cole, J. (1990). The third United Kingdom Environmental 
Mutagen Society collaborative tr ia l : overview, a summary and assessment. 
Mutagenesis. 5, 85-88.
Arlett, C.F., Smith, D.M., Clarke, G.M., Green, M.H.L., Cole, J., McGregor, D.B. 
and Asquith, J.C. (1989). Mammalian cell gene mutation assays based upon 
colony formation. In: Statistical evaluation of mutagenicity test data, ed. D. 
Kirkland. Cambridge Univ. Press, pp.66-101.
Arlett, C.F., Turnbull, D., Harcourt, S.A., Lehmann, A.R. and Colella, C.M. 
(1975). A comparison of the 8-azaguanine and ouabain-resistance systems for 
the selection of induced mutant Chinese hamster cells. Mutat. Res. 33, 261- 
278.
Armel, P. and Williams, G.M. (1988). The molecular nature of spontaneous 
and chemically induced mutations in the hypoxanthine-guanine 
phosphoribosyl transferase gene in rat liver epithelial cells. Mutat. Res. 202. 
147-153.
260
Armstrong, M.J., Bean, C.L. and Galloway, S.M. (1992). A quantitative 
assessment of the cytotoxicity associated with chromosomal aberration 
detection in Chinese hamster ovary cells. Mutat. Res. 265, 45-60.
Ashby, J. (1988). Comparison of techniques for monitoring human exposure 
to genotoxic chemicals. Mutat Res. 204. 543-551.
Ashby, J. and Tennant, R.W. (1988). Chemical structure, Salmonella 
mutagenicity and extent of carcinogenicity as indicators of genotoxic 
carcinogenesis among 222 chemicals tested in rodents by the US NCI/NTP. 
Mutat. Res. 204. 17-115.
Ashby, J., Tennant, R.W., Zeiger, E. and Stasiewiez, S. (1989). Classification 
according to chemical structure, mutagenicity to Salmonella and levels of 
carcinogenicity of a further 42 chemicals tested for carcinogenicity by the US 
National Toxicology Program. Mutat. Res. 223. 73-103.
Asita, A. (1989). A comparative study of the clastogenic activity of ethylating 
agents. Mutagenesis, 4, 432-436.
Auerbach, C. and Robson, J.M. (1946). Chemical production of mutations. 
Nature, 157. 302.
Auletta, A.E., Dearfield, K.L. and Cimino, M.C. (1993). Mutagenicity test 
schemes and guidelines : US EPA Office of Pollution Prevention and Toxics 
and Office of Pesticides Program. Environ. Molec. Mutagen. 21, 38-45.
Baan, R.A. (1987). DNA damage and cytogenetic end points. In: Cytogenetics 
: basic and applied aspects. Ed. G. Obe and A. Basler. Springer-Verlage, 
Berlin, pp.327-337.
Baird, P.A., Anderson, T.W., Newcombe, H.B. and Lowry, R.B. (1988). Genetic 
disorders in children and young adults : a population study. Am. J. Hum. 
Genet. 42, 677-693.
Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.A., Preisinger, A.C., Jessup, 
J.M. van Tuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R. 
and Vogelstein, B. (1989). Chromosome 17 deletions andp53 gene mutations 
in colorectal carcinomas. Science, 244, 217-221.
Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markowitz, S., 
Wilson, J.K.V., Hamilton, S. and Vogelstein, B. (1990). p53 gene mutations 
occur in combination with 17p allelic deletions or late events in colorectal 
tumorigenesis. Cancer Res. 50, 7717-7722.
Balakrishna Murthy, P. and Prema, K. (1979). Sister chromatid exchanges in 
oral contraceptive users. Mutat. Res. 68, 149-152.
261
Balmain, A., Ramsden, M., Bowden, G.T. and Smith, J. (1984). Activation of 
the mouse cellular Harvey-ras gene in chemically induced benign skin 
papillomas. Nature, 307. 658-660.
Barbacid, M. (1985). Oncogenes in human cancers and in chemically induced 
animal tumours. Prog. med. Virol. 32, 86-100.
Bartsch, H., Terracini, B., Malaveille, C., Tomatis, L., Wahrendorf, J., Brun, G. 
and Dodet, B. (1983). Quantitative comparisons of carcinogenicity, 
mutagenicity and electrotrophilicity of 10 direct acting alkylating agents and 
of the initial 06:7-alkylguanine ratio in DNA with carcinogenic potency in 
rodents. Mutat. Res. 110. 187-219.
Bean, C.L., Armstrong, M.J. and Galloway, S.M. (1992). Effect of sampling 
time on chromosome aberration yield for 7 chemicals in Chinese hamster 
ovary cells. Mutat. Res. 265. 31-44.
Beebee, T. and Burke, J. (1988). Gene structure and transcription. IRL Press, 
Oxford, pp.38.
Bender, M.A., Griggs, H.G. and Bedford, J.S. (1974). Mechanisms of 
chromosomal aberration production. III. Chemicals and ionising radiation. 
Mutat. Res. 23, 197-212.
Benjamin, M.B., Potter, H., Yandell, D.W. and Little, J.B. (1991). A system for 
assaying homologous recombination at the endogenous human thymidine 
kinase gene. Proc. Natl. Acad. Sci. (USA), 88, 6652-6656.
Bingham, E. (1988). Extent of carcinogenicity testing of commercial chemicals. 
Ann. N Y  Acad. Sci. 534, 1038-1041.
Bishop, J.M. (1983). Cellular oncogenes and retroviruses. Ann. Rev. Biochem., 
52, 301-354.
Bishop, J.M. (1987). The molecular genetics of cancer. Science, 235. 305-311.
Bishop, J.M. (1988). The molecular genetics of cancer : 1988. Leukaemia, 2, 
199-208.
Bishop, J.M. (1989). Oncogenes and clinical cancer. In: Oncogenes and the 
Molecular Origins of Cancer. R.A. Weinberg. Cold Spring Harbor Laboratory 
Press, pp.327-358.
Boehm, T. and Rabbitts, T.H. (1989). A chromosomal basis of lymphoid 
malignancy in man. Eur. J. Biochem. 185. 1-17.
Bos, J.L. (1988). The ras gene family and human carcinogenesis. Mutat. Res., 
195. 255-271.
262
Bos, J.L. (1989). ras oncogenes in human cancer : a review. Cancer Res. 49, 
4682-4689.
Boyum, A. (1968). Separation of leucocytes from blood and bone marrow. 
Scand. J. Clin. Lab. Invest., 21, Suppl.97.
Bradley, M.O., Bhuyan, B., Francis, M.C., Langenbach, R., Peterson, A. and 
Huberman, E. (1981). Mutagenesis by chemical agents in V79 Chinese 
hamster cells : A review and analysis of the literature. Mutat. Res. 87, 81- 
142.
Bradley, W.E.C., Belouchi, A  and Messing, K. (1988). The aprt heterozygote/ 
hemizygote system for screening mutagenic agents allows detection of large 
deletions. Mutat. Res. 199. 131-138.
Bradley, W.E.C. and Messing, K. (1989). Studies of mutation at the hprt locus. 
Workshop on mutation at the hprt locus, Stockholm, May 26-28,1988. Mutat. 
Res. 216, 65-88.
Bradshaw, H.D. Jr. and Deininger, P.L. (1984). Human thymidine kinase gene 
: molecular cloning and nucleotide sequence of a cDNA expressible in 
mammalian cells. Molec. Cell Biol. 4, 2316-2320.
Branda, R.F., Sullivan, L.M., O’Neill, J.P., Falta, M.T., Nicklas, J.A., Hirsch, B., 
Vacek, P.M. and Albertini, R.J. (1993). Measurement of HPRT mutant 
frequencies in T-lymphocytes from healthy human populations. Mutat. Res., 
285. 267-279.
Bressac, B., Kew, M., Wands, J. and Ozturk, M. (1991). Selective C to T 
mutations of p53 gene in hepatocellular carcinoma from Southern Africa. 
Nature, 350, 429-431.
Brown, R. and Thacker, J. (1984). The nature of mutants induced by ionising 
radiation in cultured hamster cells. I. Isolation and initial characterisation 
of spontaneous, ionising radiation-induced and ethyl methanesulphate- 
induced mutants resistant to 6-thioguanine. Mutat. Res. 129, 269-281.
Cairns, J. (1975). Mutations, selection and the natural history of cancer. 
Nature, 255, 197-200.
Cariello, N.F., Keohavong, P., Kat, A.G. and Thilly, W.G. (1990). Molecular 
analysis of complex human cell populations : mutational spectra of MNNG 
and ICR-191. Mutat. Res., 231. 165-176.
Carrano, A.V. (1973). Chromosome aberrations and radiation-induced cell 
death. II. Predicted and observed cell survival. Mutation Res. 17, 355-366.
263
Carrano, AV. and Natarajan, A.T. (1988). ICPEMC Publ. No.14 : 
Considerations for population monitoring using cytogenetic techniques. 
Mutat. Res. 304. 379-406.
Carrano, AV., Thompson, L.H., Stetka, D.G., Minkler, J.L., Mazrimas, J A  and 
Fong, S. (1979). DNA crosslinking, sister-chromatid exchange in specific-locus 
mutations. Mutation Res. 63, 175-188.
Casciano, D A , Talaska, G. and Clive, D. (1991). The potent hepatocarcinogen 
methapyrilene induces mutations in L5178Y mouse lymphoma cells in the 
apparent absence of DNA adduct formation. Mutat. Res. 263. 127-132.
Caskey, C.T. (1987). Disease diagnosis by recombinant DNA methods. 
Science, 236. 1223-1232.
Cavenee, W.K., Dryja, T.P., Phillips, RA , Benedict, W.F., Godbout, R., Gallie,
B.L., Murphree, A.L., Strong, L.C. and White, R.L. (1983). Expression of 
recessive alleles by chromosomal mechanisms in retinoblastoma. Nature, 
305. 779-784.
Chamberlain, J.S., Gibbs, R.A., Ranier, J.E., Nguyen, P.N. and Caskey, C.T.
(1988). Deletion screening of the Duchenne muscular dystrophy locus via 
multiplex DNA amplification. Nucl. Acids Res. 16, 11141-11156.
Chaudhry, M A  and Fox, M. (1990). Methylmethane-sulphonate and X-ray- 
induced mutations in the Chinese hamster hprt gene : mRNA phenotyping 
using polymerase chain reactions. Mutagenesis, 5, 497-504.
Chinault, AC. and Caskey, C.T. (1984). The hypoxanthine phosphoribosyl- 
transferase gene : A model for the study of mutation in mammalian cells. 
Prog. Nucl. Acid. Res. Molec. Biol. 31, 205-313.
Chrysostomou, A, Seshadri, R.S. and Morley, A A  (1984). Mutation frequency 
in nurses and pharmacists exposed to cytotoxic drugs. Aust. N.Z. J. Med. 14, 
831-834.
Chu, E.H.Y. (1971). Mammalian cell genetics. III. Characterization of X-ray- 
induced forward mutations in Chinese hamster cell cultures. Mutat. Res. 11. 
23-34.
Chu, E.H.Y. (1983). Mutation systems in cultured mammalian cells. Ann. N Y  
Acad. Sc. 407, 221-230.
Chu, E.H.Y. and Mailing, H.V. (1968). Mammalian cell genetics. II. Chemical 
induction of specific locus mutations in Chinese hamster cells in vitro. Proc. 
Natl. Acad. Sci. (USA), 61, 1306-1312.
Clayson, D.B. (1987). The need of biological risk assessment in reaching 
decisions about carcinogens. ICPEMC Publ. No. 13. Mutat. Res. 185,243-269.
264
Cleveland, D.W. (1989). Gene regulation through messenger RNA stability. 
Curr. Opinion Cell Biol. 1, 1148-1153.
Clive, D. (1989). Mammalian cell genotoxicity : a major role for non-DNA 
targets? Mutat. Res. 223. 327-328.
Clive, D., Glover, P., Applegate, M. and Hozier, J. (1990). Molecular aspects 
of chemical mutagenesis in L5178Y/7£+/' mouse lymphoma cells. 
Mutagenesis, 5, 191-197.
Clive, D., Glover, P., Krehl, R. and Poorman-Allen, P. (1991). Mutagenicity of 
2-amino-N6-hydroxyadenine (AHA) at three loci in L5178Y/£&+/* mouse 
lymphoma cells : molecular and preliminary cytogenetic characterizations of 
AHA-induced tk'1' mutant. Mutat. Res. 253. 73-82.
Clive, D., Johnson, K.O., Spector, J.F.S., Batson, AG. and Brown, M.M.M. 
(1979). Validation and characterisation of the L5178YTK+ mouse lymphoma 
mutagen assay system. Mutat. Res. 59, 61-108.
Clive, D., McCuen, R., Spector, J.F.S., Piper, C. and Mavournin, K.H. (1983). 
Specific gene mutations in L5178Y cells in culture. A report of the US 
Environmental Protection AGency Gene-Tox Program. Mutation Res. 115. 
225-251.
Clive, D. and Spector, J.F.S. (1975). Laboratory procedure for assessing 
specific locus mutations at the TK locus in cultured L5178Y mouse 
lymphoma cell. Mutat. Res. 31, 17-29.
Cobb, R.R., Martin, J., Korytynski, E., Monteith, L. and Hughes T.J. (1989). 
Preliminary molecular analysis of the TK locus ion L5178Y large- and small- 
colony mouse lymphoma mutants. Mutat. Res. 226. 253-258.
Cole, J. and Arlett, C.F. (1984). The detection of gene mutations in cultured 
mammalian cells. In: Mutagenicity Testing : A  Practical Approach. Ed. S. 
Venitt and J.M. Parry. IRL Press, Washington, pp.233-273.
Cole. J., Arlett, C., Green, M.H.L., Lowe, J. and Muriel, C.W (1983a). A 
comparison of the agar cloning and microtitration techniques for assaying cell 
survival and mutation frequency in L5178Y mouse lymphoma cells. Mutation 
Res., I l l ,  371-386.
Cole, J., Diot, M.-C., Richmond, F.N. and Bridges, B.A (1990b). Comparative 
induction of gene mutations and chromosome damage by l-methoxy-1,3,5- 
cycloheptatriene (MCHT), 2. Results using L5178Y mouse lymphoma cells to 
detect both gene and chromosome damage; validation with ionizing radiation 
methyl methanesulphonate, ethyl methanesulphonate and benzo[a]pyrene. 
Mutat. Res. 230. 81-91.
265
Cole, J., Fox, M., Garner, C., McGregor, D. and Thacker, J. (1983). Gene 
mutation assays in cultured mammalian cells. In: Report of the UKEMS 
Sub-Committee on Guidelines for Mutagenicity Testing. Part 1. Ed. B.J. 
Dean, UKEMS, Swansea, pp.65-102.
Cole, J., Fox, M., Garner, R.C., McGregor, D.B. and Thacker, J. (1990). Gene 
mutation assays in cultured mammalian cells. In: Basic Mutagenicity Tests 
: UKEMS recommended procedures Park I  revised. Ed. D.J. Kirkland, 
Cambridge University Press, pp.87-114.
Cole, J., Green, M.H.L., James, S.E., Henderson, L. and Cole, H. (1988). A 
further assessment of factors influencing measurements of thioguanine- 
resistant mutant frequency in circulating T-lymphocytes. Mutat. Res. 204. 
493-507.
Cole, J., Green, M.H.L., Stephens, G., Waugh, AP.W., Beare, D., 
Steingrimsdottir, H. and Bridges, B.A (1990a). HPRT somatic mutation 
data. In: Mutation and the Environment Part C. Ed. H.L. Mendelsohn and 
R.J. Albertini. Wiley-Liss Inc. NY, pp.25-35.
Committee on Mutagenicity of Chemicals in Food, Consumer Products and the 
Environment (1989). Guidelines for the testing of chemicals for 
mutagenicity. Dept, of Health, Report on Health and Social Subjects No.35. 
HMSO.
Cotton, R.G.H. (1989). Detection of single base changes in nucleic acids. 
Biochem. J., 263. 1-10.
Cowell, J.K. (1982). Double minutes and homogeneously staining regions : 
gene amplification in mammalian cells. Ann. Rev. Genet. 16, 21-59.
Croce, C.M. (1987). Role of chromosome translocations in human neoplasia. 
Cell, 49, 155-156.
Croce, C.M. and Nowell, P.C. (1985). Molecular basis of human B-cell 
neoplasia. Blood, 65, 1-7.
Crosby, R.M., Richardson, K.K., Craft, T.R., Benforado, KB., Liber, H.L. and 
Skopek, T.R. (1988). Molecular analysis of formaldehyde-induced mutations 
in human lymphoblasts and E. coli. Environ. Molec. Mutagen, 12, 155-166.
Davidson, B.L., Pashmforoush, M., Kelley, W.N. and Palella, T.D. (1988). 
Genetic basis of hypoxanthine guanine phosphoribosyltransferase deficiency 
in a patient with the Lesch-Nyhan syndrome (HPRT FLINT). Gene, 63. 
331-336.
Davies, K.E. and Read, A.P. (1988). Molecular basis of inherited disease. IRL 
Press, Oxford, pp. 1-9.
266
Davies, M.J., Evans, J.G. and Rumsby, P.C. (1992). Single-strand conformation 
polymorphism analysis of p53 gene mutations in spontaneous and chemically- 
induced mouse liver tumours. Mutagenesis, 7, 381.
Davies, M.J., Lovell, D.P. and Anderson, D. (1992). Thioguanine-resistant 
mutant frequency in T-lymphocytes from a healthy human population. 
Mutat. Res. 265. 165-171.
de Klein, A. (1987). Oncogene activation by chromosomal rearrangement in 
chronic myelocytic leukaemia. Mutat. Res. 186. 161-172.
Deaven, L.L. and Petersen. D.F. (1973). The chromosomes of CHO, an 
aneuploid Chinese hamster cell line : G-band, C-band and autoradiographic 
analyses. Chromosoma (Berl.), 41. 129-144.
DeMarini, D.M., Brockman, H.E., de Serres, F.J., Evans, H.H., Stankowski Jr, 
L.F. and Hsie, A.W. (1989b). Specific-locus mutations induced in eukaryotes 
(especially mammalian cells) by radiation and chemicals : a perspective. 
Mutat. Res., 220. 11-29.
DeMarini, D.M., Doerr, C.L., Meyer, M.K., Brock, K.H., Hozier, J. and Moore, 
M.M. (1987). Mutagenicity of ra-AMSA and o-AMSA in mammalian cells due 
to clastogenic mechanism : possible role of topoisomerase. Mutagenesis, 2, 
349-355.
DeMarini, D.M., Lewtas, J. and Brockman, H.E. (1989a). Utility of short-term 
tests for genetic toxicity. Cell Biol, and Toxicol. 5,189-200.
Dempsey, J., Seshadri, R.S. and Morley, A.A. (1985). Increased mutation 
frequency following treatment with cancer chemotheraphy. Cancer Res. 45. 
2873-2877.
Dempsey, J.L., Morley, A.A., Seshardri, R.S., Emmerson, B.T., Gordon, R. and 
Bhagat, C.I. (1983). Detection of the carrier state for an X-linked disorder, 
the Lesch-Nyhan syndrome, by the use of lymphocyte cloning. Hum. Genet. 
64, 288-290.
Dewdney, R.S., Lovell, D.P., Jenkinson, P.C. and Anderson, D. (1986). 
Variation in sister chromatid exchange amoung 106 members of the general 
UK population. Mutat. Res. 171. 43-51.
Dotto, G.P., Parade, L.F. and Weinberg, R.A. (1985). Specific growth response 
of ms-transformed fibroblasts to tumour promotors. Nature, 318. 472-475.
Douglas, G.R., Blakey, D.H. and Clayson, D.B. (1988). ICPEMC Working Paper 
NO.5. Genotoxicity tests as predictors of carcinogens : an analysis. Mutat. 
Res. 196, 83-93.
267
Dowd, M.A, Gaulden, M.E., Proctor, B.L. and Seibert, G.B. (1986).' 
Formaldehyde-induced acentric chromosome fragments and chromosome 
stickiness in Chortophaga neuroblasts. Environ. Mutagenesis, 8, 401-411.
Downward, J., Tarden, Y., Mayes, E., Scrace, G., Toffy, N., Stockwell, P., 
Ullrich, A., Schlessinger, J. and Waterfield, M.D. (1984). Close similarity of 
epidermal growth factor receptor and v-erb B oncogene protein sequences. 
Nature, 307, 521-527.
Drake, J.W. and de Serres, F.J. (1980). Report I I : Rational for deployment of 
short-term assays for evidence of carcinogenicity. IARC Monograph, Suppl.2. 
Long-term and short-term screening assays for carcinogens. IARC, Lyon, 
pp.426.
Dunn, J.M., Phillips, R.A., Becker, AJ. and Gallie, B.L. (1988). Identification 
of germline and somatic mutations affecting the retinoblastoma gene. 
Science, 241, 1797-1800.
Dusre, L., Covey, J.M., Collins, C. and Sinha, B.K (1989). DNA damage, 
cytotoxicity and free radical formation by mitomycin C in human cells. 
Chem.-Biol. Interact. 71, 63-78.
Edwards, J.H. (1988). The importance of genetic disease and the need for 
prevention. Phil. Trans. R. Soc. Lond. B. 319, 211-227.
Evans, H.H., Mench, J., Horng, M.-F., Ricanati, M., Sanchez, C. and Hozier, J. 
(1986). Locus specificity in the mutability of L5178Y mouse lymphoma cells. 
The role of multilocus lesions. Proc. Natl. Acad. Sci. (USA), 83, 4378-4383.
Evans, H.J. (1976). Cytological methods of detecting chemical mutagens. In: 
Chemical Mutagens : Principles and Methods for their Detection, Vol.4. Ed. 
A. Hollander, Plenum Press, N,Y! pp. 1-25.
Evans, H.J. (1986). The role of human cytogenetics in studies of mutagenesis 
and carcinogenesis. In: Genetic Toxicology of Environmental Chemicals. Part 
A : Basic Principles and Mechanisms of Action. Ed. C. Ramel, B. Lambert 
and J. Magnusson, Alan R. Liss, N.Y. pp.41-69.
Evans, H.J. (1988). Mutation cytogenetics: past, present and future. Mutat. 
Res. 204, 355-363.
Evans, J.G., Collins, M.A., Savage, S.A., Lake, B.G. and Butler, W.H. (1986). 
The histology and development of hepatic nodules in C3H/He mice following 
chronic administration of phenobarbitone. Carcinogenesis, 7, 627-631.
Farber, E. (1984). The multistep nature of cancer development. Cancer Res. 
44, 4217-4223.
268
Fearon, E.R. (1992). Genetic alterations underlying colorectal tumorigenesis.', 
Cancer Surveys, 12, 119-136.
Fearon, E.R., Cho, K.R., Nigro, J.M., Kern, S.E., Simons, J.W., Rupert, J.M., 
Hamilton, S.R., Presinger, A.C., Thomas, G., Kinzler, KW. and Vogelstein, B.
(1990). Identification of a chromosome 18q gene that is altered in colorectal 
cancer. Science, 247. 49-50.
Fearon, G.R. and Vogelstein, B. (1991). A genetic model for colorectal 
tumorigenesis. Cell, 61, 759-767.
Featherstone, T., Marshall, P.D. and Evans, H. J. (1987). Problems and pitfalls 
in assessing human T-lymphocyte mutant frequencies. Mutation Res, 179. 
215-230.
Feinberg, A.P. and Vogelstein, B. (1983a). Hypomethylation of ras oncogenes 
in primary human cancers. Biochem. Biophys. Res. Comm. 111. 47-54.
Feinberg, A.P. and Vogelstein, B. (1983b). A technique for radiolabeling DNA 
restriction endonuclease fragments to high specific activity. Anal. Biochem. 
132. 6-13.
Ferguson, M.J., Gaulden, M.E. and Seibert, G.B. (1985). Chromosome 
fragments and other abnormalities induced by mitomycin C in the neuroblast 
of Chortophaga viridifascdiata. Environ. Mutagenesis, 7, 547-561.
Ford, D.K and Yerganian, G. (1958). Observations on the chromosomes of 
Chinese hamster cells in tissue culture. J. Natl. Cancer Inst., 21, 393-425.
Fourney, R.M., Miyakoshi, J., Day, R.S. and Peterson, M.C. (1988). Northern 
blotting : efficient RNA staining and transfer. Focus, 10, 5-7.
Fuscoe, J.C., Fenwick, R.G., Ledbetter, D.H. and Caskey, C.T. (1983). Deletion 
and amplification of the HGPRT locus in Chinese hamster cells. Molec. Cell 
Biol. 3, 1086-1096.
Fuscoe, J.C., Ockey, C.H. and Fox, M. (1986). Molecular analysis of X-ray- 
induced mutants at the HPRT locus in V79 Chinese hamster cells. Int. J. 
Radiat. Biol. 49, 1011-1020.
Galloway, S.M., Berry, P.K., Nichols, W.W., Wolman, S.R., Soper, K.A., Stolley, 
P.D. and Archer (1986). Chromosome aberrations in individuals 
occupationally exposed to ethylene oxide, and in a large control population. 
Mutat. Res. 170, 55-74.
Gaulden, M.E. (1986). Sodium-chrloide-induced chromosome-stickiness: an 
examination of living cells of its relation to chromosome breakage. Environ. 
Mutagenesis, 8, Suppl.6, 30.
269
Gaulden, M.E. (1987). Hypothesis: Some mutagens directly alter specific  ^
chromosomal proteins (DNA topoisomerase II and peripheral proteins) to 
produce chromosome stickiness, which causes chromosome aberrations. 
Mutagenesis, 2, 357-365.
Gebhert, E. (1987). Cytogenetic studies in human neoplasia. In: Cytogenetics 
: basic and applied. Ed. G. Obe and A. Basler, Springer-Verlag, Berlin, 
pp. 113-140.
Gennett, I.N. and Thilly, W.G. (1988). Mapping large spontaneous deletion 
endpoints in the human HPRT gene. Mutat. Res. 201. 149-160.
George, D.L., Scott, A.F., de Martinville, B. and Francke, U. (1984). Amplified 
DNA in 71 mouse adrenal tumour cells : isolation of DNAs complementary 
to an amplified c-Ki-ras gene and localisation of homologous sequences to 
mouse chromosome 6. Nucleic Acid Res. 12, 2731-2743.
Ghosal, D. and Saedler, H. (1978). DNA sequences of the mini-insertion 152-6 
and its relation to the sequence of 152. Nature, 275. 611-617.
Gibbs, R.A. and Caskey, C.T. (1987). Identification and localization of 
mutations atthe Lesch-Nyhan locus by ribonuclease A cleavage. Science, 236. 
303-305.
Gibbs, R.A, Nguyen, P.-N., Edwards, A, Civitello, A.B. and Caskey, C.-T.
(1990). Multiplex DNA deletion detection and exon sequencing of the 
hypoxanthine-phosphoribosyltransferase gene in Lesch-Nyhan families. 
Genomics, 7, 235-244.
Gibbs, R.A., Nguyen, P.N., McBride, L.J., Koepf, S.M. and Caskey, C.T. (1989). 
Identification of mutations leading to the Lesch-Nylan syndrome by 
automated direct DNA sequencing of in vitro amplified cDNA. Proc. Natl. 
Acad. Sci. 86, 1919-1923.
Goelz, S.E., Vogelstein, B., Hamilton, S.R. and Feinberg, A.P. (1985). 
Hypomethylation of DNA from benign and maligant human colon neoplasms. 
Science, 228. 187-190.
Goldstein, M., Anderson, C.T., Reuben, R. and Dancis, J. (1985). Self- 
mutilation in Lesch-Nyham disease is caused by dopaminergic denervation. 
Lancet, 1, 338-339.
Goodrich, D. and Lee, W.H. (1990). The molecular genetics of retinoblastoma. 
Cancer Surveys, 9, 525-554.
Goodrow, T.L., Storer, R.D., Leander, K.B., Prahalada, S.R., van Zwieten, M.J. 
and Bradley, M.O. (1992). Murine p53 intron sequences 5-8 and their use in 
polymerase chain reaction/direct sequencing analysis of p53 mutations in 
CD-I mouse liver and lung tumors. Molec. Carcinogen, 5, 9-15.
270
Green, M.H.L. and Muriel, W.J. (1976). Mutagen testing using TRP+ reversion 
in Eschericha coli. Mutat. Res. 38, 3-32.
Griffin, B.E. (1986). Structure of DNA and its relationship to carcinogenesis. 
In: Introduction to the Cellular and Molecular Biology of Cancer. Ed. L.M. 
Franks and N. Teich, Oxford Univ. Press, pp. 111-130.
Grist, S.A., McCarron, M., Kutlaca, A., Turner, D.R. and Morley, A.A. (1992). 
In vivo human somatic mutation : frequency and spectrum with age. Mutat. 
Res. 266, 189-196.
Groden, J., Thliveris, A., Samonwitz, W., Carlson, M., Gelbert, L., Albertsen, 
H., Joslyn, G., Stevens, J., Spirio, L., Robertson, M., Sargeant, L., Krapcho, 
K., Wollf, E., Burt, R , Hughes, J.P., Warrington, J., McPherson, J., Wasmulh, 
J., LePaslier, D., Abderrahim, H., Cohen, D., Leppert, M. and White, R.
(1991). Identification and characterisation of the familial adenomatous 
polyposis coli gene. Cell, 66, 589-600.
Guerrero, I. and Pellicer, A. (1987). Mutational activation of oncogenes in 
animal model systems of carcinogenesis. Mutat. Res. 185. 293-308.
Gupta, R.S. and Singh, B. (1982). Mutagenic response of five independent 
genetic loci in CHO cells to a variety of mutagens. Development and 
characteristics of a mutagen screening system based on selection of multiple 
drug resistance markers. Mutat. Res. 94, 449-466.
Gurney, T. (1984). One-dimensional electrophoresis of nucleic acids in agarose 
using denaturation with formaldehyde and identification of 3H-labelled RNA 
by fluorography. In: Methods in Molecular Biology Vol. 2: Nucleic Acids. Ed. 
J.M. Walker. Human Pressa, N.J. pp,77-92.
Haber, D.A. and Housman, D.E. (1992). Role of the WT1 gene in Wolms’ 
tumour. Cancer Surveys, 12, 105-117.
Hakoda, M., Akiyama, M., Kyoizumi, S., Awa, AA., Yamakido, M. and Otake, 
M. (1988). Increased somatic cell mutant frequency in atomic bomb 
survivors. Mutat. Res. 201. 39-48.
Hakoda, M., Nishioka, K. and Kamatani, N. (1990). Homozygous deficiency at 
autosomal locus aprt in human somatic cells in vivo induced by two different 
mechanisms. Cancer Res. 50, 1738-1741.
Hall, A. (1986). Oncogenes. Genetic Engineering, 5, 62-116.
Harris, H., Miller, O.J., Klein, G., Worst, P. and Tachibana, T. (1969). 
Suppression of malignancy by cell fusion. Nature, 223. 363-368.
Hartman, P.E. (1983). Mutagens : some possible health impacts beyond 
carcinogenesis. Environ. Mutagen 5, 139-152.
271
Hayward, W.S., Neel, B.G. and Astrin, S.M. (1981). Activation of a cellular one 
gene by promotor insertion in ALV-induced lymphoid leukosis. Nature, 290. 
475-480.
Heddle, J.A. (1988). Prediction of chemical carcinogenicity from in vitro 
genetic toxicity. Mutagenesis 3, 287-291.
Heddle, J A , Hite, M., Kirkhart, B., Mavournin, K , Mac Gregor, J.T., Newell,
G.W. and Salamone, M.F. (1983). The induction of micronuclei as a measure 
of genotoxicity. Mutat. Res. 123. 61-118.
Hedner, K, Hogstedt, B., Kolnig, A-M., Mark-Vendel, E., Strombeck, B. and 
Mitelman, F. (1982). Sister chromatid exchanges and structural chromosome 
aberrations in relation to age and sex. Hum. Genet. 62, 305-309.
Heflich, R.H., Beranek, D.T., Kodell, R.L. and Morris, S.M. (1982). Induction 
of mutations and sister-chromatid exchanges in Chinese hamster ovary cells 
by ethylating agents. Mutat. Res. 106. 147-161.
Heim, S. and Mitelman, F. (1989). Primaiy chromosome abnormalities in 
human neoplasia. Adv. Cancer Res. 52, 1-43.
Heldin, C.H. and Westermark, B. (1984). Growth factors: mechanism of action 
and relation to oncogenes. Cell, 37, 9-20.
Henderson, L., Cole, H., Cole, J., James. S.E. and Green, M.H.L. (1986). 
Detection of somatic mutations in man : evaluation of the microtitre cloning 
assay for T-lymphocytes. Mutagenesis, 1, 195-200.
Hennings, H., Shores, R., Wenk, M.L., Spangler, E.F., Tarone, R. and Yuspa, 
S.H. (1983). Malignant conversion of mouse skin tumours is increased by 
tumoric initiators and unaffected by tumour promotors. Nature, 304. 67-69.
Hershfield, M.S. and Seegmiller, T.E. (1977). Regulation of de novo purine 
synthesis in human lymphoblasts. J. Biol. Chem. 252. 6002-6010.
Holliday, R. (1989). A. different kind of inheritance. Sci. Am. 260. 40-48.
Holliday, R. and Jeggo, P A  (1985). Mechanisms for changing gene expression 
and their possible relationship to carcinogenesis. Cancer Surveys, 4, 557-581.
Hozier, J. (1991). A molecular geneticist’s view of complex genomic lesions. 
Environ. Molec. Mutagen, 18, 255-258.
Hozier, J., Sawyer, J., Clive, D. and Moore, M. (1982). Cytogenetic distinction 
between the TK+ and TK' chromosomes in the L5178Y TK 3.7.2C mouse 
lymphoma cell line. Mutat. Res. 105. 451-456.
272
Hozier, J.C., Sawyer, J., Clive, D. and Moore, M.M. (1985). Chromosome 1L 
aberrations in small colony L5178Y TK*/' mutants early in their clonal 
history. Mutation Res. 147. 237-242.
Hsu, I.C., Metcalf, R.A., Sun, T., Welsh, J.A., Wang, N.J. and Harris, C.C.
(1991). Mutational hotspot in the p53 gene in human hepatocellular 
carcinoma. Nature, 350. 427-428.
Huang, P., Siciliano, M.J. and Plunkett, W. (1989). Gene deletion, a 
mechanism of induced mutation by arabinosyl nucleosides. Mutat. Res. 210. 
291-301.
Humphries, S.E., Whitall, R., Minty, A., Bucking, M. and Williamson, R. (1981). 
There are approximately 20 actin genes in the human genome. Nucleic Acids 
Res., 9, 4895-4908.
Htittner, E., Mergner, U., Braun, R. and Schoneich, J. (1990). Increased 
frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of 
workers employed in cyclophosphamide production. Mutat. Res. 243.101-107.
IARC Monographs on the evaluation of carcinogenic risks in humans (1987). 
Supplement 7. Overall evaluations of carcinogenicity: an updating of IARC 
Monographs Volumes 1 to 42, Lyon, IARC.
ICPEMC Publ. No.16 (1988). Testing for mutagens and carcinogens; the role 
of short-term genotoxicity assays. Mutat. Res. 205. 3-12.
Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, AL. (1990). Increased 
expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 
335. 675-679.
Ishidate, M., Harnois, M.C. and Sofuni, T. (1988). A comparative analysis of 
data on the clastogenicity of 951 chemical substances tested in mammalian 
cell cultures. Mutation Res. 195. 151-213.
Ishidate, M., Sofuni, T. and Yoshikawa, K  (1981). Chromosomal aberration 
tests in vitro as a primary screening tool for environmental mutagens and/or 
carcinogens. Gann Monogr. Cancer Res. 27, 95-108.
Jensen, J.C. and Thilley, W.G. (1986). Spontaneous and induced chromosomal 
aberrations and gene mutations in human lymphoblasts : mitomycin C, 
methylnitrosourea and ethylnitrosourea. Mutat. Res. 160. 95-102.
Jenson, R.H., Bigbee, W.L. and Langlois, R.G. (1990). Multiple endpoints for 
somatic mutations in humans provide complementary views for biodosimetry, 
genotoxicity and health risks. In: Mutation and the Environment Part C. Ed.
H.L. Mendelsohn and R.J. Albertini. Wiley-Liss Inc. NY, pp.81-92.
273
Jones, I.M., Burckhert-Schultz, K, Strout, C.L. and Cripen, T.L. (1987).. 
Factors that affect the frequency of thioguanine-resistant lymphocytes in 
mice following exposure to ethylnitrosourea. Environ. Mutagen, 9, 317-329.
Kaden, D.A., Bardwell, L., Newmark, P., Anisowicz, A., Skopek, T.R. and Sager, 
R. (1989). High frequency of large spontaneous deletions of DNA in tumor- 
derived CHEF cells. Proc. Natl. Acad. Sci. (USA). 86, 2306-2310.
Kao, F.-T. and Puck, T.T. (1969). Genetics of somatic mammalian cells. IX. 
Quantitation of mutagenesis by physical and chemical agents. J. Cell 
Physiol. 74, 245-258.
Kavathas, P., Bach, F.H. and DeMars, R. (1980). Gamma ray-induced loss of 
expression of HLA and glyoxylase I alleles in lymphoblastoid cells. Proc. 
Natl. Acad. Sci. (USA), H , 4251-4255.
Kelley, W.N., Greene, M.L., Rosenbloom, F.M., Henderson, J.F. and Seegmiller, 
J.E. (1969). Hypoxanthine guanine phosphoribosyltransferase deficiency in 
gout. Ann. Intern. Med. 70, 155-206.
Keohavong, P., Liu, V.F. and Thilly, W.G. (1991). Analysis of point mutations 
induced by ultraviolet light in human cells. Mutation Res., 249. 147-159.
King, H.W.S. and Brookes, P. (1984). On the nature of the mutations induced 
by the diolepoxide of benzo(a)pyrene in mammalian cells. Carcinogenesis, 5, 
965-970.
Kirkland, D.J. (1992). Chromosomal aberration tests in vitro : problems with 
protocol design and interpretation of results. Mutagenesis, 1, 95-106.
Kirkland, D.J. (1993). Genetic toxicology testing requirements : official and 
unofficial view from Europe. Environ. Molec. Mutagen, 21, 8-14.
Kinzler, K.W., Nilbert, M.C., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, 
K.J., Preisinger, A.C., Hamilton, S.R., Hedge, P., Markham, A., Carlson, M., 
Joslyn, G., Groden, J., White, R., Miki, Y., Miyoshi, Y., Nishisho, I. and 
Nakamura, Y. (1991). Identification of a gene located at chromosome 5q21 
that is mutated in colorectal cancers. Science, 351, 1366-1370.
Klein, G. (1979). Lymphoma development in mice and humans : diversity of 
initiation is followed by convergent cytogenetic evolution. Proc. Natl. Acad. 
Sci. (USA), 76, 2442-2446.
Klinedinst, D.K. and Drinkwater, N.R. (1991). Reduction to homozygosity is 
the predominant spontaneous mutational event in cultured human 
lymphoblastoid cells. Mutat. Res. 250, 365-374.
Knudson, A.G.J. (1977). Genetics and etiology of human cancer. Adv. Human 
Genet. 8, 1-66.
274
Koberle, B. and Speit, G. (1991). Molecular characterization of mutations at 
the hprt locus in V79 Chinese hamster cells induced by bleomycin in the 
presence of inhibitors of DNA repair. Mutat. Res. 249. 161-167.
Konecki, D.S., Brennand, J., Fuscoe, J.C., Caskey, C.T. and Chinault, A.C.
(1982). Hypoxanthine-guanine phosphoribosyltransferase genes of mouse and 
Chinese ham ster: construction and sequence analysis of cDNA recombinants. 
Nucl. Acid Res. 21, 6763-6775.
Kozak, C.A and Ruddle, F.H. (1977). Assignment of genes for thymidine 
kinase and galactokinase to Mus musculus chromosome 11 and the 
preferential segregation of this chromosome in Chinese hamster/mouse 
somatic cell hybrids. Somatic Cell Genet. 33, 121-133.
Kraemer, KH., Water, H.L. and Buchanan, J.K  (1980). Survival of human 
lymphoblastoid cells after DNA damage measured by growth in microtitre 
wells. Mutat. Res. 72, 285-294.
Krawetz, S.A., States, J.C. and Dixon, G.H. (1986). Isolation and fractionation 
of total nucleic acids from tissues and cells. J. Biochem. Biophys. Methods, 
12, 29-36.
Kress, S., Konig, J., Schweizer, J., Lohrke, H., Bauer-Hofmann, R. and 
Schwartz, M. (1992). p53 mutations are absent from carcinogen-induced 
mouse liver tumors but occur in cell lines established from these tumors. 
Molec. Carcinogen, 6, 148-158.
Krieg, P.A. and Melton, D.A (1987). In vitro RNA synthesis with SP6 RNA 
polymerase. Methods in Enzymology, 155. 397-415.
Kronenberg, A. and Little, J.B. (1989). Molecular characterization of 
thymidine kinase mutants of human cells induced by densely ionizing 
radiation. Mutat. Res. 211. 215-224.
Kunz, B.A (1988). Mutagenesis and deoxyribonucleotide pool imbalance. 
Mutation Res. 200. 133-147.
Lacqueur, G.L. (1968). Toxicology of cycasin. Cancer Res. 28, 2262-2267.
LaForgia, S., Morse, B., Levy, J., Barnea, G., Cannizzaro, L.A., Li, F., Nowell, 
P.C., Boghosian-Sell, L., Glick, J., Weston, A, Harris, C.C., Drabkin, H., 
Patterson, D., Croce, C.M., Schlessinger, J. and Huebner, K. (1991). Receptor 
protein-tyrosine phosphate k is a candidate tumor suppressor gene at human 
chromosome region 3p21. Proc. Natl. Acad. Sci. (USA), 88, 5036-5040.
Leder, A., Pattengale, P.K., Kuo, A., Stewart, T.A. and Leder, P. (1986). 
Consequences of widespread deregulation of the c-myc gene in transgenic 
mice : multiple neoplasms and normal development. Cell, 415. 485-495.
275
Lehmann, AR. and Norris, P.G. (1989). DNA repair and cancer : speculations 
based on studies with xeroderma pigmentosum, Cockayn’s syndrome and 
trichothiodystrophy. Carcinogenesis, 10, 1353-1356.
Lehrach, H., Diamond, D., Wozney, J.M. and Boedtker, H. (1977). RNA 
molecular weight determinations by gel electrophoresis under denaturing 
conditions : a critical re-examination. Biochem., 16, 4743-4751.
Lesch, M. and Nyhan (1964). A familial disorder of uric acid metabolism and 
central nervous system function. Am. J. Med. 36, 561-570.
Levine, A.J. (1992). The p53 tumour suppressor gene and product. Cancer 
Surveys, 12, 59-79.
Levine, A  J., Momand, J. and Finlay, C.A. (1991). The p53 tumour suppressor 
gene. Nature, 351. 435-456.
Lewis, J.A. (1986). Structure and expression of Chinese hamster thymidine 
kinase gene. Molec. Cell Biol. 6, 1998-2010.
Li, AP. (1984). Use of Aroclor 1254-induced rat liver homogenate in the 
assaying of promutagens in Chinese hamster ovary cells. Environ. Mutagen., 
6, 539-544.
Li, A.P. and Shimizu, R.W. (1983). A modified agar assay for the quantitation 
of mutation at the hypoxanthine guanine phosphoribosyl transferase gene 
locus in Chinese hamster ovary cells. Mutation Res. 111. 365-370.
Li, F.P. (1988). Cancer families : human models of susceptibility to neoplasia. 
Cancer Res. 48, 5381-5386.
Liber, H.L., Benforado, K, Crosby, R.M., Simpson, D. and Skopek, T.R. (1989). 
Formaldehyde-induced and spontaneous alterations in human hprt DNA 
sequence and mRNA expression. Mutat. Res. 226. 31-37.
Liber, H.L., Call, M.K. and Little, J.B. (1987). Molecular and biochemical 
analyses of spontaneous and X-ray induced mutants in human lymphoblastoid 
cells. Mutat. Res. 178. 143-153.
Liber, H.L., Yandell, D.W. and Little, J.B. (1989a). A comparison of mutation 
induction at the tk and hprt loci in human lymphoblastoid cells; quantitative 
differences are due to an additional class of mutations at the autosomal tk 
locus. Mutat. Res. 216. 9-17.
Lilleberg, S.L., Cabance, M.A., Raju, R.R., Wagner, L.M. and Kier, L.D. (1992). 
Alterations in the structural gene and the expression of p53 in rat liver 
tumors induced by aflatoxin B^ Molec. Carcinogen, 6, 159-172.
276
Lin, P.-F., Lieberman, H.B., Yeh, D.-B., Xu, T., Zhao, A.-Y. and Ruddle, F.H. 
(1985). Molecular cloning and structural analysis of murine thymidine kinase 
genomic and cDNA sequences. Molec. Cell Biol. 5, 3149-3156.
Liskay, R.M. and Evans, R.J. (1980). Inactive X chromosome DNA does not 
function in DNA mediated cell transformation for the phosphoribosyl- 
transferase gene. Proc. Natl. Acad. Sci (USA), 76, 5779-5783.
Little, C.D., Nan, M.M., Carney, D.N., Gazdar, A.F. and Minna, J.D. (1983). 
Amplification and expression of the c-myc oncogene in human lung cancer cell 
lines. Nature, 306. 194-196.
Little, J.B. (1989). In vitro models of carcinogenesis : expression of recessive 
gene by chromosomal mutations. Environ. Hlth. Perspect. 81, 63-66.
Lopez-Galindez, C., Lopez, J.A, Melero, J.A., de la Fuente, L., Martinez, C., 
Ortin, J. and Perucho, M. (1988). Analysis of genetic variability and mapping 
of point mutations in influenza virus by the RNaseA mismatch cleavage 
method. Proc. Natl. Acad. Sci (USA), 85, 3522-3526.
Love, D.R. and Davies, K.E. (1989). Duchenne muscular dystrophy: the gene 
and the protein. Mol. Biol. Med. 6, 7-17.
Lukash, L.L., Boldt, J., Pegg, AE., Dolan, M.E., Maher, V.M. and McCormick, 
J.J. (1991). Effect of O0-alkylguanine-DNA alkytransferase on the frequency 
and spectrum of mutations induced by N-methyl-NLnitro-n-nitrosoguanidine 
in the HPRT gene of diploid human fibroblasts. Mutat. Res. 250. 397-409.
MacLean, N. (1989). Genes and gene regulation. Edward Arnold, London. 
pp.75-77.
Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982). Molecular Cloning : a 
laboratory manual. Cold Spring Habor Laboratory.
Marcus, A.C., Shopland, D.R., Crane, L.A and Lynn, W.R. (1989). Prevalence 
of cigarette smoking in the United States : estimates from the 1985 current 
population survey. J. Natl. Cancer Inst. 81, 409-414.
Margolin, B.H. and Shelby, M.D. (1985). Sister chromatid exchanges: A re­
examination of the evidence for sex and race differences in humans. 
Environ. Mutagen, 7, Suppl.4, 63-72.
Maron, D.M. and Ames, B.N. (1983). Revised methods for the Salmonella 
mutagenicity test. Mutat. Res. 113. 173-215.
Marshall, C.J. (1988). The ras oncogenes. J. Cell Sci. Suppl. 10, 157-169.
Marshall, C.J. (1989). Oncogenes and cell proliferation : an overview. In: 
Oncogenes. Ed. D.M. Glover and B.D. Hames. IRL Press, Oxford, pp. 1-21.
277
Marx, J. (1989). Many gene changes found in cancer. Science, 249,1386-1388.\
Mattano, S.S., Palella, T.D. and Mitchell, B.S. (1990). Mutations induced at 
the hypoxanthine-guanine phosphoribosyltransferase locus of human 
T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate 
pools. Cancer Res., 50, 4566-4571.
McCallum, R.I., Woolley, V. and Petrie, A. (1983). Lung cancer associated with 
chloromethyl methyl ether manufacture : an investigation at two factories 
in the United Kingdom. Br. J. Indust. Med. 40, 384-389.
McCann, J., Choi, E., Yamasaki, E. and Ames, B.N. (1975). Detection of 
carcinogens as mutagens in the Salmonella/ microsome test : assay of 300 
chemicals. Proc. Natl. Acad. Sci. (USA), 72, 5135-5139.
McCormick, J.J. and Maher, V.M. (1989). Malignant transformation of 
mammalian cells in culture, including human cells. Environ. Molec. Mutagen. 
14, 105-113.
McMaster, G.K. and Carmichael, G.G. (1977). Analysis of single and double 
stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal 
and acridine orange. Proc. Natl. Acad. Sci (USA), 74, 4835-4838.
Melton, D.A., Krieg, P.A., Rebagliati, M.R., Maniatis, T., Zinn, K  and Green, 
M.R. (1984a). Efficient in vitro synthesis of biologically active RNA and RNA 
hybridization probes from plasmids containing a bacteriophage SP6 promotor. 
Nucl. Acid. Res., 18, 7035-7056.
Melton, D.W., Konecki, D.S., Brennand, J. and Caskey, C.T. (1984b). 
S tructu re, expression and m utation of th e  hypoxanthine 
phosphoribosyltransferase gene. Proc. Natl. Acad. Sci. (USA), 81,2147-2151.
Melton, D.W., Konecki, D.S., Ledbetter, D.H., Hejtmancik, J.F. and Caskey,
C.T. (1981). In vitro translation of hypoxanthine guanine phosphoribosyl­
transferase mRNA. Characterization of a mouse neuroblastoma cell line that 
has elevated levels of hypoxanthine guanine phosphoribosyl-transferase 
protein. Pro. Natl. Acad. Sci. (USA), 78, 6977-6980.
Melton, D.W., McEwan, C., McKie, A.B. and Reid, A.M. (1986). Expression of 
the mouse HPRT gene : deletional analysis of the promoter region of an X- 
chromosome linked housekeeping gene. Cell, 44, 319-328.
Meneghini, R. (1988). Genotoxicity of active oxygen species to mammalian 
cells. Mutat. Res., 195, 215-230.
Merrill, G.F., Harland, R.M., Groudine, M. andMcKnight, S.L. (1984). Genetic 
and physical analysis of the chicken tk gene. Molec. Cell Biol. 4, 1769-1776.
278
Messing, K. and Bradley, W.E.C. (1985). In vivo mutant frequency rises among 
breast cancer patients after exposure to high doses of p-radiation. Mutat. 
Res. 152, 107-112.
Meuth, M. (1990). The structure of mutation in mammalian cells. Biochim 
et Biophy. Acta. 1032, 1-17.
Moore, M.M., Clive, D., Hozier, J.C., Howard, B.E., Batson, A.G., Turner, N.T. 
and Sawyer, J. (1985). Analysis of trifhiorothymidine-resistant (TFTr) 
mutants of L5178Y/TK+/' mouse lymphoma cells. Mutation Res. 151, 
161-174.
Moore, M.M. and Doerr, C.L. (1990). Comparison of chromosome aberration 
frequency and small-colony TK-deficient mutant frequency in L5178Y/TK=/' 
-3.7.2C mouse lymphoma cells. Mutagenesis, 5, 609-614.
Moore, M.M., Harrington-Brock, K , Parker, L., Doerr, C.L. and Hozier, J.C. 
(1991a). Genotoxicity of 2-amino-6-N-hydroxyadenine (AHA) to mouse 
lymphoma and CHO cells. Mutation Res. 253, 63-71.
Moore, M.M., Parker, L., Huston, J., Harrington-Brock, K  and Deanfield, K.L. 
(1991b). Comparison of mutagenicity results for nine compounds evaluated 
at the hgprt locus in the standard and suspension CHO assays. Mutagenesis, 
6, 77-85.
Morgan, T.L., Fleck, E.W., Poston, K.A., Denovan, B.A., Newman, C.N., 
Rossiter, B.J.F. and Miller, J.H. (1990). Molecular characterization of X-ray- 
induced mutations at the HPRT locus in plateau-phase Chinese hamster 
ovary cells. Mutat. Res. 232, 171-182.
Morley, A  A. (1990). Human somatic mutation - where are we going? In: 
Mutation and the Environment, Part C. Ed. M.L. Mendelsohn and R.J. 
Albertini. Publ. Wiley-Liss Inc, NY. pp. 1-4.
Morley, A.A. (1991). Mitotic recombination in mammalian cells in vivo. Mutat. 
Res. 250, 345-349.
Morley, A.A., Trainor, K.J., Dempsey, J.L and Seshadri, R.S. (1985). Methods 
for study of mutations and mutagenesis in human lymphocytes. Mutat. Res., 
147, 363-367.
Muriel, W.J., Cole, J. and Lehmann, A.R. (1987). Molecular analysis of 
ouabain-resistant mutants of the mouse lymphoma cell line L5178Y. 
Mutagenesis, 1, 383-389.
Myers, R.M., Sheffield, V.C. and Cox, D.R. (1988). Detection of single base 
changes in DNA : ribonuclease cleavage and denaturing gradient gel 
electrophoresis. In: Genome Analysis: a practical approach. Ed. K.E. Davies, 
IRL Press, Oxford, pp. 103.
279
Myhr, B.C. and Mayo, J.K  (1987). Mutagenicity of rat-liver S9 to L5178Y 
mouse lymphoma cells. Mutat. Res. 189. 27-37.
Natarajan, A.T., Simons, J.W.I.M., Vogel, E.W. and van Zeeland, A.A. (1984). 
Relationship between cell killing, chromosomal aberrations, sister-chromatid 
exchanges and point mutations induced by monofunctional alkylating agents 
in Chinese hamster cells. A correlation with different ethylation products in 
DNA. Mutat. Res. 128. 31-40.
Natarajan, A.T., Mullenders, L.F.H. and Zwanenburg, T.S.B. (1986). 
Modulation of mutagen-induced biological effects by inhibitors of DNA repair 
In: Genetic Toxicology of Environmental Chemicals Part A: Basic Principles 
and Mechanisms of Action. Ed. C. Ramel, B. Lambert and J. Magnuss. Alan 
R. Liss Inc. NY, pp.373-384.
Nestmann, E.R., Brillinger, R.L., Gilman, J.P.W., Rudd, C.J. and Swierenga, 
S.H.H. (1991). Recommended protocols based on a survey of current practice 
in genotoxicity testing laboratories. II. Mutation in Chinese hamster ovary, 
V79 Chinesehamster lung and L5178Y mouse lymphoma cells. Mutat. Res. 
246. 255-284.
Nigro, J.M., Baker, S.J., Preisinger, AC., Jessup, J.M., Hostetter, R., Cleary, 
K , Bigner, S.H., Davidson, N., Bayling, S., Devilee, P., Glover, T., Collins, 
F.S., Weston, A., Modali, R., Harris, C.C. and Vogelstein, B. (1989). 
Mutations in the p53 gene occur in diverse human tumour types. Nature, 
342. 705-708.
Nishi, Y., Hasegawa, M.M., Taketomi, M., Ohkawa, Y. and Inui, N. (1984). 
Comparison of 6-thioguanine-resistant mutation and sister chromatid 
exchanges in Chinese hamster V79 cells with forty chemical and physical 
agents. Cancer Res. 44, 3270-3279.
Nowell, P.C. (1976). The clonal evolution of tumor cell populations. Science, 
194. 23-28.
Nowell, P.C. and Croce, C.M. (1988). Chromosomal approaches to oncogenes 
and oncogenesis. FASEB J. 2, 3054-3060.
Nussbaum, R.L., Crowder, W.E., Nyhan, W.L. and Caskey, C.T. (1983). A 
three-allele restriction-fragment length polymorphism at the hypoxanthine 
phosphoribosyltransferase locus in man. Proc. Natl. Acad. Sci. (USA), 80. 
4035-4039.
Nusse, R. (1986). The activation of cellular oncogenes by retroviral insertion. 
Trends in Genetics, 2, 244-247.
O’Donovan, M.R. (1990). Mutation assays of ethyl methanesulphonate, 
benzidine andbenzo[a]pyrene using Chinese hamster V79 cells. Mutagenesis, 
5, 9-13.
280
Omfelt, A. (1986). Chemical induction of spindle disturbances. In: Genetic\ 
Toxicology of Environmental Chemicals. Part A  : Basic Principles and 
Mechanisms of Action. Ed. C. Ramel, B. Lambert and J. Magnusson, Alan R. 
Liss, N.Y. pp.333-342.
Organisation of Economic Co-operation and Development (1983). Guidelines 
for the testing of chemicals. OECD, Paris.
Orkin, S.H. and Kazazian, H.H. (1984). The mutation and polymorphism of 
the human /?-globin gene and its surrounding DNA Ann. Rev. Genet. 18. 
131-171.
Panganiban, AT. (1985). Retroviral DNA integration. Cell, 42, 5-6.
Patel, P.I., Nussbaum, R.L., Framson, P.E., Ledbetter, D., Caskey, C.T. and 
Chinault, AC. (1984). Organization of the HPRT gene and related sequences 
in the human genome. Somat. Cell Mol. Genet. 10, 483-493.
Paul, W.E., Sredni, B. and Schwartz, R.H. (1981). Long-term growth and 
cloning of non-transformed lymphocytes. Nature, 294. 697-699.
Perera, F. and Boffetta, P. (1988). Perspectives on comparing risks of 
environmental carcinogens. J.N.C.I. 80, 1282-1293.
Periera, M.A. and Chang, L.W. (1981). Binding of chemical carcinogens and 
mutagens to rat hemoglobin. Chem.-Biol. Interact. 33, 301-305.
Peters, G. (1989). Oncogenes at viral integration sites. In: Oncogenes. Ed:
D.M. Glover and B.D. Hames. IRL Press, Oxford, pp.23-66.
Piechaczyk, M., Blanchard, J.-M., Bonnieu, A, Fort, P., Mechti, N., Rech, J., 
Cuny, M., Martyl, L., Ferre, F., Lebleu, B. and Jeanteur, P. (1988). Role of 
RNA structures in c-myc and c-fos gene regulations. Gene, 72, 287-295.
Ponder, B. (1988). Gene losses in human tumours. Nature, 335, 400-402.
Pool, B.L., Yalkinoglu, A.O., Klein, P. and Schlehofer, J.R. (1989). DNA 
amplification in genetic toxicology. Mutation Res. 213, 61-72.
Powell, S.M., Zilz, N., Beazer-Barclay, Y., Bryan, T.M., Hamilton, S.R., 
Thibodeau, S.N., Vogelstein, B. and Kinzler, K.W. (1992). APC mutations 
occur early during colorectal tumorigenesis. Nature, 359, 235-237.
Prosser, J., Thompson, A.M., Craston, G. and Evans, H.J. (1990). Evidence 
that p53 behaves as a tumour suppressor gene in sporadic breast tumours. 
Oncogene, 5, 1573-2579.
281
Purves, D.C., McAuslane, J.A.N. and Lumley, C.E. (1993). Genotoxicity testing, 
of pharmaceuticals : current practices and strategies. Poster presentation : 
BTS Spring Meeting, Univ. of Kent, April 5-7.
Rabbitts, T. J. (1985). The c-myc proto-oncogene: involvement in chromosomal 
abnormalities. Trends Genet. 1, 327-331.
Rabbitts, T.H. and Rabbitts, P.H. (1989). Molecular pathology of chromosomal 
abnormalities and cancer genes in human tumours. In: Oncogenes. Ed: D.M. 
Glover and B.D. Hames. IRL Press, Oxford, pp.67-111.
Radman, M., Jeggo, P. and Wagner, R. (1982). Chromosomal rearrangement 
and carcinogenesis. Mutat. Res. 98, 249-264.
Ramel, C. (1986). Deployment of short-term assays for the detection of 
carcinogens; genetic and molecular considerations. Mutat. Res., 168. 327-342.
Ramel, C. (1988). Short-term testing - are we looking at wrong endpoints? 
Mutat. Res. 205. 13-24.
Rannug, U., Sundvall, A. and Ramel, C. (1978). The mutagenic effects of 1,2- 
dichloroethane on Salmonella typhimurium. I. Activation through 
conjugation with glutathione in vitro. Chemico-Biol. Interact. 20, 1-16.
Recio, L., Simpson, D., Cochrane, J., Liber, H. and Skopek, T.R. (1990). 
Molecular analysis of hprt mutants induced by 2-cyanoethylene oxide in 
human lymphoblastoid cells. Mutat. Res. 242. 195-208.
Rixon, M.W. and Gelinas, R.E. (1988). A fetal globin gene mutation in y non­
deletion hereditary persistence of fetal hemoglobin increases promotor 
strength in a nonerythroid cell. Molec. Cell. Biol. 8, 713-721.
Ross, J. (1989). The turnover of messenger RNA. Sci. Am., 260. 28-35.
Rossi, A.M., Tates, A.D., van Zeeland, A.A. and Vrieling, H. (1992). Molecular 
analysis of mutations affecting hprt mRNA splicing in human T-lymphocytes 
in vivo. Environ. Mol. Mutagen, 19, 7-13.
Rossiter, B.J.F. and Caskey, C.T. (1990). Molecular scanning methods of 
mutation detection. J. Biolog. Chem. 265. 12753-12756.
Rossiter, B.F., Fuscoe, J.C., Muzny, D.M., Fox, M. and Caskey, C.T. (1991)/ 
The Chinese hamster HPRT gene : restriction map, sequence analysis, and 
multiplex PCR deletion screen. Genomics, 9, 247-256.
Roth, J.R. (1974). Frameshift mutations. Ann. Rev. Genetics. 8, 319-346. /
282
Rowley, J.D. (1973). A new consistent chromosomal abnormality in chronic, 
myelogenous leukemia identified by quinacrine fluorescence and Giemsa 
staining. Nature, 243. 290-293.
Sager, R. (1989). Tumour suppressor genes : the puzzle and the promise. 
Science 246. 1406-1412.
Saini, K.S., Summerhayes, I.C. and Thomas, P. (1990). Molecular events 
regulating messenger DNA stability in eukaryotes. Molec. Cell Biochem. 96. 
15-23.
Sala-Trepat, M., Cole, J., Green, M.H.L., Rigaud, G., Vilcoq, J.R. and 
Monstacchi, E. (1990). Genotoxic effects of radiotheraphy and 
chemotheraphy on the circulating lymphocytes of breast cancer patients. III. 
Meausrement of mutant frequency to 6-thioguanine resistance. Mutagenesis, 
5, 593-598.
Schull, W.J. (1991). The segregation of cancer-causing genes in human 
populations. Mutat. Res. 247. 191-198.
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989). Molecular Cloning : A  
Laboratory Manual 2nd edition. Cold Spring Harbor Laboratory Press.
Schwab, M., Alitalo, K, Klempnauser, K.H., Varmus, H.E., Bishop, J.M., 
Gilbert, F., Brodeur, G., Goldstein, M. and Trent, J. (1983). Amplified DNA 
with limited homology to myc cellular oncogene is shared by human 
neuroblastoma cell lines and a neuroblastoma tumour. Nature 305.245-248.
Scott, D., Danford, D.J., Dean, B.J. and Kirkland, D.J. (1990). Metaphase 
chromosome aberrations assays in vitro. In: Basic Mutagenicity Tests : 
UKEMS recommended procedures Part I  revised. Ed. D.J. Kirkland. 
Cambridge University Press, pp.62-86.
Scott, D., Galloway, S.M., Marshall, R.R., Ishidate Jr., M., Brusick, D., Ashby, 
J. and Myhr, B.C. (1991). Genotoxicity under extreme culture conditions. 
A report from ICPEMC Task Group 9. Mutat. Res. 257. 147-204.
Seegmiller, J.E., Rosenbloom, F.M. and Kelley, W.N. (1967). An enzyme defect 
associated with a sex-linked human neurological disorder and excessive 
purine synthesis. Science, 155. 1682-1684.
Seifert, A.M., Bradley, W.E.C. and Messing, K. (1987). Exposure of nuclear 
medicine patients to ionizing radiation is associated with rises in HPRT' 
mutant frequency in peripheral T-lymphcytes. Mutat. Res. 191. 57-63.
Sharp, P.A. (1987). Splicing of messenger RNA precursors. The Harvey 
Lectures Series 81. Alan R. Liss Inc., NY, pp.1-31.
283
Shelby, M.D. (1988). The genetic toxicity of human carcinogens and its\ 
implications. Mutat. Res. 204, 3-15.
Shim, J.S., Lee, H.K., Kim, Y.-H., Roh, J.K. and Anderson, D. (1989). Sister 
chromatid exchanges in 52 Korean women living in the vicinity' of an 
industrial complex. Mutat. Res. 224. 511-515.
Singer, B. (1975). The chemical effects of nucleic acid alkylation and their 
relationship to mutagenesis and carcinogenesis. Prog, in Nucleic Acid Res. 
Molec. Biol. 15, 219-284.
Singer, B. (1983). Mutagenic effects of nucleic acid modification and repair 
assessed by in vitro transcription. In: Induced Mutagenesis, Basic Life Sci. 
Vol.23, Ed. C.W. Lawrence. Plenum Press, NY, pp. 1-28.
Singh, B. and Gupta, R.S. (1983). Comparison of the mutagenic responses of 
12 anticancer drugs at the hypoxanthine-guanine phosphoribosyltransferase 
and adenosine kinase loci in Chinese hamster ovary cells. Environ. 
Mutagenesis, 5, 871-880.
Smith, S.S. (1991). DNA methylation in eukaryotic chromosome stability. 
Molec. Carcinogen. 4, 91-92.
Sobels, F.H. (1987). Environmental mutagenesis in retrospect. Mutation Res. 
181, 299-310.
Soper, K.A., Stolley, P.D., Galloway, S.M., Smith, J.G., Nichols, W.W. and 
Wolman, S.R. (1984). Sister chromatid exchange (SCE) report on control 
subjects in a study of occupationally exposed workers. Mutat. Res. 129, 77-88.
Soussi, T., Caron de Fromental, C., Mechali, M., May, P. and Kress, M. (1987). 
Cloning and characterization of a cDNA from Xenopus laevis coding for a 
protein homologous to human and murine p53. Oncogene, 1, 71-78.
Southern, E. (1975). Detection of specific sequences among DNA fragments 
separated by gel electrophoresis. J. Mol. Biol. 98, 503-517.
Stallings, A.L., Adair, G.M., Sicilliano, J., Greenspan, J. and Siciliano, M.J.
(1983). Genetic effects of chromosomal rearrangements in Chinese hamster 
ovaiy cells : expression and chromosomal assignment of TK, GALK, ACPI, 
ADA and ITPA loci. Mol. Cell Biol. 3, 1967-1974.
Stanbridge, E.J. (1976). Suppression of malignancy in human cells. Nature, 
260, 17-20.
Stanbridge, E.J. (1985). A case for human tumor suppressor genes. Bioassays, 
3, 252-255.
284
Stanbridge, E.J. (1990). Identifying tumor suppressor genes in human 
colorectal cancer. Science, 247. 12-13.
Stanbury, J.B., Wyngaarden, J.B., Frederickson, D.S., Goldstein, J.L. and 
Brown M.S. (1983). The metabolic basis of inherited diseases. McGraw-Hill, 
NY.
Stankowski, L.F., Tindall, KR. and Hsie, A.W. (1986). Quantitative and 
molecular analysis of ethyl methanesulfonate- and ICR 191-induced mutation 
in AS52 cells. Mutat. Res. 160. 133-147.
Stein, W.D. (1991). Analysis of cancer incidence data on the basis of 
multistage and clonal growth models. Adv. Cancer Res. 56, 161-213.
Steingrimsdottir, H., Rowley, G., Dorado, G., Cole, J. and Lehmann, A.R.
(1992). Mutations which alter splicing in the human hypoxanthine-guanine 
phosphoribosyltransferase gene. Nucl. Acid Res., 20, 1201-1208.
Stout, J.T. and Caskey, C.T. (1985). HPRT : gene structure, expression and 
mutation. Ann. Rev. Genet. 19, 127-148.
Stratton, M.R., Williams, S., Fisher, C., Ball, A., Westbury, G., Gusterson, B.A., 
Fletcher, C.D.M., Knight, J.C., Fung, Y.-K, Reeves, B.R. and Cooper, C.S.
(1989). Structural alterations of the RBI gene in human soft tissue tumours. 
Br. J. Cancer, 60, 302-305.
Strauss, G.H. and Albertini, R.J. (1979). Enumeration of 6-thioguanine- 
resistant peripheral blood lymphocytes in man as a potential test for somatic 
cell mutations arising in vivo. Mutat. Res. 61, 353-379.
Szybalski, W. and Szybalski, E.H. (1962). Drug sensitivity as a genetic marker 
for human cell lines. U. Mich. Med. Bull. 28, 277-293.
Tamura, G., Kihana, T., Nomura, K , Terada, M., Sugimura, T. and Hirohashi, 
S. (1991). Detection of frequent p53 gene mutations in primary gastric 
cancer by cell sorting and polymerase chain reaction single-strand 
conformation polymorphism analysis. Cancer Res. 52, 3056-3058.
Tates, A.D., van Dam, F.J., van Mossel, H., Schoemaker, H., Thyssen, J.C.P., 
Woldring, V.M., Zwinderman, A.H. and Natarajan, A.T. (1991). Use of the 
clonal assay for the measurement of frequencies of HPRT mutants in 
T-lymphocytes from five control populations. Mutat. Res. 253. 199-213.
Teich, N.M. (1986). Oncogenes and Cancer. In: Introduction to the Cellular 
and Molecular Biology of Cancer. Ed. L.M. Franks and N. Teich. Oxford 
Univ. Press, pp.200-228.
Teng, S.P., Woodson, S.A. and Crothers, D.M. (1989). DNA sequence 
specificity of mitomycin cross-linking. Biochemistry, 28, 3901-3907.
285
Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K , 
Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B. and Minor, 
R. (1987). Prediction of chemical carcinogenicity in rodents from in vitro 
genetic toxicity assays. Science 236, 933-941.
Thacker, J. (1986). The nature of mutants induced by ionising radiation in 
cultured hamster cells. III. Molecular characterization of HPRT-deficient 
mutants induced by y-rays or a-particles showing that the majority have 
deletions of all or part of the hprt gene. Mutat. Res. 160. 267-275.
Thacker, J., Fleck, E.W., Morris, T., Rossiter, B.J.F. and Morgan, T.L. (1990). 
Localization of deletion breakpoints in radiation-induced mutants of the hprt 
gene in hamster cells. Mutat. Res. 232. 163-170.
Thacker, J. (1985). The molecular nature of mutants in cultured mammalian 
cells : A Review. Mutat. Res. 150. 431-442.
Thacker, J. and Ganesh, A.N. (1989). Molecular analysis of spontaneous and 
ethyl methanesulphonate-induced mutations of the hprt gene in hamster 
cells. Mutat. Res. 210. 103-112.
Tomasz, M., Chawia, A.K. and Lipman, R. (1988). Mechanism of 
monofunctional and bifunctional alkylation of DNA by mitomycin C. 
Biochemistry, 27, 3182-3187.
Tomatis, L. (1988). Environmental cancer risk factors : a review. Acta 
Oncologica, 27, 465-472.
Tompa, A, and Sapi, E. (1989). Detection of 6-thioguanine resistance in human 
peripheral blood lymphocytes (PBL) of industrial workers and lung cancer 
patients. Mutat. Res. 210, 345-351.
Topal, M.D. (1988). DNA repair, oncogenes and carcinogenesis. 
Carcinogenesis, 9, 691-696.
Trainer, K.J., Wigmore, D.J., Chrysostomou, A., Dempsey, J.L., Seshadri, R. 
and Morley, A.A. (1984). Mutation frequency in human lymphocytes 
increases with age. Mech. Ageing Devel. 27, 83-86.
Triesman, R., Orkin, S.H. and Maniatis, T. (1983). Specific transcription and 
RNA splicing defects in five cloned /?-thallasemia genes. Nature, 302, 
591-596.
Turner, D.R., Grist, S.A., Janatipour, M. and Morley, A.A. (1988). Mutations 
in human lymphocytes commonly involved gene duplication and resemble 
those seen in cancer cells. Proc. Natl. Acad. Sci. (USA). 85, 3189-3192.
286
United States Public Health Service (1989). The health consequences of 
smoking - cancer : a report of the surgeon general. Rockville MD, US Dept. 
Health and Human Services, Office on Smoking and Health.
Van Zeeland, A.A. (1988). Molecular dosimetry of alkylating agents : 
quantitative comparison of genetic effects on the basis of DNA adduct 
formation. Mutagenesis, 3, 179-191.
Van Zeeland, A.A. and Simons, J.W.I.M. (1976). Linear dose-response 
relationships after prolonged expression times in V79 Chinese hamster cells. 
Mutat. Res. 35, 129-138.
Varmus, H. (1989). An historical overview of oncogenes. In: Oncogenes and 
the Molecular Origins of Cancer. Ed. R.A. Weinberg. Cold Spring Harbor 
Laboratory Press, pp.3-44.
Varmus, H.E. (1982). Recent evidence for oncogenesis by insertion 
mutagenesis and gene activation. Cancer Surv. 2, 301-319.
Venitt, S. (1987). Use of mutagenicity assays in studies of human cancer. 
Anticancer Res. 7, 949-954.
Verlaan de Vries, M., Bogaard, M.E., van den Elst, H., van Boom, J.H., van der 
Eb, A.J. and Bos, J.L. (1986). A dot-blot screening procedure for mutated ras 
oncogenes using synthetic oligodesoxynucleotides. Gene, 50, 313-320.
Verma, I.M. and Sassone-Corsi, P. (1987). Proto-oncogene fos : Complex but 
versatile regulation. Cell, 51, 513-514.
Vig, B.K. (1986). Sequence of centromere separation : multicentric 
chromosomes, repetitive DNA and aneuploidy. In: Genetic Toxicology of 
Environmental Chemicals. Part A  : Basic Principles and Mechanisms of 
Action. Ed. C. Ramel, B. Lambert and J. Magnusson. Alan R. Liss, N.Y. 
pp.333-342.
Vijayalaxmi and Evans, H.J. (1984). Induction of 6-thioguanine-resistant 
mutants and SCEs by 3 chemical mutagens (EMS, ENU and MMC) in 
cultured human blood lymphocytes. Mutat. Res. 129. 283-289.
Vogelstein, B. (1991). Genetic alterations in colorectal tumors. Adv. in 
Oncology, 7, 3-6.
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., 
Leppert, M., Nakamura, Y., White, R., Smits, A.M.M. and Bos, J.L. (1988). 
Genetic alterations during colorectal-tumor development. New Engl. J. Med. 
319. 525-532.
287
Vogelstein, B., Fearon, E.R., Kern, S.E., Hamilton, S.R., Preisinger, A.C.* 
Nakamura, Y. and White, R. (1989). Allelotype of colorectal carcinomas. 
Science, 244, 207-211.
Vogelstein, B. and Kinzler, K.W. (1992). p53 Function and dysfunction. Cell, 
70, 523-526.
Vogelstein, B. and Kinzler, KW. (1993). The multistep nature of cancer. 
Trends in Genetics, 9, 138-141.
Vrieling, H., Niericker, M.J., Simons, J.W.I.M. and van Zeeland, A.A. (1988). 
Molecular analysis of mutations by N-ethyl-N-nitrosourea at the HPRT locus 
in mouse lymphoma cells. Mutat. Res. 198. 99-106.
Vrieling, H., Simons, J.W.I.M., Arwert, F., Natarajan, A.T. and van Zeeland, 
A.A. (1985). Mutations induced by X-rays at the HPRT locus in cultured 
Chinese hamster cells are large deletions. Mutat. Res. 144, 281-287.
Vrieling, H., Simons, J.W.I.M. and van Zeeland, A.A. (1988). Nucleotide 
sequence determination of point mutations at the mouse HPRT locus using 
in vitro amplification of HPRT mRNA sequences. Mutation Res., 198, 
107-113.
Vrieling, H., Thijseen, J.C.P., Rossi, A.M., van Dam, F.J., Natarajan, A.T., 
Tates, Ad. D. and Van Zeeland, A.A. (1992). Enhanced hprt mutant frequency 
but no significant difference in mutation spectrum between a smoking and 
a non-smoking human population. Carcinogenesis, 13, 1625-1631.
Wada, S., Miyanishi, M., Nishimoto, Y., Kambe, S. and Miller, R.W. (1968). 
Mustard gas as a cause of respiratory neoplasia in man. Lancet i, 1161-1163.
Waldren, C., Cornell, L., Sognier, M.A and Puck, T.T. (1986). Measurement 
of low levels of X-ray mutagenesis in relation to human disease. Proc. Natl. 
Acad. Sci. (USA). 83, 4839-4843.
Ward, M.A., Yu, M., Glickman, B.W. and Grosovsky, A.J. (1990). Loss of 
heterozygosity in mammalian cell mutagenesis : molecular analysis of 
spontaneous mutants at the aprt locus in CHO cells. Carcinogenesis, 11, 
1485-1490.
Waterfield, M.D., Scrace, T., Whittle, N., Stroobart, P., Johnsson, A., Wasteson, 
A., Westermark, B., Heldin, C.H., Huang, J.-S. and Devel, T.F. (1983). 
Platelet derived growth factor is structurally related to the putative 
transforming protein p28 sis of simian sarcoma virus. Nature 304. 35-39.
Waters, M.D., Stack, H.F. and Brady, A.L. (1986). Analysis of the spectra of 
genetic activity in short-term tests. In: Genetic Toxicology of Environmental 
Chemicals. Part A  : Basic Principles and Mechanisms of Action. Ed. C. 
Ramel, B. Lambert and J. Magnusson. Alan R. Liss, N.Y. pp.99-109.
288
Watson, W.P. (1987). Post-radiolabelling for detecting DNA damage.\ 
Mutagenesis, 2, 319-332.
Weatherall, D.J. (1991). The New Genetics and Clinical Practice 3rd edition. 
Oxford Univ. Press, pp.34.
Weinberg, R.A. (1988). Finding the anti-oncogene. Sci. Am. 259. 34-41.
Weinberg, R.A. (1989). Oncogenes and multistep carcinogenesis. In: 
Oncogenes and the Molecular Origins of Cancer. Ed R.A. Weinberg Cold 
Spring Harbor Laboratory Press, pp.307-326.
Weisburger, J.H., Griswold Jr., D.D., Prejean, J.D., Casey, A.E., Wood Jr., H.B. 
and Weisburger, E.K. (1975). The carcinogenic properties of some of the 
principal drugs used in cancer chemotherapy. Recent Results. Cancer Res. 
52, 1-17.
Weisburger, J.H. and Williams, G.M. (1989). Types and amount of carcinogens 
as potential human cancer hazards. Cell Biol. Toxicol. 5, 377-392.
Weith, A., Martinsson, T., Cziepluch, G., Bruderlein, S., Amler, L.C. and 
Berthold, F. (1989). Neuroblastoma consensus deletion maps to lp36 1-2. 
Genes, Chromosomes and Cancer, 1, 159-166.
Whaley, J.M. and Little, J.B. (1990). Molecular characterization of hprt 
mutants induced by low- and high-LET radiations in human cells. Mutat. 
Res. 243, 35-45.
White, R. and Caskey, C.T. (1988). The human as an experimental system in 
molecular genetics. Science, 240, 1483-1488.
Williams, G.M. and Weisburger, J.H. (1988). Application of a cellular approach 
to carcinogen identification. Mutat. Res. 205, 79-90.
Winnaker, E.L. (1987). From genes to clones: introduction to gene technology. 
VCH, New York.
Winter, E., Yamamoto, F., Almoguera, C. and Perucho, M. (1985). A method 
to detect and characterize point mutations in transcribed genes : application 
and over expression of the mutant c-Ki-ras allele in human tumour cells. 
Proc. Natl. Acad. Sci. (USA), 82, 7575-7579.
Xu, Z., Yu, Y., Hsie, A.W., Caskey, C.T., Rossiter, B. and Gibbs, R.A. (1989). 
Deletion screening at the hypoxanthine-guanine phosphoribosyltransferase 
locus in Chinese hamster cells using the polymerase chain reaction. 
Teratogen. Carcinogen. Mutagen 9, 177-187.
289
Yandell, D.W., Campbell, J.A., Dayton, S.H., Peterson, R., Walton, D., Little,, 
J.B., McConkie-Rosell, A., Buckley, E.G. and Dryja, T.P. (1989). Oncogenic 
point mutations in the human retinoblastoma gene : their application to 
genetic counselling. N. Engl. J. Med. 321. 1689-1695.
Yandell, D.W., Dryja, T.P. and Little, J.B. (1986). Somatic mutations at a 
heterozygous autosomal locus in human cells occur more frequently by allele 
loss than by intragenic structural alterations. Somat. Cell. Mol. Genet. 12, 
255-263.
Yandell, D.W., Dryja, T.P. and Little, J.B. (1990). Molecular genetic analysis 
of recessive mutations at a heterozygous autosomal locus in human cells. 
Mutation Res. 229. 89-102.
Yunis, J.J., Soreng, A.L. and Bowe, A.E. (1987). Fragile sites and targets of 
diverse mutagens and carcinogens. Oncogene, 1, 59-69.
Zarbl, H., Sukumar, S., Arthur, A.V., Martin-Zanca, D. and Barbacid, M. (1985). 
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during 
initiation of mammary carcinogenesis in rats. Nature 315, 382-385.
Zhang, L.-H., Vrieling, H., van Zeeland, A.A. and Jenssen, D. (1992). Spectrum 
of spontaneously occurring mutations in the hprt gene of V79 Chinese 
hamster cells. J. Mol. Biol., 223. 627-635.
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
